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Obesity has been classified as a global epidemic by the World Health Organisation, 
with 13% of the world’s adult population estimated to be obese in 2016. An increased 
risk of multiple diseases is associated with obesity, including cardiovascular disease 
and type two diabetes. Obesity itself is defined as an excess of white adipose tissue 
(AT) and a body mass index of over 30 kg/m2. The excess adipose tissue present in 
obesity can become dysfunctional and display increased hypoxia, fibrosis, and 
necrotic adipocyte death. It is AT dysfunction which is thought to be responsible for 
obesity associated disease and the primary cause of AT dysfunction is a limited 
capacity of adipose tissue to expand. Obesity and by proxy adipose tissue expansion 
are known to be partially genetically regulated, with heritability estimates ranging from 
40% to 70%. In order to identify the genetic variation underlying obesity, genome wide 
association studies (GWAS) have been utilised. Multiple GWAS studies, including a 
study into BMI by Kichaev et al (2019), have found that genetic variation at the FOXP1 
locus is associated with adiposity levels. However, whether FOXP1 directly regulates 
adipose levels is entirely unknown. Here I generated a series of predicted loss of 
function foxp1 alleles in zebrafish. My goal was to determine whether foxp1 influenced 
AT growth and expansion in vivo. To this end a CRISPR/Cas9 system was employed 
to generate stable foxp1 mutant zebrafish. Changes in AT expansion were then 
assessed in the F2 generation, with live imaging of total AT area providing information 
on changes in growth dynamics between wild type and mutant fish. Mutant fish were 
found to have reduced levels of adipose tissue during normal development and also 
accumulated less AT in response to a high fat diet. In addition to generating foxp1 
mutants I also generated a novel transgenic line which labels both adipocytes and 
adipose progenitor cells. Using the transgenic line, I performed high resolution in vivo 
imaging of zebrafish AT and compiled novel information about adipose progenitor cell 
behaviour. Adipose progenitor cell behaviour was also assessed in foxp1 mutant 
zebrafish. In summary, I have tested the role of foxp1 in adipose tissue expansion 
and found evidence to suggest that foxp1 is required for adipose tissue expansion. I 
have also generated a novel transgenic line which has allowed for unprecedented in 
vivo imaging of adipose tissue expansion. This is the first data to suggest that foxp1 
plays an in vivo role in adipose tissue expansion. Further investigations into the 
mechanisms by which foxp1 influences AT expansion could lead to the creation of 
prediction strategies to prevent the development of unhealthy obesity. 
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Lay summary  
 
Obesity is now a global health epidemic with 13% of the world’s adult population 
classified as obese in 2016. Multiple diseases are associated with obesity, including 
cardiovascular disease and type two diabetes. Obesity is characterised by excess fat, 
also known as adipose tissue, and is defined as a body mass index (BMI) of over 30 
kg/m2. Not everyone with obesity will develop associated diseases and therefore it is 
not excess fat alone which influences disease susceptibility. While obesity is primarily 
thought of as a lifestyle disease it is also known to be influenced by an individual’s 
genetic makeup. However, which genes control fat levels and which genes lead to 
increased risks of developing obesity associated diseases are largely unknown. In 
this project I have investigated how a gene called foxp1 influences fat levels and have 
found that foxp1 is required for fat expansion. Further investigations into how foxp1 
acts to influence fat levels could lead to the creation of prediction strategies to prevent 
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1.1 – Obesity, obesity associated disease and adipose tissue 
dysfunction  
 
1.1.1 – The global prevalence of obesity is increasing   
Levels of overweight and obesity, defined by Body Mass Indexes (BMI) of over 
25 kg/m2 and 30 kg/m2 respectively, are currently a global epidemic (Figure 1.1A & 
B) (Collaborators et al., 2017, WHO). Previously considered an issue confined to the 
developed world, obesity has now become a truly global problem with the worldwide 
prevalence of obesity nearly tripling between 1975 and 2016 (Figure 1.1A, B & C) 
(WHO). For example, in Africa the prevalence of obesity has nearly doubled between 
1980 and 2015, going from 6.2% to 12.7% (Figure 1.1C) (Collaborators et al., 2017). 
Despite the global reach of obesity, it is still much more common in the west. In 2015 
28.3% of Americans were obese, as were 22.9% of Europeans (Figure 1.1A & B) 
(Collaborators et al., 2017). Among adults the prevalence of obesity is generally 
higher amongst women and if current trends continue 18% of men and 21% of women 
are predicted to be obese by 2025 (Collaborators et al., 2017, Collaboration, 2016). 









Figure 1.1 – The global prevalence of obesity 
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Figure 1.1 – The global prevalence of obesity. A. Schematic of global obesity levels 
in adult males, adapted from GBD 2015 obesity collaborators (2017). B. Schematic 
of global obesity levels in adult females, adapted from GBD 2015 obesity collaborators 
(2017). C. Trends in age standardized prevalence of obesity among adults, adapted 
























1.1.2 – Obesity is linked to increased disease risk  
Obesity is classified as a health problem due to the increased disease risk 
which it confers (Martin et al., 2015). For example, in 2015 excess weight contributed 
to 4 million deaths and 120 million disability adjusted life years (DALYs) (Figure 1.2A) 
(Collaborators et al., 2017). In the UK 9000 premature deaths occur each year as the 
result of obesity, accounting for 8.7% of all deaths (Agha and Agha, 2017). Numerous 
medical complications are associated with obesity and these extend to nearly every 
organ system, with cardiovascular disease, diabetes and cancer being common 
complications (Martin et al., 2015, Haffner, 2006). Cardiovascular disease has been 
shown to be the leading cause of deaths and DALYs relating to high BMI, and was 
responsible for 2.7 million deaths and 66.3 million DALYs in 2015 (Figure 1.2A) 
(Collaborators et al., 2017). Diabetes was the second leading cause, responsible for 
0.9 million deaths and 39.1 million DALYs (Figure 1.2A) (Collaborators et al., 2017). 
Overall obesity is linked to multiple diseases, with cardiovascular disease and 
diabetes being leading causes of obesity related death.   
Numerous studies have examined the links between obesity and disease. For 
example, multiple epidemiological studies have shown that obesity is an independent 
cardiovascular disease predictor (Hubert et al., 1983, Rabkin et al., 1977, Manson et 
al., 1990, Kenchaiah et al., 2002). Cardiovascular diseases associated with obesity 
include, coronary heart disease, heart failure, hypertension, and sudden cardiac 
death (Koliaki et al., 2019). Obesity is thought to lead to cardiovascular disease by 
inducing maladaptive adaptations in cardiovascular structure and function (Figure 
1.2B) (Koliaki et al., 2019). These alterations increase cardiac workload and 
predispose obese individuals to heart failure (Figure 1.2B) (Koliaki et al., 2019). 
Obesity is also linked to type two diabetes (Al-Goblan et al., 2014). Briefly type 1 
diabetes is caused by an inability of the body to produce insulin due to the 
autoimmune destruction of pancreatic β-cells, while type two diabetes is caused by 
the absence of insulin secretion, due to low amounts of insulin production from 
pancreatic β-cells and peripheral insulin resistance (Figure 1.2C) (Al-Goblan et al., 
2014). Insulin sensitivity varies across BMI, however there is a strong association 
between obesity and insulin sensitivity (Al-Goblan et al., 2014). Diabetes occurs in 
individuals who lack sufficient insulin secretion to match the degree of insulin 
resistance (Al-Goblan et al., 2014). Obesity causes increased secretion of leptin, 
cytokines, and nonesterified fatty acids (NEFAs) (Al-Goblan et al., 2014). Increased 
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levels of NEFAs are associated with both insulin resistance and a decline in 
pancreatic β-cell function (Al-Goblan et al., 2014). Increased levels of NEFAs are 
therefore one way in which obesity can lead to the development of diabetes (Al-
Goblan et al., 2014). Finally, obesity is associated with an increased risk of developing 
various cancers, with strong epidemiological evidence linking obesity to increased 
cancer risk and mortality (Park et al., 2014, Barlow et al., 2006, Calle et al., 2003). 
Secretion of adipokines from adipocytes has been shown to influence the tumour 
microenvironment and to influence the progression of cancer (Park et al., 2014). 
Furthermore, cytokines released from AT during obesity have been shown to 
stimulate cancer stem cell growth and survival (Park et al., 2014).  In summary obesity 
causes changes in the body which increase the likelihood of developing diseases 





Figure 1.2 – Obesity is associated with increased disease risk 
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Figure 1.2 – Obesity is associated with increased disease risk A. Graph showing 
deaths in 2015 due to obesity associated disease. Adapted from GBD 2015 obesity 
collaborators (2015). B. Schematic showing how obesity can lead to heart failure. 
Adapted from (Pandey et al., 2018). C. Schematic showing the effect of β-cell 





























1.1.3 – Adipose tissue acts primarily as an energy storage organ  
Obesity is characterised by over nutrition and the accumulation of fat 
(Collaborators et al., 2017). Nearly every species of animal has found a way to store 
excess energy in the form of fat (Gesta et al., 2007). For example, Caenorhabditis 
elegans stores fat in the intestinal epithelium, while sharks store fat in the liver (Gesta 
et al., 2007). However, in most species excess energy is stored in white adipose 
tissue (WAT) (Gesta et al., 2007). WAT acts as a dynamic energy store, storing lipid 
in times of energy excess and mobilising lipid in times of energy deficit (Ma et al., 
2015). In addition to it’s energy storage role, WAT also has several additional 
functions including providing mechanical cushioning in regions of high stress such as 
the palm and heel, and providing cushioning to organs such as the heart and kidneys 
(Ghaben and Scherer, 2019). Adipose tissue also acts as an endocrine organ and 
secretes a variety of signalling proteins, known as adipokines (Ghaben and Scherer, 
2019). Overall white adipose tissue has multiple functions, with its function as an 
energy store being the focus of this chapter. 
In addition to WAT, mammals also possess brown and beige adipose tissue 
(Gesta et al., 2007). No tissue resembling brown adipose tissue (BAT) has yet been 
described in reptiles, amphibians or fish (Gesta et al., 2007). BAT is characterised by 
the expression of uncoupling protein 1 (UCP1) and generates heat through adaptive 
thermogenesis (Gesta et al., 2007). In rodents and humans BAT is most abundant 
during early development (Gesta et al., 2007). BAT is found in the interscapular region 
in rodents and in axillary, cervical, perirenal and periadrenal locations in humans 
(Gesta et al., 2007). Beige adipose tissue has been described as typical WAT tissue 
which contains some brown adipocytes and has been observed following cold 
exposure (Gesta et al., 2007). In summary, in addition to WAT mammals also possess 
thermogenic BAT however the remainder of this chapter will focus on the role of white 
adipose tissue.  
 
1.1.4 – Adipose tissue is comprised of multiple cell types  
Adipose tissue is comprised primarily of adipocytes (Figure 1.3A) (Ma et al., 
2015). Within adipose tissue, adipocytes are found tightly packed together and 
surrounded by a richly vascularised loose connective tissue (Figure 1.3A) (Ma et al., 
2015). Other cell types found in adipose tissue include, preadipocytes, fibroblasts, 
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endothelial cells and immune cells (Figure 1.3A) (Ma et al., 2015). Adipocytes are 
the specialised cells within adipose tissue which store energy within lipid droplets 
(Figure 1.3B) (Ma et al., 2015). Although some lipid accumulation can occur in other 
cell types, adipocytes differ from other cells due to the presence of large lipid droplets 
which are surrounded by the protein perilipin (Figure 1.3B) (Gesta et al., 2007). 
Adipocytes are characterised by the presence of a singular lipid droplet, a peripheral 
nucleus and their large size, with cells typically being 100 µm in diameter (Figure 
1.3B) (Ma et al., 2015). In summary adipose tissue is comprised of multiple cell types, 
with adipocytes acting to store energy.  
Adipocytes store energy in response to insulin (Figure 1.3C) (Haczeyni et al., 
2018). Elevations in blood glucose occur in response to food intake and this stimulates 
the secretion of insulin from pancreatic β-cells (Haczeyni et al., 2018). In response, 
adipocytes take up and convert glucose into neutral lipid for later use (Figure 1.3C) 
(Haczeyni et al., 2018). This process, known as lipogenesis, involves long chain fatty 
acid synthesis and the formation of triglycerides (Figure 1.3C) (Haczeyni et al., 2018). 
The reverse process of lipolysis also takes place in response to insulin signalling, with 
insulin signalling inhibiting lipolysis (Figure 1.3C) (Haczeyni et al., 2018). Here 
triglycerides are broken down into glycerol and free fatty acids and are released from 
the cell (Figure 1.3C) (Haczeyni et al., 2018). In addition to storing triglycerides, 
adipocytes can also store cholesterol (Haczeyni et al., 2018). Adipose tissue behaves 
as a cholesterol sink, with 25% of total bodily cholesterol stored within the adipose of 
normal weight individuals (Haczeyni et al., 2018). Both cholesterol and triglycerides 
enter adipocytes via specific transporter molecules, which are often found within 
caveolae (Haczeyni et al., 2018). Caveolae are lipid dense domains within the plasma 
membrane enriched with glycosphingolipids, proteins and cholesterol molecules, and 
they are abundant in adipocytes (Haczeyni et al., 2018). Overall adipocytes act in 
response to insulin signalling to store energy within lipid droplets.    
 
1.1.5 – Adipose tissue is found throughout the body  
Adipose tissue is generally thought to be mesodermal in origin (Gesta et al., 
2007). In rodents WAT develops mainly after birth, while in humans WAT 
development begins early in the second trimester of gestation (Gesta et al., 2007). 
WAT location also differs between species with invertebrates, amphibians and many 
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reptiles storing most adipose intraabdominally (Gesta et al., 2007). In contrast 
mammals, birds and some species of fish have both intraabdominal and 
subcutaneous adipose tissue (SAT), which is located beneath the skin (Figure 1.3D) 
(Gesta et al., 2007, Minchin and Rawls, 2017b). In humans WAT is found throughout 
the body with major intraabdominal depots being the omentum, which is a fold of fat 
around the stomach, and mesenteric AT, which surrounds the intestines (Figure 
1.3D) (Gesta et al., 2007). Major subcutaneous depots are found in the buttocks, 
thighs and abdomen (Figure 1.3D) (Gesta et al., 2007). In mice major intraabdominal 
depots are the mesenteric and perigonadal depots and major SAT depots include 
inguinal SAT, which is located near the hindlimbs (Figure 1.3D) (Cleal et al., 2017, 
Gesta et al., 2007). In addition to being stored intraabdominally and subcutaneously, 
WAT can also be found in many other areas such as the retro-orbital space and within 
the bone marrow (Gesta et al., 2007). In summary WAT is found throughout the body 
and can be broadly classified as intraabdominal AT and SAT.  
Intraabdominal adipose tissue, also known as visceral adipose tissue (VAT), 
and SAT are known to have different properties (Gesta et al., 2007). For example, 
expression profiling has revealed significant differences in the expression of 100s of 
genes between subcutaneous and visceral depots in both mice and humans (Gesta 
et al., 2006, Vidal, 2001, Vohl et al., 2004). Differentially expressed genes include 
genes involved in cell differentiation and adipogenesis (Vohl et al., 2004). For 
example, CEBPA expression has been shown to be higher in SAT, while CEBPD 
expression is higher in VAT (Vohl et al., 2004). VAT and SAT also show altered 
secretion of adipokines, rates of lipolysis and thermogenic potential (Ghaben and 
Scherer, 2019). The differing properties of VAT and SAT mean that SAT is considered 
to be broadly protective (Cleal et al., 2017). For example, numerous human and 
rodent studies have correlated increased SAT relative to VAT with preserved 
metabolic function, for subjects of similar weights (Ghaben and Scherer, 2019). 
Furthermore, transplantation of SAT into visceral adipose regions in mice has been 
shown to improve metabolic parameters (Tran et al., 2008). Taken together this data 
suggests that VAT and SAT have slightly different properties and that SAT is broadly 
protective.  
While the heterogeneity of adipocytes from different depots has been 
established, more recent data has suggested that adipocytes within the same depot 
also display heterogeneity (Hepler et al., 2018, Schwalie et al., 2018, Sempere et al., 
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2014). These studies have isolated adipose progenitor cells from within adipose 
tissue and have then used single cell RNA-Seq to look at differences in gene 
expression (Hepler et al., 2018, Schwalie et al., 2018, Sempere et al., 2014). Adipose 
progenitor cells are fibroblast like cells which differentiate to form adipocytes 
(Siersbaek et al., 2012). A study by Schwalie et al (2018) identified multiple 
populations of adipose progenitor cells and found that one population was capable of 
inhibiting adipocyte differentiation. Another study used single cell RNA-Seq to identify 
three adipose progenitor cell populations in one human adipose depot and found 
these cells to show differing rates of lipolysis (Raajendiran et al., 2019). In summary 
there is not only heterogeneity between adipose depots but also heterogeneity within 







Figure 1.3 – Adipose tissue is composed primarily of adipocytes and is located 
throughout the body 
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Figure 1.3 – Adipose tissue is composed primarily of adipocytes and is located 
throughout the body. A. Schematic showing the cell types present in adipose tissue. 
B. Schematic of a white adipocyte with a singular lipid droplet. C. Schematic of 
lipolysis and lipogenesis. Adapted from Badimon et al (2015). D. Schematic showing 
some of the major adipose depots found in human, mouse and zebrafish. Mouse 
schematic adapted from (Schoettl et al., 2018). Human schematic adapted from 






















1.1.6 – Obesity leads to adipose tissue dysfunction  
Obesity is characterised by excess adipose tissue accumulation and adipose 
tissue dysfunction during obesity is thought to confer disease risk (Lafontan, 2014). 
Under a normal state, nutrient excess causes adipocytes to store lipid and expand in 
size (Crewe et al., 2017). These adipocytes will then reach the diffusional limit of 
oxygen, resulting in mild hypoxia which induces a stress signal to drive angiogenesis 
and remodelling of the extracellular matrix (Figure 1.4A) (Crewe et al., 2017). This 
response leads to healthy adipose tissue expansion (Figure 1.4). However, 
lipodystrophy, ageing and obesity can all lead to dysfunctional adipose tissue 
expansion (Crewe et al., 2017).  At some point during obesity adipose tissue depots 
expand beyond the tissues capacity for adequate angiogenesis, resulting in persistent 
hypoxia (Figure 1.4B) (Crewe et al., 2017). This in turn leads to necrotic adipocyte 
death, which triggers inflammation and the initiation of a wound healing response 
(Figure 1.4B) (Crewe et al., 2017). Macrophages and neutrophils are then recruited 
and produce toxic products such as reactive oxygen species which further injure 
surrounding cells and promote fibrosis (Figure 1.4B) (Crewe et al., 2017). During 
normal wound healing this process would end following the removal of the injury signal  
(Crewe et al., 2017). However, during obesity this injury signal persists and causes 
the chronic activation of immune cells which results in further tissue damage, fibrosis 
and AT dysfunction (Figure 1.4B) (Crewe et al., 2017). The resulting dysfunctional 
adipose tissue then loses its ability to store lipid, resulting in ectopic deposition of lipid 
in the liver and insulin resistance (Lafontan, 2014). The disease risk associated with 












Figure 1.4 – Dysfunctional adipose tissue is characterised by inflammation, 
fibrosis and impaired angiogenesis 
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Figure 1.4 – Dysfunctional adipose tissue is characterised by inflammation, 
fibrosis and impaired angiogenesis. A.  Schematic showing healthy adipose tissue 
expansion. Adapted from (Crewe et al., 2017). B. Schematic showing dysfunctional 

























1.1.7 – Adipose morphology modulates adipose tissue dysfunction   
One factor known to influence adipose tissue dysfunction is adipose 
morphology. Adipose morphology is defined as the number and size distribution of 
adipocytes within adipose tissue (Hoffstedt et al., 2010). A hyperplastic adipose 
morphology is characterised by the presence of many small adipocytes, while a 
hypertrophic adipose morphology is characterised by the presence of few large 
adipocytes (Hoffstedt et al., 2010). Inter-individual variation in adipose morphology is 
present in human populations, with both morphologies being associated with different 
metabolic parameters (Hoffstedt et al., 2010, Salans et al., 1973, Veilleux et al., 2011). 
For example, a hypertrophic morphology is associated with adipocyte apoptosis, and 
increased levels of blood cholesterol and triglycerides (Hoffstedt et al., 2010). 
Furthermore, larger adipocytes are known to secrete less adiponectin and more 
inflammatory cytokines such as IL-6 and TNF- α (Skurk et al., 2007). Basal lipolysis 
is also increased in hypertrophic adipocytes, increasing the release of free fatty acids 
(Wueest et al., 2009). In contrast a hyperplastic morphology is associated with 
improved metabolic parameters and therefore with improved, glucose, insulin and 
lipid profiles (Hoffstedt et al., 2010). Taken together this shows that a hyperplastic 
adipose morphology is associated with a normal metabolic profile, while a 
hypertrophic adipose morphology is associated with a dysregulated metabolic profile. 
Therefore, targeting adipose morphology with an aim to generate a more hyperplastic 
adipose morphology would be one way to improve obesity associated adipose tissue 
dysfunction.  
Adipose tissue morphology is controlled by changes in adipocyte number or 
changes in adipocyte size. Changes in adipocyte size are controlled by lipid entering 
and leaving the cell. Lipids are stored in adipocytes via fatty acid uptake or lipogenesis 
(Figure 1.5C) (Lapid and Graff, 2017). Lipids are stored in adipocytes in the form of 
triglycerides (Lapid and Graff, 2017). Adipocytes can decrease in size by releasing 
lipid through lipolysis, in this process triglycerides undergo hydrolysis to release fatty 
acids (Figure 1.5D) (Lapid and Graff, 2017). Both lipolysis and lipid uptake by 
adipocytes are highly regulated by a number of factors, including a wide range of 
environmental factors (Spiegelman and Flier, 1996). Adipocytes can increase in 
number through the proliferation and subsequent differentiation of progenitor cells, in 
a process known as adipogenesis (Figure 1.5A) (Siersbaek and Mandrup, 2011). 
Adipocytes can also decrease in number via apoptosis (Figure 1.5B) (Tsuboyama-
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Kasaoka et al., 2000). It is known that adipocyte number remains stable in adults, 
irrespective of weight loss or gain, with a roughly 10% turnover of adipocytes each 
year (Spalding et al., 2008). In summary, adipose tissue can expand by increasing 
adipocyte cell number or size and I will now focus on increases in cell number as a 











Figure 1.5 – Adipose tissue expands by increases in adipocyte cell number and 
cell size. A. Schematic showing how adipocytes increase in number. B. Schematic 
showing how adipocytes decrease in number. C. Schematic showing how adipocytes 






1.1.8 – Healthy adipose tissue expansion can alleviate obesity associated 
AT dysfunction   
The adipose tissue expandability hypothesis suggests a reason for adipose 
tissue dysfunction (Virtue and Vidal-Puig, 2008). This hypothesis states that the 
capacity of an individual to expand their fat mass is a more important determinant of 
obesity associated metabolic dysfunction than the absolute amount of adipose tissue 
that an individual possesses (Virtue and Vidal-Puig, 2008). To test this hypothesis 
various mouse models have been employed (Kim et al., 2007, Virtue and Vidal-Puig, 
2008). One study limited adipose tissue expansion by generating a mouse with a 
dominant negative mutation in the proadipogenic factor Pparg (Peroxisome 
proliferator activated receptor gamma) (Virtue and Vidal-Puig, 2008). The Pparg 
mutant mice were then crossed onto the ob/ob background (Virtue and Vidal-Puig, 
2008). The ob/ob mouse contains a mutation in the leptin receptor which causes it to 
eat excessively and become profoundly overweight (Virtue and Vidal-Puig, 2008). The 
mice generated were found to be much more insulin resistant than ob/ob controls, 
despite having 14% less adipose tissue (Virtue and Vidal-Puig, 2008). In contrast, a 
mouse model in which adipose tissue expansion is apparently limitless shows 
improved metabolic parameters (Kim et al., 2007). Overexpression of adiponectin in 
ob/ob mice led to a significant increase in adipocyte cell number and overall 
expansion of adipose tissue mass (Kim et al., 2007). Despite having a body weight 
50% greater than ob/ob mice, the adiponectin overexpressing mice had lower 
glucose, insulin and triglyceride levels in blood plasma (Kim et al., 2007). Overall, data 
from the two mouse models demonstrates that it is the ability of adipose tissue to 
expand which determines whether the tissue becomes dysfunctional. Therefore, 









1.2 – The genetic control of adipose tissue expansion and 
morphology 
 
1.2.1 – Adipogenesis drives AT expansion and is controlled by a network 
of transcription factors  
Adipogenesis is the process by which fibroblast like progenitor cells 
differentiate to become mature lipid filled adipocytes (Figure 1.6A) (Siersbaek et al., 
2012). Much is known about adipose progenitor cells themselves and this is discussed 
further in chapter 4. Adipogenesis is controlled by a tightly regulated transcriptional 
cascade and much of our knowledge of the molecular mechanisms which control 
adipocyte differentiation come from in vitro studies of preadipocyte cell line models 
and primary cell cultures (Siersbaek et al., 2012). These cells can be induced to 
undergo adipogenesis, and differentiate into mature adipocytes, using a standard 
hormonal cocktail containing, insulin, cAMP elevating agent, glucocorticoids and 
growth factors (Figure 1.6A & B) (Siersbaek et al., 2012). Many studies using these 
cell line models have revealed the core transcriptional cascade which controls 
adipogenesis (Siersbaek et al., 2012).  
Preadipocyte cell line models undergo synchronous differentiation in response 
to the addition of a chemical stimulus (Siersbaek et al., 2012). Addition of the 
hormonal cocktail to preadipocytes leads to the activation of multiple early pro-
adipogenic transcription factors and the repression of anti-adipogenic factors 
(Siersbaek et al., 2012). These early transcription factors have been referred to as 
the first wave of transcription factors and include the CCAT enhancer binding protein 
(Cebp) family members Cebpb and Cebpd (Figure 1.6B) (Siersbaek et al., 2012, 
Tang et al., 2003, Tanaka et al., 1997). Other early transcription factors include 
Krox20 (early growth response 2, Egr2), Stat5a (Signal transducer and activator of 
transcription 5a) and members of the Klf (Kruppel-like factors) family (Figure 1.6B) 
(Siersbaek et al., 2012, Chen et al., 2005, Oishi et al., 2011, Floyd and Stephens, 
2003). This first wave of transcription factors then brings about the expression of a 
second wave of transcription factors (Siersbaek et al., 2012). The most important 
factors in the second wave are Cebpa and Pparg, which are considered to be master 
regulators of adipogenesis (Figure 1.6B) (Siersbaek et al., 2012, Rosen et al., 1999). 
In addition to Cebpa and Pparg, several other transcription factors including Srebp-
1c (sterol regulatory element-binding protein-1c) and Klf15 have been shown to 
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regulate the late phase of adipogenesis (Figure 1.6B) (Siersbaek et al., 2012, Kim 
and Spiegelman, 1996). These late phase adipogenic factors then induce the gene 
expression programme which leads to the mature adipocyte phenotype (Siersbaek et 
al., 2012). Overall, adipogenesis is controlled by a complex network of transcription 




















Figure 1.6 – Adipogenesis is controlled by a network of transcription factors. A. 
Schematic showing adipogenesis. B. Schematic showing the transcriptional control 
of adipogenesis. The master regulators of adipogenesis, Pparg and Cebpa, are 













1.2.2 - Adipogenesis leads to changes in chromatin structure  
In addition to gene expression changes, extensive chromatin remodelling also 
takes place during adipogenic differentiation. Multiple studies have examined genome 
wide changes in chromatin organisation in response to adipogenic differentiation 
(Sarusi Portuguez et al., 2017, Siersbaek et al., 2011, Siersbaek et al., 2014, 
Siersbaek et al., 2017). For example, DNase-Seq has been used to map sites of open 
chromatin, which are indicative of enhancer regions, during 3T3-L1 adipogenic 
differentiation (Siersbaek et al., 2011). This revealed extensive chromatin remodelling 
which could be grouped into four distinct temporal profiles (Siersbaek et al., 2011). 
These profiles consisted of; sites which are induced early in adipogenesis and remain 
open, sites transiently induced 4 hours after induction, sites transiently induced 24 
hours after induction and sites which open late in adipogenesis (Siersbaek et al., 
2011). In addition, multiple transcription factors have been shown to bind 
cooperatively at transcription factor hotspots during adipogenesis (Siersbaek et al., 
2014). Finally, it has been shown that genome reorganisation takes place during 
adipogenesis and that the factor RXR is central to genome reorganisation at the 
beginning of adipogenesis (Sarusi Portuguez et al., 2017). In summary, as well as 
leading to changes in gene expression, the adipogenic pathway also causes 
extensive changes in chromatin remodelling.  
 
1.2.3 - Pparg and Cebpa act together as master regulators of 
adipogenesis  
Cebpa and Pparg are master regulators of adipogenesis and act cooperatively 
to bring about adipogenesis (Linhart et al., 2001). Cepba and Pparg are also the best 
studied regulators of adipogenesis (Linhart et al., 2001). Cebpa is a basic leucine 
zipper transcription factor which is most abundantly expressed in adipose tissue, the 
liver and the placenta (Linhart et al., 2001). Cell culture studies have also shown that 
Cebpa expression can trigger the differentiation of preadipocytes into mature 
adipocytes, though this requires Pparg expression (Linhart et al., 2001). PPARG is a 
nuclear receptor which heterodimerises with RXRA (Retinoid X receptor alpha) and 
binds DR1 (direct repeat 1) sites in the DNA (Lefterova et al., 2008). The DR1 site is 
a direct repeat of the AGGTCA element, conserved to various degrees and separated 
by a single nucleotide (Lefterova et al., 2008). Pparg has been found to be both 
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necessary and sufficient for adipogenesis in vitro (Lefterova et al., 2008). PPARG and 
CEBPA have also been found to bind adjacent sites during adipogenesis (Lefterova 
et al., 2008). A 2008 study used ChIP followed by DNA hybridisation to whole genome 
tilling array to determine the PPARG binding sites in the 3T3-L1 preadipocyte cell line 
(Lefterova et al., 2008). 5299 PPARG binding sites were identified and consensus 
CEBP binding motifs were found in the vicinity of over 90% of these sites (Lefterova 
et al., 2008). Furthermore, examination of PPARG and CEBPA binding sites near 
genes upregulated during differentiation revealed that 60% of genes were bound by 
both factors, 3% of genes were bound by PPARG only and 25% of genes were bound 
by CEBPA only (Lefterova et al., 2008). Together this demonstrates that Pparg and 
Cepba are key factors required for adipogenesis and that they act cooperatively to 
drive adipogenic differentiation.  
 
1.2.4 - Pparg, a master regulator of adipogenesis, influences adipose 
morphology and expansion in vivo 
In addition to regulating adipogenesis in vitro, Pparg has also been shown to 
regulate adipogenesis in vivo. Whole body Pparg knockout mice are embryonic lethal, 
due to defects in placental function (Barak et al., 1999). Therefore, adipose tissue 
specific Pparg knockout mice have been generated to investigate the function of 
Pparg in adipose tissue expansion in vivo (Wang et al., 2013a). A study by Wang et 
al (2013) generated adipose specific Pparg knockout mice by crossing Pparg floxed 
mice to an Adipoq-Cre line. The Adipoq-Cre line is driven by the regulatory region of 
adiponectin and so expression is limited to adipocytes (Wang et al., 2013a). The 
knockout mice were found to have a near complete loss of adipose tissue and the few 
adipocytes which were present were found to be vastly enlarged (Figure 1.7A) (Wang 
et al., 2013a). In addition, the knockout mice were observed to have enlarged livers, 
with substantial lipid accumulation and were also found to be insulin resistant (Wang 
et al., 2013a). These findings are in line with observations from humans, in which 
dominant negative mutations in PPARG have been associated with severe insulin 
resistance and diabetes (Barroso et al., 1999). In summary, Pparg signalling can 
modulate adipose morphology and thereby impact insulin signalling.  
Pparg overexpression has also been shown to impact adipogenesis in vivo 
(Sugii et al., 2009). In order to investigate the role of Pparg in adipogenesis, a 
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transgenic mouse which expressed a dominant active form of Pparg was generated 
(Sugii et al., 2009). The mouse expressed a VP16 PPARG fusion protein, which was 
created by fusing the activation domain of the herpes simplex virus VP16 protein to 
PPARG (Saez et al., 2004, Sugii et al., 2009). The resultant protein was capable of 
regulating Pparg target genes independent of ligand and was under the control of an 
AP2 promoter (Sugii et al., 2009). The AP2 promoter drives expression only in 
adipocytes and pre-adipocytes and so expression of the dominant active protein was 
restricted to adipose tissue (Sugii et al., 2009). The transgenic mice were found to 
exhibit normal growth and AT development but adipocytes in WAT were found to have 
a more hyperplastic morphology than those of WT mice (Figure 1.7B) (Sugii et al., 
2009). Furthermore, the transgenic mice had lower fasting glucose levels and 
enhanced insulin sensitivity, following a high fat diet (Sugii et al., 2009). Taken 
together this demonstrates that Pparg signalling can modulate adipose morphology 
and improve insulin sensitivity, thereby providing proof of principle that modulation of 
adipose morphology can improve systemic metabolic health.  
 
1.2.5 - A key regulator of adipogenesis, Cebpa, can alter adipose levels 
in vivo 
Similarly to Pparg, Cebpa can also influence adipogenesis in vivo. Whole body 
Cebpa knockout mice die shortly after birth due to severe hypoglycaemia, caused by 
defects in liver development (Flodby et al., 1996, Wang et al., 1995). To overcome 
this problem, a study by Linhart et al (2001) generated a transgenic mouse model in 
which Cebpa expression was restricted to the liver. A transgenic line in which Cebpa 
is expressed under the albumin promoter was generated and crossed to the Cebpa 
knockout line (Linhart et al., 2001). This produced a mouse in which Cebpa was 
expressed only in hepatocytes and improved the survival of the Cebpa knockout mice 
almost 3 fold (Linhart et al., 2001). When the knockout mice were examined no WAT 
was found, demonstrating that Cebpa is required for the commitment of preadipocytes 
to white adipocytes (Figure 1.7C) (Linhart et al., 2001). Serum insulin levels were 
found to be increased, despite normal glucose levels, suggestive of peripheral insulin 
resistance (Linhart et al., 2001). In summary, Cebpa seems to be essential for the 
development of mature white adipocytes in vivo and perturbation of Cebpa signalling 




Figure 1.7 – Pparg and Cebpa influence adipose tissue levels in vivo. A. H&E 
stain of WAT. Con (Control littermates) FKO (AT specific Pparg knock out). I shows 
inguinal WAT. G shows gonadal WAT. Stars show the presence of very large 
adipocytes. Adapted from (Wang et al., 2013a). B. H&E stain of WAT from adipose 
specific Pparg overexpression mice. TG (Transgenic) Adapted from (Sugii et al., 
2009). C. Macroscopic absence of WAT in the interscapular region of 7 day old 
transgenic knockout mice and Oil red O staining of WAT in the dermis. Adapted from 
(Linhart et al., 2001). 
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1.2.6 – Project Aim - Identification of novel genes which control AT 
expansion and AT morphology 
The network of transcription factors which control adipogenesis in cell line 
models is well described (Siersbaek et al., 2012). From this work two key regulators 
of adipogenesis have emerged, Pparg and Cebpa (Siersbaek et al., 2012). Further in 
vivo studies have shown that both genes are required for adipose tissue expansion 
and can influence systemic metabolic health (Linhart et al., 2001, Wang et al., 2013a). 
In addition, Pparg overexpression studies have shown Pparg to be capable of 
modulating adipose morphology and improving insulin sensitivity (Sugii et al., 2009). 
Taken together this provides proof of principle that alterations in adipose expansion 
and adipose morphology can influence systemic metabolic health. As Pparg and 
Cebpa have been well studied in the context of AT expansion the aim of my thesis 
was to identify novel factors which influence adipose expansion and adipose 
morphology. In doing this I have identified the gene Foxp1 (Forkhead box P1) and 
this gene is the main focus of my thesis.  
 
1.2.7 - Genome wide association studies are used to identify novel genes 
associated with complex traits and disease  
Data from genome wide association studies (GWAS) can be used to identify 
novel genes which may regulate adipose tissue expansion and morphology. GWAS 
studies are often used to look for associations between genetic variation and specific 
traits or diseases (Visscher et al., 2012). GWAS studies use single nucleotide 
polymorphisms (SNPs) as a marker of a region in which genetic variation is 
associated with a specific trait or disease (Nica and Dermitzakis, 2013). However, the 
SNP itself will often not be responsible for the observed association and instead marks 
a region of the genome which contains many more SNPs, each of which may be 
responsible for the observed association (Nica and Dermitzakis, 2013). Therefore, 
further testing is required to identify the causal SNP and any resultant gene 
expression changes (Nica and Dermitzakis, 2013). Overall GWAS studies have the 
power to identify novel genes associated with specific traits and diseases.  
GWAS studies are particularly useful when looking at the genetic causes of 
complex diseases and traits such as obesity or BMI (Manolio et al., 2009). Both 
obesity and BMI are polygenic traits influenced by many genes (Manolio et al., 2009). 
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For example, many genes are thought to influence body weight, with the total number 
of genes which have a small effect on body weight predicted to exceed 100 (Hinney 
et al., 2010). In recent years GWAS studies have identified many loci associated with 
BMI, with variants often found within non-coding regions (Speakman et al., 2018). 
One example of this is the FTO gene, which was identified by a GWAS study in 2007 
as being associated with BMI, and with genetic variation at the FTO loci being linked 
to food intake (Speakman et al., 2018). Therefore, GWAS studies can identify novel 
candidate genes which may influence adipose tissue expansion.     
 
1.2.8 - Multiple genome wide association studies have found that genetic 
variation at the FOXP1 locus is associated with altered body weight  
GWAS studies have been used to identify genetic variation associated with 
BMI (Hoffmann et al., 2018, Kichaev et al., 2019, Speakman et al., 2018). For 
example, a study in 2019 looked at the genetic variation associated with BMI (Kichaev 
et al., 2019). This study used data from the UK Biobank to identify novel associations 
between genotype and complex traits in 459,000 individuals (Kichaev et al., 2019). 
One association found was between genetic variation at the FOXP1 locus and BMI 
(Figure 1.8B) (Kichaev et al., 2019). This was not the only study to find that genetic 
variation at the FOXP1 locus is associated with adiposity traits, as an earlier study in 
2012 found a similar association (Fox et al., 2012). This study looked at the genetic 
variation associated with levels of subcutaneous and visceral adipose tissue and used 
a smaller sample size of 5560 women and 4997 men of European ancestry (Fox et 
al., 2012). Computed tomography was used to measure abdominal adipose depots 
and an association between variation at the FOXP1 locus and levels of SAT was 
found (Fox et al., 2012). Finally, a GWAS study in 2019 looking at the genetic variation 
associated with Anorexia Nervosa also found an association with the FOXP1 locus 
(Figure 1.8A) (Watson et al., 2019). Anorexia is characterised primarily by a very low 
BMI and the 2019 study used 16,992 cases and 55,525 controls, all of European 
ancestry, to look for associations between genetic variation and anorexia nervosa 
(Watson et al., 2019). Genetic variation at 8 loci were found to be associated with 
anorexia, and one of these loci was found within an intron of the FOXP1 gene (Figure 
1.8A) (Watson et al., 2019). In summary, three independent GWAS studies have 
found that variation at the FOXP1 locus is associated with traits related to body 
31 
 
weight. These studies therefore suggest that FOXP1 may play a role in controlling 





















Figure 1.8 – GWAS studies have identified genetic variation at the FOXP1 locus 
associated with body weight. A. SNP in intron 2 of the FOXP1 gene associated with 
anorexia nervosa, identified (Watson et al., 2019). B. SNPs upstream of FOXP1 
associated with BMI, identified by (Kichaev et al., 2019). Figure created using UCSC 















1.2.9 - FOXP1 mRNA levels are positively associated with BMI  
In addition to GWAS data, data from other studies have implicated FOXP1 in 
the control of body weight and adipose levels (Civelek et al., 2017). Data from the 
2017 METSIM (Metabolic Syndrome in Men) study found that FOXP1 mRNA levels 
in SAT are positively associated with both BMI (P = 1.20x10-10) and increased waist-
hip ratio (P = 7.76x10-4) (Civelek et al., 2017). The study by Civelek et al (2017) took 
subcutaneous adipose tissue from 770 extensively phenotyped Finish men of the 
METSIM study and measured mRNA levels. FOXP1 mRNA levels in SAT were also 
associated with increased insulin levels (P = 3.15x10-3), increased proinsulin levels 
(P = 7.27x10-3), decreased Matsuda insulin sensitivity index (P = 1.26x10-3), 
decreased adiponectin (P = 7.68x10-4), decreased HDL cholesterol (P = 3.13x10-5) 
and increased blood triglycerides (P = 5.15x10-4) (Civelek et al., 2017). In summary, 
FOXP1 expression levels in SAT are associated with increased body weight and 
adverse metabolic outcomes.  
 
1.2.10 - Foxp1 is a transcription factor which belongs to the Fox family  
Foxp1 or Forkhead Box P1 is a transcription factor which belongs to the Fox 
family of genes (Figure 1.9A) (Hannenhalli and Kaestner, 2009). The Fox family is an 
ancient family of genes, which are found in species ranging from yeast to humans 
(Hannenhalli and Kaestner, 2009). The unifying feature of all FOX proteins is the 
roughly 100 residue forkhead DNA binding domain, which is highly conserved across 
all members of the family (Hannenhalli and Kaestner, 2009). The conservation of the 
DNA binding domain between orthologous family members is striking, with the 
drosophila melanogaster and human FOXA1 DNA binding domains showing 90% 
similarity (Hannenhalli and Kaestner, 2009). The forkhead domain (FHD) itself is 
formed of three alpha helices (H), three beta sheets (S) and two wing regions (W) 
which flank the third beta sheet (Figure 1.9A) (Hannenhalli and Kaestner, 2009). The 
structure of this region when bound to DNA adopts a butterfly like winged shape, and 
this has led to the FHD to also be termed the winged helix domain (Hannenhalli and 
Kaestner, 2009). Foxp1 therefore belongs to a large family of genes, which are 




1.2.11 - Foxp1 is expressed throughout the body    
The mouse Foxp1 gene was first identified in 2001 during a screen for new 
Fox family members, performed on a mouse lung cDNA library (Shu et al., 2001). 
Since then it’s expression has been described in multiple tissues during development, 
including in neural, intestinal and cardiovascular tissues (Shu et al., 2001). FOXP1 is 
also widely expressed in adult tissues (Fagerberg et al., 2014). The Genotype-Tissue 
Expression (GTEx) project, which used RNA Seq to classify tissue specific expression 
of genes across all major human organs and tissues, found that FOXP1 is widely 
expressed across human tissues (Figure 1.9B) (Fagerberg et al., 2014). FOXP1 was 
found to be expressed in the adrenal gland, bone marrow, brain, colon, adipose, heart, 
kidney, liver, lung, pancreas, prostate, skin, spleen, stomach, ovary, testis and 
bladder (Figure 1.9B) (Fagerberg et al., 2014). Highest expression was found in the 
lung, ovary and prostate (Fagerberg et al., 2014). Of note is the expression of FOXP1 
in adipose tissue, which has also been shown in mice (Figure 1.9C) (Fagerberg et 
al., 2014, Liu et al., 2019). In summary, Foxp1 is widely expressed and is expressed 


















Figure 1.9 – Foxp1 is a transcription factor which is expressed throughout the 
body. A. The 3D structure of the FOXP1 DNA binding domain. The alpha helices (H) 
and Beta sheets (S) are shown. Adapted from (Chu et al., 2011). B. Schematic 
showing the human expression of FOXP1. Expression data was taken from GTex 
(Fagerberg et al., 2014) and the schematic was produced using Biorender. C. H&E 
and immunostaining of SAT from mice. Dapi staining is shown in blue and FOXP1 






1.2.12 - Foxp1 drives the proliferation and differentiation of progenitor 
cells  
Variation at the FOXP1 locus has been associated with BMI and body weight, 
suggesting that FOXP1 may be a novel gene which influences adipose tissue 
expansion (Kichaev et al., 2019, Watson et al., 2019). FOXP1 is a transcription factor 
which is known to be expressed in adipose tissue (Fagerberg et al., 2014). However, 
it is unknown if FOXP1 acts on adipose tissue to bring about transcriptional changes 
which influence adipose tissue expansion. The known roles of Foxp1 in other tissues 
provide insights into how Foxp1 may influence adipose tissue expansion. For 
example, Foxp1 is known to have roles in progenitor cells. Therefore, Foxp1 may act 
in progenitor cells to influence adipose tissue expansion.  
Foxp1 is known to drive the proliferation and differentiation of progenitor cells 
in multiple tissues (Fu et al., 2018, Gabut et al., 2011, Hu et al., 2006, Leishman et 
al., 2013, Li et al., 2017). For example, Foxp1 has been shown to maintain 
multipotency in mammary gland stem cells (Fu et al., 2018). Mice with loss of Foxp1 
expression in the mammary gland showed stunted mammary gland development, 
suggesting that Foxp1 is required for the differentiation of mammary stem cells into 
specialised cells types (Fu et al., 2018). Foxp1 has also been shown maintain the 
proliferation of embryonic stem cells (ESCs), with an alternative splicing event in 
Foxp1 found to be active in ESCs (Gabut et al., 2011). This alternative splicing event 
was found to stimulate the expression of pluripotency genes and to repress the 
expression of genes involved in lineage specification and differentiation (Gabut et al., 
2011). Finally, Foxp1 has been shown to drive progenitor cell proliferation and 
differentiation in bone marrow mesenchymal stem cells (MSCs) (Li et al., 2017). In 
this study, MSCs were isolated from the bone marrow of Foxp1 bone marrow MSC 
specific knockout mouse and were found to have decreased osteogenic differentiation 
in culture and a reduced ability to expand (Li et al., 2017). This suggests that Foxp1 
is required to maintain the proliferation of bone marrow MSCs. Taken together these 
data show that Foxp1 drives the proliferation and differentiation of progenitor cells 
from multiple tissues and suggests a clear mechanism by which Foxp1 could influence 




1.2.13 - Foxp1 influences adipose tissue expansion and controls 
brown/beige adipocyte differentiation  
Whole body Foxp1 knockout mice could provide additional information on 
whether Foxp1 influences adipose tissue expansion. However, when a whole body 
Foxp1 mouse knockout was generated in 2004, it was found to be embryonic lethal 
due to defects in heart development (Wang et al., 2004). Homozygous mutants were 
found to die at embryonic day E14.5 and displayed several signs of cardiovascular 
failure, such as oedema, perivascular haemorrhage, and a slower heart rate than WT 
litter mates (Wang et al., 2004). The homozygous mutants also died before the 
development of adipose tissue and so leave open the question of whether Foxp1 is 
required for adipose tissue expansion. The study also highlights the fact that Foxp1 
is a widely expressed transcription factor and will play many roles in different tissues. 
In summary whole body Foxp1 knockout mice die before the development of adipose 
tissue and so do not provide clues as to whether Foxp1 is required for adipose tissue 
expansion.  
Evidence exists to suggest that Foxp1 is important for adipose tissue 
expansion (Liu et al., 2019). A recent study examining the role of Foxp1 in 
brown/beige adipocyte differentiation found that loss of Foxp1 expression in white 
adipose tissue led to smaller adipose tissue depots (Figure 1.10) (Liu et al., 2019). 
The study by Liu et al (2019) generated two adipose specific Foxp1 knockout mice 
lines. The lines were generated by crossing Foxp1 floxed mice to aP2 Cre mice, in 
which Cre is expressed by adipocytes and adipose progenitors, and by crossing to 
adiponectin Cre mice, in which Cre is expressed by adipocytes (Liu et al., 2019). Both 
strains of mice were found to have smaller brown and white AT depots and were found 
to gain less weight in response to an eight week high fat diet (Figure 1.10A. B. C. & 
D) (Liu et al., 2019). Together this suggests that Foxp1 is required for AT expansion. 
However, the study focused on brown and beige adipose tissue expansion and how 
Foxp1 influenced WAT expansion was not investigated (Liu et al 2019). In summary 
the study by Liu et al (2019) suggests that Foxp1 is required for AT expansion, though 







Figure 1.10 – Foxp1 is required for the expansion of WAT. A. Reduced size of 
sWAT depot in Foxp1Ad
Δ/Δ mice. sWAT (subcutaneous WAT). Scale bar is 2 cm. B. 
Foxp1Ad
Δ/Δ mice gain less weight in response to a high fat diet. C. Reduced size of 
sWAT depot in Foxp1aP2
Δ/Δ mice. sWAT (subcutaneous WAT). Scale bar is 1 cm D. 
Foxp1aP2
Δ/Δ mice gain less weight in response to a high fat diet. Figure adapted from 









1.2.14 - The Foxp subfamily shows divergent DNA binding to the Fox 
family   
Foxp1 belongs to the Fox gene family, which is comprised of multiple 
subfamilies (Figure 1.11A) (Hannenhalli and Kaestner, 2009). The Foxp subfamily 
has four members, Foxp1, Foxp2, Foxp3 and Foxp4, and is considered one of the 
most distantly related Fox family members (Figure 1.11A) (Wang et al., 2003). Like 
other Fox family members, the FHD of FOXP proteins is also made up of three alpha 
helices (H), three beta sheets (S) and two wing regions (W) (Figure 1.9A) (Medina et 
al., 2016). In most FOX proteins the first wing, which connects Beta-sheets 2 and 3, 
is a 5-7 amino acid sequence, however this sequence is truncated in the Foxp 
subfamily (Stroud et al., 2006). The sequence of wing 2 is also diverged in the Foxp 
subfamily and the heightened variability of these regions suggests that the wings may 
have specialised functions within each subfamily (Stroud et al., 2006). The FHD of 
Foxp1 may therefore recognise a slightly different DNA sequence than other Fox 
family members. This suggests that the transcriptional changes brought about from 
FOXP1 binding DNA will differ from those caused by other FOX family members.  
The divergent nature of the FHD in the Foxp subfamily suggests that FOXP 
proteins may bind DNA differently to other Fox family members. In addition to its FHD 
domain, FOXP1 also contains a N-terminal zinc finger domain (Wang et al., 2003). 
Zinc finger domains function as interaction domains and can bind DNA, RNA or 
proteins (Wang et al., 2003). Consequently, unlike most Fox family members which 
bind DNA as a monomer, Foxp1 is known to bind DNA as a dimer (Stroud et al., 
2006). Although Foxp1 exists as both a monomer and dimer in solution, dimerization 
has been found to be essential for DNA binding with Foxp1 forming both homodimers 
and heterodimers with other Foxp subfamily members (Li et al., 2004). It has been 
suggested that this manner of dimerization would allow both copies of Foxp1 to bind 
DNA simultaneously and that FOXP1 proteins may loop DNA or mediate 
interchromosomal interactions (Stroud et al., 2006). In summary FOXP1 proteins bind 
DNA as dimers and therefore it is important to consider the normal binding partners 






1.2.15 - Foxp1 acts as a transcriptional repressor  
Foxp1 is a transcription factor which acts as a transcriptional repressor (Li et 
al., 2004). A luciferase reporter assay was used to show that Foxp1 confers 
transcriptional repression (Figure 1.11B) (Li et al., 2004). Expression vectors 
containing full length Foxp1, Foxp2, and Foxp4 cDNAs were cotransfected into lung 
epithelial cells with a pCC10.luc reporter (Li et al., 2004). The mouse CC10 promoter 
contains a FOX protein consensus DNA binding site and is active in lung epithelial 
cells (Li et al., 2004). On contransfection, activity of the mouse CC10 promoter was 
significantly repressed (Figure 1.11B) (Li et al., 2004). Activity of a CMV promoter, 
which does not contain a FOX consensus site, was not affected (Figure 1.11B) (Li et 
al., 2004). Together this shows that Foxp1 acts as a transcriptional repressor.  
 
1.2.16 - Foxp1 interacts with members of the adipogenic network  
Foxp1 is a transcriptional repressor and has been shown to interact with 
multiple transcription factors in multiple tissues (Li et al., 2004, Li et al., 2017). Of 
interest, Foxp1 has been shown to interact with transcription factors known to control 
adipogenesis (Li et al., 2017). Coimmunoprecipitation assays in the 3T3-L1 cell line 
have shown that FOXP1 interacts with both CEBPB and CEBPD (Figure 1.11C) (Li 
et al., 2017). Cebpb and Cebpd are both active early in the adipogenic pathway and 
activate a master regulator of the process, Pparg (Li et al., 2017). It has also been 
shown that Foxp1 can repress Pparg expression (Figure 1.11D) (Li et al., 2017). 
C3H10T1/T2 cells, which are functionally similar to MSCs, were transfected with 
plasmids expressing CEBPB and CEBPD and Pparg-luciferase activity measured 
(Figure 1.11D) (Li et al., 2017). Coexpression of FOXP1 significantly reduced 
luciferase activity, showing that Foxp1 can repress Cebpb/Cebpd transactivation of 
Pparg (Figure 1.11D) (Li et al., 2017). Furthermore, it has been suggested that Foxp1 
can directly repress Pparg (Li et al., 2017). A FOXP1 consensus binding site has been 
identified upstream of the Pparg transcriptional start site and ChIP-PCR has been 
used to show that there is strong FOXP1 binding at this site (Li et al., 2017). Taken 
together this suggests that FOXP1 binds to and represses the expression of known 
drivers of adipogenesis. The binding partners of FOXP1 in adipose tissue and the 
effect of Foxp1 on known regulators of adipogenesis should therefore be taken into 




Figure 1.11 - Foxp1 acts as a transcriptional repressor. A. Phylogenetic tree 
showing the Fox family of transcription factors. The Foxp transcription factors are 
highlighted by the red box. Numbers represent bootstrap values. Adapted from 
(Hannenhalli and Kaestner, 2009). B. Luciferase reporter assay showing Foxp1 acts 
as a transcriptional repressor. Adapted from (Li et al., 2004). C. 
Coimmunoprecipitation of FOXP1-His and with CEBPB-Flag or CEBPD Flag, 
following transfection into 3T3-L1 cells. Adapted from (Li et al., 2017). D. Luciferase 
reporter assay in C3H10T1/T2 cells, n = 3. Adapted from (Li et al., 2017).  
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1.3 - Zebrafish as a model of adipose tissue expansion  
 
Adipose tissue in zebrafish was first described by Song and Cone in 2007 
(Song and Cone, 2007). In the years since then much has been learnt about adipose 
tissue in zebrafish and zebrafish have emerged as a useful model through which to 
study adipose tissue. It is now known that zebrafish possess adipose tissue which is 
anatomically, morphologically, and molecularly homologous to that of mammalian 
white adipose tissue (Flynn et al., 2009, Imrie and Sadler, 2010, Minchin and Rawls, 
2017b). It is the presence of this homologous adipose tissue combined with unique 
features of the zebrafish, such as the ability to perform in vivo imaging, that make 
zebrafish an exciting model to study adipose tissue. In this section, I outline the 
current understanding on adipose tissue development and function in zebrafish and 
provide a rationale for using zebrafish to investigate the hypothesis that foxp1 
maintains progenitor cell populations in AT and is required for AT expansion.   
 
1.3.1 - Zebrafish are a widely used model organism in biomedical 
research  
Zebrafish (Danio rerio) are a species of small freshwater fish, native to south 
Asia. Zebrafish have been used in scientific research since the 1960s but it is in the 
last 10-15 years that much of the research using zebrafish has taken place (Teame 
et al., 2019). Some of the main advantages of using zebrafish in research are their 
high fecundity, external fertilisation, rapid development and transparent embryos 
(Lieschke and Currie, 2007). Other advantages include, the availability of a fully 
sequenced zebrafish genome and the relative ease of genetic manipulation (Lieschke 
and Currie, 2007). Zebrafish are also vertebrates and so contain structures and organ 
systems important in human disease (Lieschke and Currie, 2007). 70% of zebrafish 
genes are conserved to humans and 84% of genes known to be associated with 
human disease have an orthologous gene in zebrafish (Teame et al., 2019). Together 
these features make zebrafish a useful research tool and zebrafish have been used 
to study a wide range of topics, including organ development, cancer, and heart 
regeneration (Drummond and Davidson, 2016, Gonzalez-Rosa et al., 2017, White et 
al., 2013). In summary zebrafish are a useful model organism and have been used to 
study a wide range of biomedical questions.   
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1.3.2 - Adipose tissue in zebrafish is morphologically homologous to 
mammalian white adipose tissue  
An emerging area of zebrafish research is the study of adipose tissue, and 
adipose tissue in zebrafish is known to be morphologically homologous to mammalian 
white adipose tissue (Flynn et al., 2009, Imrie and Sadler, 2010). One of the first 
studies to identify WAT in zebrafish used a combination of histological sectioning, lipid 
staining with Oil Red O and analysis of cell morphology to identify zebrafish WAT 
(Imrie and Sadler, 2010). The morphology of mammalian white adipocytes is very 
distinctive and zebrafish adipocytes appear to share this morphology. Zebrafish 
adipocytes have been described as cells containing a singular lipid droplet, a small 
amount of cytoplasm and a peripheral nucleus (Imrie and Sadler, 2010). Although the 
presence of a singular lipid droplet is a defining characteristic of mature mammalian 
adipocytes, the presence of multiple small lipid droplets is a hallmark of early terminal 
differentiation of mammalian adipocytes (Figure 1.12A) (Flynn et al., 2009). The 
presence of multiple lipid droplets has also been observed in zebrafish adipocytes, 
through the use of electron microscopy (Figure 1.12A) (Flynn et al., 2009). Another 
defining characteristic of mammalian white adipocytes is their large size (Ma et al., 
2015). Zebrafish adipocytes are also large in size and have been found to exceed 100 
µm in diameter (Flynn et al., 2009). Finally, ultrastructural analysis has shown that 
zebrafish adipocytes are metabolically active and show enrichment in filamentous 
mitochondria and caveolae (Figure 1.12A) (Flynn et al., 2009). These features are 
again reminiscent of mammalian adipocytes. Taken together this data demonstrates 
that zebrafish adipocytes are morphologically homologous to mammalian white 
adipocytes.  
 
1.3.3 - Adipose tissue in zebrafish is functionally homologous to 
mammalian white adipose tissue  
In addition to being morphologically homologous to mammalian white adipose 
tissue, zebrafish adipose tissue is also functionally homologous to mammalian white 
adipose tissue. In mammals adipose tissue acts as a dynamic energy store, storing 
lipid in times of energy excess and mobilising lipid in times of energy deficit (Ma et al., 
2015). Adipose tissue in zebrafish has also been shown to act as an energy store and 
zebrafish have been shown to mobilise lipid from adipose tissue (Figure 1.12B) 
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(Flynn et al., 2009). A study in 2009 starved zebrafish and monitored adipose tissue 
levels using Nile Red staining (Figure 1.12B) (Flynn et al., 2009). Nile Red stains the 
neutral lipid within adipose tissue (Flynn et al., 2009). It was found that Nile Red 
staining decreased on starvation, suggesting that lipid had been mobilised and used 
as an energy source (Figure 1.12B) (Flynn et al., 2009). Conversely, it has also been 
shown that adipose tissue in zebrafish increases in size in response to energy excess 
(Oka et al., 2010). Oka et al (2010) placed zebrafish on an eight week high fat diet 
and monitored their response by measuring body weight (Figure 1.12C). The 
zebrafish were fed the freshly hatched nauplii of brine shrimp, Artemia, which have a 
relatively high fat content (Oka et al., 2010). The control diet group was fed enough 
Artemis to meet their calorie requirements, while the high fat diet group was overfed 
(Oka et al., 2010). Following the diet, the high fat diet group were found to have a 
significantly greater BMI than the control diet group, suggesting that these fish had 
increased levels of AT and were using AT as an energy store (Figure 1.12C) (Oka et 
al., 2010). Other more recent studies, which use Nile Red to measure AT levels 
directly, have also shown that a high fat diet in zebrafish leads to increased levels of 
AT (Minchin and Rawls, 2017b). In summary, adipose tissue in zebrafish acts as an 
energy store and is functionally similar to mammalian white adipose tissue.     
 
1.3.4 - Adipose tissue in zebrafish is molecularly homologous to 
mammalian white adipose tissue  
The genetic regulation of adipose tissue appears to be conserved to zebrafish. 
For example, many genes known to be expressed in mammalian white adipose tissue 
are also expressed in zebrafish adipose tissue. The master regulator of mammalian 
adipogenesis, pparg, is known to be expressed in zebrafish (Flynn et al., 2009). in 
situ hybridisations have demonstrated that, like in mammals, pparg is expressed by 
adipocytes in zebrafish (Figure 1.12D) (Flynn et al., 2009, Imrie and Sadler, 2010). 
Unlike pparg, which is widely expressed, the gene fabp4 is known to be expressed 
exclusively in adipose (Flynn et al., 2009). Zebrafish possess two orthologs of Fabp4, 
fabp11a and fabp11b, and in situ hybridisations have shown that fabp11a is 
expressed in zebrafish adipocytes (Figure 1.12D) (Flynn et al., 2009). Transcription 
factors important for the control of adipogenesis in mammals, such as cepba and 
cebpb, have also been found to be expressed in zebrafish adipose tissue (Imrie and 
Sadler, 2010). Finally, qPCR was used to show that the hormones adiponectin and 
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adipsin, which are expressed by mammalian AT, are expressed in zebrafish AT (Imrie 
and Sadler, 2010). Together this suggests that zebrafish AT expresses many of the 









Figure 1.12 – Zebrafish AT is morphologically, functionally and molecularly 





Figure 1.12 – Zebrafish AT is morphologically, functionally and molecularly 
homologous to mammalian AT. A. Electron microscopy images showing that 
zebrafish AT is morphologically homologous to mammalian AT.  Asterisks show lipid 
droplets. Arrow heads show caveolae. Sb (swim bladder). In (intestinal tract) Scale 
bar is 100 µm in top left panel, 200 nm in top right panel and 1 µm in bottom panel. 
Adapted from (Flynn et al., 2009). B. Nile red images showing decreased Nile Red 
staining in response to starvation. Scale bar is 1 mm.  Adapted from (Flynn et al., 
2009). C. Graphs showing increase in BMI of zebrafish over-fed compared to normally 
fed fish. Adapted from (Oka et al., 2010). D. In situ hybridisations showing expression 
of pparg and fabp11a in adipose tissue. Adipose tissue is shown by Nile red staining 


















1.3.5 - Adipose tissue in zebrafish is anatomically homologous to 
mammalian white adipose tissue and the development of zebrafish 
adipose tissue has been mapped.  
Adipose tissue in zebrafish is found in discrete depots, much like in mammals 
(Minchin and Rawls, 2017b). A comprehensive classification of zebrafish adipose 
depots exists and shows zebrafish to possess 34 regionally distinct AT depots (Figure 
1.13A) (Minchin and Rawls, 2017b). This system classified depots by anatomical 
location, with depots classified as internal AT and subcutaneous AT (Figure 1.13A) 
(Minchin and Rawls, 2017b). Internal AT was also further broken down into visceral 
AT and non-visceral AT (Figure 1.13A) (Minchin and Rawls, 2017b). Overall adipose 
tissue in zebrafish is anatomically conserved, with adipose found in discrete depots.  
The zebrafish AT depot classification system also provides a list of 
developmental milestones, detailing when during development AT depots are likely to 
be present (Minchin and Rawls, 2017b). Imrie and Sadler (2010) first reported that AT 
development in zebrafish is controlled by both fish size and time. However, more 
recent work by Minchin and Rawls (2017) has provided a more comprehensive 
timeline of adipose tissue development in zebrafish. The study used 362 fish between 
20 and 39 dpf (days post fertilisation) and created regression models, so that AT size 
could be predicted across a range of postembryonic fish (Minchin and Rawls, 2017b). 
The appearance of new AT depots was used to define discrete milestones and 26 
milestones were identified (Minchin and Rawls, 2017b). It was found that, while 
increase in adipose tissue area remained steady throughout the dataset, growth of 
individual depots showed distinct trajectories (Minchin and Rawls, 2017b). This led to 
the development of models of growth for each depot and provided a tool through 
which deviation from normal AT growth could be assessed (Minchin and Rawls, 
2017b). In summary, adipose tissue in zebrafish is found in discrete depots and a 
detailed timeline of normal AT growth exists.  
 
1.3.6 - Lipophilic dyes can be used to stain adipose tissue in zebrafish  
Adipose tissue in zebrafish was first identified using histological sectioning and 
staining (Imrie and Sadler, 2010). These methods are often used when analysing 
mammalian WAT, however this can lead to incomplete preservation of WAT 
architecture and provides limited information on cellular dynamics (Xue et al., 2010). 
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Fortunately, the nature of zebrafish makes them well suited to overcome the 
challenges of imaging WAT in mammals. A dye commonly used to stain adipose 
tissue in zebrafish is Nile Red (Flynn et al., 2009). Nile Red stains neutral lipid and so 
will stain the lipid found within adipocytes but will not stain polarised lipid, such as that 
found in cell membranes (Flynn et al., 2009). This staining can be used in live 
zebrafish and the small size of zebrafish means that it can be used to measure whole 
body adiposity (Flynn et al., 2009). Furthermore, Nile Red staining and measurement 
of fluorescence area have been shown to be a good proxy for total AT area (Tingaud-
Sequeira et al., 2011). Tingaud-Sequeira et al (2011) demonstrated that there is a 
good correlation between the fluorescence area stained by Nile Red and the total 
triglyceride content of a fish. In addition to Nile Red other fluorescent dyes can be 
used to stain AT in zebrafish (Figure 1.13B) (Minchin and Rawls, 2011, Minchin and 
Rawls, 2017a). Detailed methods also exist for the imaging of live zebrafish using 
both a stereomicrosope and a confocal microscope (Figure 1.13B) (Minchin and 
Rawls, 2011, Minchin and Rawls, 2017a). In summary techniques exist which allow 

















Figure 1.13 – Zebrafish AT is anatomically homologous to mammalian WAT and 
can be imaged in vivo. A. Schematic showing the location of AT depots in zebrafish. 
Adapted from (Minchin and Rawls, 2017b). B. Zebrafish visceral AT stained with 
lipophilic dyes. The Tg(kdrl:mCherry) line expressed mCherry fluorescent protein in 
the endothelial cells of the vasculature.  Adapted from (Minchin and Rawls, 2011).  
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1.3.7 - The genetic control of adipose tissue development is conserved 
in zebrafish  
In addition to expressing similar genes to mammalian AT, zebrafish AT also 
appears to be under the same genetic control as mammalian AT. Evidence for this 
comes from growth hormone mutants. Energy metabolism and somatic growth are 
known to be closely linked in humans, with childhood obesity being linked to increased 
linear growth and undernutrition linked to growth retardation (McMenamin et al., 
2013). Conversely, altered levels of growth hormones (GH) have also been linked to 
changes in adiposity in mammals (McMenamin et al., 2013). GH deficient children are 
short and mildly obese and inactivation of GH in rodents leads to obesity, independent 
of food intake (McMenamin et al., 2013). This mammalian growth hormone deficient 
phenotype has also been observed in zebrafish (McMenamin et al., 2013). A study in 
2013 found that zebrafish GH mutants show severe growth defects and increased 
adiposity (Figure 1.14A & B) (McMenamin et al., 2013). The zebrafish mutants were 
also found to have significantly more AT than size matched WT fish and a more 
hypertrophic adipose morphology (Figure 1.14A & C) (McMenamin et al., 2013). The 
phenotype of GH deficient zebrafish seems to be very similar to that of GH deficient 
children and rodents and suggests that the genetic control of adipose tissue is 
conserved to zebrafish.  
 
1.3.8 - Zebrafish can be used as a tool to test if genes identified by human 
GWAS studies have a role in adipose tissue expansion 
Zebrafish can be used to test the role of novel genes involved in the regulation 
of AT expansion. In this thesis I have used zebrafish to investigate the role of the gene 
foxp1 in AT expansion. Zebrafish have previously been used to test if genes identified 
through human GWAS studies affect measures of adiposity. One example of this is 
the 2015 study by Minchin et al, which looked at the role of the gene plxnd1 (Plexin 
D1) in body fat distribution (Minchin et al., 2015). GWAS studies had implicated 
PLXND1 in body fat distribution and type 2 diabetes, however the role of PLXND1 in 
adiposity and insulin resistance was unknown (Minchin et al., 2015). The study made 
use of plxnd1 zebrafish mutants and found that these mutants had decreased levels 
of VAT, a more hyperplastic VAT morphology and improved glucose tolerance 
following a high fat diet (Figure 1.14D & E) (Minchin et al., 2015). In humans it was 
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discovered that there is a positive association between VAT PLXND1 mRNA levels 
and a more hypertrophic VAT morphology, and that PLXND1 mRNA is significantly 
increased in the VAT of obese patients with type 2 diabetes (Minchin et al., 2015). In 
conclusion it has been demonstrated that zebrafish can be used to elucidate the role 
of novel genes in adipose tissue distribution and that these findings can be relevant 
to human disease. Therefore, zebrafish are a suitable model in which to investigate 
the hypothesis that foxp1 maintains progenitor cell populations in AT and is required 
























Figure 1.14 – The genetic control of adipose tissue expansion is conserved to 
zebrafish. A. Nile red images of size matched WT and GH mutant zebrafish. Adapted 
from (McMenamin et al., 2013). B. Graph showing total lipid in WT and GH mutant 
zebrafish. Adapted from (McMenamin et al., 2013). C. Confocal imaging of LipidTOX 
stained SAT. Imaging from day 12 (d12) shown. Scale bar is 100 µm. Adapted from 
(McMenamin et al., 2013). D. Graph showing AT areas in WT and plxnd1 mutant 
zebrafish. Adapted from (Minchin et al., 2015). E. Maximum intensity projections of 
VAT stained with LipidTOX in WT and plxnd1 mutant zebrafish. Arrows point to EdU 








1.4– Hypotheses and Aims  
 
The overall aim of my thesis was to establish whether the genetic control of 
adipose tissue expansion is conserved between zebrafish and mammals, and to 
identify and test novel regulators of AT expansion using zebrafish as a model. The 
first part of this aim, to determine whether the genetic control of AT expansion is 
conserved between zebrafish and mammals, is addressed in chapter 5 and more 
specific aims and hypotheses relating to this aim are discussed below. The second 
part of my overall aim, to identify and test novel regulators of AT expansion, is 
addressed in chapters 3 and 4 and more specific aims and hypotheses are discussed 
below.  
 
1.4.1 – Aim 1 - Identification of factors which regulate adipose 
morphology and expansion 
The main driver of obesity associated disease risk is metabolic dysfunction. 
Metabolic dysfunction is characterised by dysfunctional adipose tissue, which is 
hypoxic, fibrotic and filled with necrotic adipocytes (Figure 1.4B) (Crewe et al., 2017). 
Dysfunctional adipose tissue is created when adipose reaches its capacity to expand 
(Figure 1.4) (Crewe et al., 2017). Mouse models have demonstrated that improving 
the ability of adipose tissue to expand can lead to a “healthy” version of obesity in 
which animals are grossly obese but show normal levels of blood glucose and are not 
insulin resistant (Kim et al., 2007). Adipose tissue expansion can be driven by 
increases in cell size or number, with hyperplastic growth improving metabolic 
parameters, such as levels of fasting glucose (Sugii et al., 2009). Therefore, one aim 
of my thesis is to identify factors which regulate adipose tissue expansion and adipose 
tissue morphology, with the aim to improve obesity associated adipose tissue 
dysfunction. 
 
1.4.2 - Hypothesis - Foxp1 maintains progenitor cell populations in white 
adipose tissue and is required for adipose tissue expansion  
Foxp1 is a transcription factor which is expressed in multiple tissues, including 
adipose tissue (Fagerberg et al., 2014). Data from GWAS studies has found an 
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association between variation at the FOXP1 locus and measures relating to adiposity, 
such as BMI and SAT levels (Fox et al., 2012, Kichaev et al., 2019). Further data 
linking Foxp1 to changes in adipose levels is provided by a recent study in 2019 which 
showed that loss of Foxp1 in adipose tissue leads to reduced levels of AT (Liu et al., 
2019). However, a mechanism to explain how Foxp1 influences adipose tissue levels 
remains to be uncovered. Foxp1 is known to drive the proliferation and differentiation 
of progenitor cells in tissues other than adipose (Fu et al., 2018, Gabut et al., 2011, 
Hu et al., 2006, Leishman et al., 2013, Li et al., 2017). For example, in embryonic 
stem cells, Foxp1 represses the expression of genes required for differentiation and 
Foxp1 is also required for the differentiation of MSCs (Gabut et al., 2011, Li et al., 
2017). From these known roles of Foxp1 in progenitor cells it is reasonable to suggest 
that Foxp1 may also act on progenitor cells in adipose tissue. This leads me to the 
hypothesis that Foxp1 maintains progenitor cell populations in adipose tissue and is 
required for adipose tissue expansion (Figure 1.15A & B). This hypothesis will be the 











Figure 1.15 – Hypothesis: Foxp1 maintains progenitor cell populations in 
adipose tissue and is required for adipose tissue expansion. A. Schematic 
showing that Foxp1 maintains progenitor cells in AT and is required for AT expansion. 
B. Schematic showing the hypothesised effect of loss of Foxp1 in AT. Loss of Foxp1 












1.4.3 – Aim 2 – Establishing zebrafish as a model of AT expansion  
Zebrafish are an emerging model of AT biology and much is known about AT 
in zebrafish. For example, zebrafish possess AT which is functionally homologous to 
mammalian WAT (Flynn et al., 2009). Furthermore, the morphology of zebrafish 
adipocytes is very similar to that of mammalian white adipocytes, with zebrafish 
adipocytes sharing their characteristic large cellular size and presence of a singular 
lipid droplet (Flynn et al., 2009, Imrie and Sadler, 2010). AT in zebrafish is also 
molecularly homologous to mammalian WAT, with tissues in both species expressing 
genes such as pparg, cebpa and fapb4 (Flynn et al., 2009, Imrie and Sadler, 2010). 
However, much of what is known of the molecular regulation of AT expansion in 
mammals is unknown in zebrafish. Therefore, the second aim of my thesis is to 
determine whether the genetic control of AT expansion is conserved between 
zebrafish and mammals and to further establish zebrafish as a model of AT 
expansion.  
 
1.4.4 – Hypothesis – The role of cebpa in AT expansion is conserved 
between zebrafish and mammals 
Cebpa is a master regulator of adipogenesis and is required for AT expansion 
in vivo (Linhart et al., 2001). Cebpa expression can trigger the differentiation of 
preadipocytes into adipocytes in vitro and mouse Cebpa knockout models show near 
complete loss of WAT (Linhart et al., 2001). While cebpa is expressed by AT in 
zebrafish, whether cebpa is required for AT expansion is unknown (Imrie and Sadler, 
2010). As many aspects of AT biology are conserved between zebrafish and 
mammals, it is reasonable to expect that the genetic control of AT expansion is also 
conserved. This leads me to the hypothesis that the role of cebpa in AT expansion is 
conserved between zebrafish and mammals. This hypothesis was addressed in 































Figure 2.1 – Generation of stable zebrafish mutants. A. Schematic showing 
gRNAs. B. Schematic showing injection of gRNAs into the zebrafish embryo. C. 
Description of the test for guide activity. D. Description of stable mutant identification 





2.1.1 - Creation of gRNAs 
The sequence of the genes of interest were identified and guide RNAs created 
(Table 2.1). 
 
Identification of functional protein domains to be targeted using CRISPR 
Protein domains targeted using CRISPR were identified using Ensembl. The 
protein summary and Domains & Features tabs were utilised to identify the domains 
of Foxp1a, Foxp1b and Cebpa. 
 
CRISPR Guide Design 
sgRNAs (single guide RNA) to target genes of interest were designed using 
the CHOPCHOP programme (Labun et al., 2016). Guides were selected based on 
proximity to the region of interest, CHOPCHOP score and a lack of predicted off target 
effects. The desired oligo was altered so that the first two bases were GA. The Sp6 
promoter sequence was then placed in front of the designed oligo and the tracrRNA 
sequence behind (Sp6-target sequence-tracrRNA). The complete sequence was then 
ordered from IDT.   
Table 2.1- Location and sequence of CRISPR guides  
Gene 
targeted  
Exon/ region targeted Sequence 
foxp1a Exon 2 – Translational start site GAATAGCAGTCCGACTGGGC  
foxp1a Exon 8 – zinc finger domain GACAGAGGATGGCCACTTTG  
foxp1a Exon 14 – fork head domain GACGAGTGGAGAATGTGAAG 
foxp1b Exon 15 – fork head domain GATAACGAAGCATACGTGAA 
Cebpa Exon 1 GAACTAGGTACGGGCGTCG 
 
Table 2.2 – Sequence of Sp6 promoter and tracrRNA 
Target Sequence  
Sp6 Promoter ATTTAGGTGACACTATA 




Annealing of CRISPR guides 
The recipe for the guide production is as follows  
Table 2.3 – recipe for annealing sgRNA guides 
Reagent Amount (µl) 
Q5 buffer 2.5 
10 mM DNTPs 0.25 
sgRNA Oligo (10 µM) 0.5 
Oligo 2 (10 µM) 0.5 
Q5 polymerase  0.25 
Nuclease free water 8 
 
Q5 polymerase and buffer (NEB, M0491S), DNTPs (NEB, N0447S). 
PCR amplification steps were as follows.  
1- 98°C for 2 minutes 
2- 55°C for 10 minutes  
3- 72°C for 10 minutes  
Products were then run on an agarose gel to check for bands. 
 
Gel Electrophoresis 
Electrophoresis was performed on a 1% agarose gel made in 1XTBE buffer 
with gel red (5 µl/100ml). PCR reactions were loaded directly onto gels and ran at 
100V for 30 minutes. A 10 Kb DNA ladder (NEB, N0469S), was also loaded onto the 
gels. DNA was visualised using a UV transilluminator (UVIDOC HD6). 
The recipe for 10X TBE is as follows  
Table 2.4 – recipe for 10X TBE 
Reagent Amount (g) 
Tris 108 
EDTA 18.6 
Boric Acid  55 
Water 1000 ml 
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CRISPR Guide Production 
mMessage mMachine SP6 transcription kit (Invitrogen, AM1340) was used to 
produce capped RNA from the PCR template. The recipe for the transcription reaction 
is as follows  
Table 2.5 – recipe for mMessage mMachine 
Reagent  Amount (µl) 
NTP Cap 5 
Buffer  1 
PCR template 1.5 
SP6 enzyme  1 
Nuclease free water 1.5 
  
The transcription reaction was incubated at 37°C overnight. The next day 1 µl 
of turbo DNase (mMessage mMachine kit) was added to the reaction mix and the 
samples incubated at 37°C for 15 minutes.  
 
CRISPR Guide cleaning  
Guides were cleaned using the zymo RNA clean and concentrate kit (Zymo 
Research, D4004). Clean RNA was eluted in 20 µl of nuclease free water. 
 
Measuring concentration of RNA  
The concentration of the clean RNA was measured using the NanoDrop 1000 
spectrophotometer. 1 µl of nuclease free water was used to calibrate the machine and 
1 µl of the eluted RNA was used to check RNA quality and concentration. A 260/280 
ratio of around 2 and a 260/230 ratio of around 2 was classified as having a high level 
of purity.  
 
2.1.2 - Injection of gRNAs 




Microinjection of guide RNAs into zebrafish embryos  
Needles for injections were made by pulling borosilicate glass capillaries 
(World Precision Instruments), using a P-97 Falming/Brown micropipette puller. 
Microinjections were performed using a picopump microinjector (PV820). All embryos 
were injected at the one cell stage. All gRNAs were injected into WIK embryos.  
The following reaction mixture was used  
Table 2.6 – Recipe for sgRNA injections 
Reagent Amount (µl) 
Cas9 (800 ng/µl) 1 
sgRNA (300 ng/µl) 1 
Phenol red 0.5 
Nuclease free water 0.5 
 
Cas9 (NEB, M0646T). Phenol Red (Sigma, P0290) 
The injection mixture was incubated at 37°C for 5 minutes. 1 nl was injected 
into each zebrafish embryo.  
 
2.1.3 - Screening for guide activity  
A T7E1 assay was used to screen for guide activity (Figure 2.1C).  
 
Genomic DNA isolation  
gDNA (genomic DNA) was extracted from pools of 5 embryos before 5 days 
of age. Embryos were placed in 100 µl of 50 mM NaOH and incubated at 95°C for 20 
minutes. 10 µl of 1 M TrisHCl was added and samples were centrifuged at 4000 rpm 
for 10 minutes. The supernatant was then transferred to a fresh tube.  
 
Design of primers to test if CRISPR guides are cutting 
PCR primers for determining if guides were cutting DNA in CRISPR mutated 
fish were designed using the Primer3Plus programme (Untergasser et al., 2007). 
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Primers were chosen which amplified regions containing CRISPR guide RNAs. 
Products were around 500 bp.  
Table 2.7 - Primers to amplify locus surrounding target site of CRISPR guide 
CRIPSR guide Forward Primer Reverse Primer 
foxp1a (ATG) ATGCTGGGTTCCACACACTT  GGCACGCATGTTTTGTCAT  
foxp1a (ZFD) CAACCAGGACAAACAGCGTA  CATTGTCCAGTGCAAACCTG  
foxp1a (FHD) GCCAGATTGGACTGGATGTT TTATTTCCAGGCCATTCTGG 
foxp1b (FHD) TTCAGTTTCAGCTCCTTCCTTC TGGAAGTCAAGCTACCAGCA 
cebpa (ATG) TTGCTTGGCTGTCGTAGATG ATCAGCGCCTACATTGATCC 
 
PCR 
PCR was used to amplify the locus surrounding the target site of the CRISPR 
guide. A GoTaq master mix was used (Promega, M783B). The recipe for the PCR is 
as follows 
Table 2.8 – Recipe for PCR reaction 
Reagent Volume (µl) 
Go Taq 5 
gDNA 2 
Primers (10 µM) 1 
Nuclease free water 2 
 
The following PCR conditions were then used  
1- 94°C for 3 minutes 
2- 94°C for 20 seconds 
3- 55°C for 30 seconds 
4- 72°C for 1 minute 
Repeat step 2 to 4, 30 times  
5- 72°C for 5 minutes 





Reannealing of PCR products from CRISPR guide injected fish 
PCR products were heated and reannealed with the following temperatures 
and timings. 95°C for 10 minutes. Then cooled to 85°C with 2°C drop in temperature 
every 10 seconds. Then cooled to 25°C with a 2°C drop in temperature every 10 
seconds. 
 
T7 Endonuclease 1 Assay 
T7 Endonuclease 1 (T7E1) enzyme (NEB, M0302S) was used to cut DNA and 
assess levels of mutagenesis. The following reaction mixture was made up 
Table 2.9 – Recipe for T7E1 reaction 
Reagent Volume (µl) 
PCR product 8 
Buffer 2 1 
T7E1 enzyme 0.3 
Nuclease free water 0.7 
 
The reaction mixture was then incubated at 37°C for 30 minutes. The products 
were separated by gel electrophoresis and differences in banding patterns assessed. 
Guides which were found to be active were reinjected into WT embryos and these 
embryos raised. G0 adult fish were then outcrossed to WT fish and their embryos 
screened for guide activity. Fish found to produce embryos which contained indels at 
the CRISPR target site, as shown by T7E1 assay, were crossed again to WT fish and 
the embryos raised.  
 
2.1.4 - Identifying the nature of mutations created by CRISPR 
DNA from F1 fish was sent for Sanger sequencing to determine the nature of 






Isolating gDNA from adult fish by fin clips 
F1 offspring of G0 fish known to produce embryos in which CRISPR guides 
are active, were fin clipped.  Fish were lightly anesthetised using MS-222. The end of 
the caudal fin rays were then removed, using scissors which had been sterilised with 
ethanol. The fish was allowed to recover in fresh system water and the fin placed in 
100 µl of 50 mM NaOH. gDNA was then extracted and amplified using PCR.  
 
Cloning PCR products into a vector for sequencing by TopoTA Cloning  
PCR products created via amplification with GoTaq were cloned into the pCR8 
vector (Invitrogen, K4500J10). The following reaction mix was made. 
Table 2.10 – Recipe for TopoTA cloning reaction 
Reagent Volume (µl) 
pCR8 vector 0.25 
Salt 0.25 
PCR product 0.25 
Nuclease free water 0.75 
  
The mixture was then incubated for 15 minutes at 25°C. This was then cooled 
to 4°C and 20 ul of One Shot Top10 chemically competent E.Coli  added (Invitrogen, 
C404003). The reaction was incubated at 4°C for 30 minutes and then a heat shock 
was performed at 42°C for 45 seconds. The mixture was cooled to 4°C and 250 µl of 
SOC (Super Optimal Broth) added. The cells were then allowed to recover at 37°C 
for 1 hour. 250 µl of the reaction mixture was then spread onto agar plates containing 
spectinomycin (Sigma, S2647-100MG) at 50 µg/ml. Plates were incubated overnight 
at 37°C.  
 
Identifying clones which contain the desired insert by colony PCR 





Table 2.11 – Recipe for colony PCR 
Reagent Volume (ul) 
GoTaq 7.5 
Primers 1 
Nuclease free Water 6.5 
 
The colony of interest was picked, with a pipette tip, re-streaked on a fresh 
agar plate and then the pipette tip was placed in the PCR reaction mixture. The re-
streaked agar plate was incubated at 37°C for 6 hours. The pipette tip was mixed in 
the reaction mixture and then removed. PCR was then performed and 2 µl of the 
products ran on an agarose gel to check for insertion into the vector. Insertion was 
determined by product size.  
Colonies where an insertion was thought to have taken place, were then 
picked from the re-streaked plate and used to inoculate 1.5 ml of LB containing 
spectinomycin. Samples were incubated shaking overnight at 37°C.  
 
Minipreps to isolate PCR products in the sequencing vector 
Minipreps were performed using QIAprep Spin Miniprep Kit (QIAGEN, 27104) 
and all centrifugations were performed using a standard table-top micro-centrifuge. 
 
Sequencing of unknown CRISPR mutant DNA 
Sequencing was performed using a Mix2Seq kit (Eurofins). Reactions were 
set up according to the manufacturers instructions.  
 
Sequence alignment of potential CRISPR mutant DNA with wild type DNA 
Sequence alignment was performed using Clustal Omega software (EMBL-
EBI). Sequences of DNA from F1 fish were aligned to the corresponding WT 





Nature of stable mutants generated   
The table below lists the stable mutants generated and gives the nature of the 
mutation in each case. In the results chapters the foxp1a(ed16/ed16) and foxp1b(ed25/ed25) 
alleles will be referred to as foxp1a(-/-) and foxp1b(-/-) respectively for simplicity.  
Table 2.12 – Stable mutants generated 
Allele name Nature of mutation 
foxp1a(ed14/ed14) 7bp indel close to the translational start site of foxp1a – results 
in a frameshift and the introduction of an early stop codon 
foxp1a(ed15/ed15) 7bp indel in the FHD of foxp1a – results in a frameshift and the 
introduction of an early stop codon 
foxp1a(ed16/ed16) 13bp indel in the FHD of foxp1a – results in a frameshift and the 
introduction of an early stop codon 
foxp1a(ed17/ed17) 45bp indel in the ZFD of foxp1a – inframe mutation 
foxp1a(ed18/ed18) 10bp indel in the ZFD of foxp1a – results in a frameshift and the 
introduction of an early stop codon 
cebpa(ed19/ed19) 38bp deletion close to the translation start site of cebpa - results 
in a frameshift and the introduction of an early stop codon 
cebpa(ed20/ed20) 7bp deletion close to the translation start site of cebpa - results 
in a frameshift and the introduction of an early stop codon 
foxp1b(ed23/ed23) 5bp deletion in the FHD of foxp1b – results in a frameshift and 
the introduction of an early stop codon 
foxp1b(ed24/ed24) 3bp deletion in the FHD of foxp1b – results in a frameshift and 
the introduction of an early stop codon 
foxp1b(ed25/ed25) 4bp indel in the FHD of foxp1b – results in a frameshift and the 
introduction of an early stop codon 
foxp1b(ed26/ed26) 12bp insertion in the FHD of foxp1b – inframe mutation 
 
2.1.5 - Genotyping stable lines  
Strategies were devised to genotype stable lines by PCR or restriction digest 






Primers were designed which recognised either the 13bp indel in the ed16 
mutants, or the WT sequence. Two PCR reactions were then set up, one containing 
the forward, reverse and WT primers, and one containing the forward, reverse and 
mutant primers. The PCR products were then run on an agarose gel and the banding 
pattern used to determine the genotype of the fish being tested (Figure 2.2A & B). 
For example, a band for the WT primer reaction and no band for the mutant primer 
mix would be identified as a WT fish (Figure 2.2A & B). The sequences of the primers 
used are shown in the table below.  






   
Ed17 
foxp1a(ed17/ed17) mutants were genotyped using PCR. As the foxp1a(ed17/ed17) 
mutation was caused by a large deletion, a normal PCR was carried out and a band 
shift looked for. The primers which had previously been used to amplify the region, 
before the T7E1 assay, were used.  
Table 2.14 – foxp1a(ed17/ed17) genotyping primers 
Primer Sequence 




foxp1a(ed18/ed18) mutants were genotyped using a restriction enzyme. The area 
spanning the foxp1a(ed18/ed18) lesion was amplified by PCR (Table 2.14). The following 




Table 2.15 – Recipe for BslI restriction digest 
Reagents Volume (µl) 
Restriction enzyme BslI 0.25 
10X buffer 1.25 
PCR product 5 
Nuclease free water 6 
 
Bsll (NEB, R0555S). The mixture was incubated at 55 °C for 15 minutes and 
ran on a 2% agarose gel (Figure 2.2C). The enzyme only cuts WT DNA.  
 
Ed19 
cebpa(ed19/ed19) mutants were genotyped by PCR. As the cebpa(ed19/ed19) mutant 
contains a large deletion, a PCR reaction was set up in which primers spanned the 
mutation site. A band shift was used to genotype fish (Figure 2.2D). The table below 
shows the sequence of the primers used.  
Table 2.16 – cebpa(ed19/ed19)) genotyping primers 
Primer Sequence 




The cebpa(ed20/ed20) mutants were genotyped by a restriction digest. The area 
spanning the cepba(ed20/ed20) lesion was amplified by PCR (Table 2.16). The following 
reaction mixture was then made.   
Table 2.17 – Recipe for BtgI restriction 
digest 
Reagents Volume (µl) 
Restriction enzyme BtgI 0.25 
10X buffer 1.25 
PCR product 5 
Nuclease free water 6 
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BtgI (NEB, R0608S). The mixture was incubated at 37 °C for 15 minutes and ran on 
a 2% agarose gel (Figure 2.2E). The enzyme cuts WT DNA twice and mutant DNA 
once.  
  
Ed23, Ed24, Ed25, Ed26 
The foxp1b(ed23/ed23), foxp1b(ed24/ed24), foxp1b(ed25/ed25) and foxp1b(ed26/ed26) 
mutants were genotyped by a restriction digest. The area spanning the lesions was 
amplified by PCR (Table 2.18). 
Table 2.18 – foxp1b(ed23/ed23), foxp1b(ed24/ed24), foxp1b(ed25/ed25) 
and foxp1b(ed26/ed26) genotyping primers 
Primer Sequence 
Forward  TTCAGTTTCAGCTCCTTCCTTC 
Reverse TGGAAGTCAAGCTACCAGCA 
 
 The following reaction mixture was then made.   
Table 2.19 – Recipe for HpyCH4IV restriction digest 
Reagents Volume (µl) 
Restriction enzyme HpyCH4IV 0.25 
10X buffer 1.25 
PCR product 5 
Nuclease free water 6 
 
HpyCH4IV (NEB, R0619S). The mixture was incubated at 37 °C for 15 minutes 








Figure 2.2 – Genotyping stable lines. A. Example of banding patterns for foxp1a(+/+), 
foxp1a(+/ed16) and foxp1a(ed16/ed16) genotypes.  B. Example of banding patterns for 
foxp1a(+/+), foxp1a(+/ed16) and foxp1a(ed16/ed16) genotypes. C. Example of banding 
patterns for foxp1a(+/+), foxp1a(+/ed18) and foxp1a(ed18/ed18) genotypes. D. Example of 
banding patterns for cebpa(+/+), and cebpa(+/ed19) genotypes. E. Example of banding 
patterns for cebpa(+/+), and cebpa(+/ed20) genotypes. F. Example of banding patterns for 























High throughput genotyping of foxp1a(ed16/ed16) and foxp1b(ed25/ed25) fish  
Having generated foxp1a(ed16/ed16);foxp1b(ed25/ed25) double mutants, it became 
impractical to genotype these fish by PCR and restriction digest. Therefore, KASP 
genotyping assays were designed. The KASP on demand service was purchased 
from LGC Biosearch Technologies. Assays were then designed and validated for the 
genotyping of foxp1a(ed16/ed16) and foxp1b(ed25/ed25) fish.   
gDNA was extracted from fish and added to the following reaction mixture 
Table 2.20 – recipe for KASP reaction mix 
Reagent Amount (µl) 






The reaction mixture was placed into a 384 well plate and then placed into a 
Roche LightCycler 480 machine. The following conditions were used for the ed16 
primers.  
1- 94°C for 15 minutes 
2- 94°C for 20 seconds  
3- 61°C for 60 seconds (decreasing by 0.6°C per cycle to achieve 
a final temperature of 55°C) 
4- Repeat steps 2 and 3, 9 times  
5- 94°C for 20 seconds  
6- 55°C for 60 seconds  
7- Repeat steps 5 and 6, 25 times  
8- 30°C for 60 seconds  
The following conditions were used for the ed25 primers  
1- 94°C for 15 minutes 
2- 94°C for 20 seconds  
3- 68°C for 60 seconds (decreasing by 0.6°C per cycle to achieve 
a final temperature of 62°C) 
4- Repeat steps 2 and 3, 9 times  
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5- 94°C for 20 seconds  
6- 62°C for 60 seconds  
7- Repeat steps 5 and 6, 25 times  
8- 30°C for 60 seconds  
Three recycle steps were then used for each of the genotyping assays. The 
recycle steps were as follows  
1- 94°C for 20 seconds  
2- 57°C for 1 minute  
3- Repeat steps 1 and 2, twice  
4- 37°C for 1 minute  
Genotypes were then assigned based on the readout of the Kasp assay. Each 
sample was assigned to a genotype based on a fluorescent readout.  

















2.2 - Generation of a transgenic line which labels adipocytes 
and pre-adipocytes  
 
To generate the transgenic line non-coding elements, identified through 
DNase Seq during adipogenesis, were used (Siersbaek et al., 2011). Highly 
conserved non-coding elements (CNEs), which were conserved to zebrafish, were 
then prioritised by GO term analysis (Hiller et al., 2013). Primers were then designed 
to the prioritised adipoCNEs and PCR amplified. The PCR products were then cloned 
into an expression vector and injected into zebrafish embryos at the one cell stage 
(Figure 2.3). The embryos were screened for GFP expression and GFP positive 
embryos raised. These fish were then outcrossed to WT fish and offspring with GFP 


















Figure 2.3 – Generation of a transgenic line which labels adipocytes. A. 
Schematic showing amplification of CNEs. B. Schematic of the construct injected. C. 
Injection of transgenic construct. D. Outcrossing of G0 fish. Green marks highlight the 
mosaic expression of GFP in G0 fish. E. Identification of F1 founder lines with GFP 




Insertion of adipoCNEs into an expression vector by LR cloning  
As described previously PCR primers were designed, and the adipoCNE 
amplified by PCR. The PCR product was then cleaned and cloned into the pCR8 
vector. Cleaned PCR products in the pCR8 vector were cloned into the pGW-
cFosEGFP (Fisher et al., 2006) vector (Figure 2.2B). The following reaction mixture 
was made  
Table 2.21 – Recipe for LR cloning  
Regents Amount (µl) 
pCR8 vector 0.25 
pGW-cFosEGFP 0.25 
TE  2 




The samples were then incubated at 25°C for 3 hours. The samples were 
cooled to 4°C and 0.4 µl of Proteinase K added. The reaction mixture was then 
incubated at 37°C for 10 minutes. A heat shock was performed by cooling the samples 
to 4°C, adding 20 µl of One Shot Top10 chemically competent E.Coli, cooling for 
another 10 minutes and then heating the samples to 42°C for 45 seconds. This was 
again cooled to 4°C and 200 µl of LB broth added. The samples were then allowed to 
recover at 37 °C for 1 hour. 250 µl of the reaction mixture was spread onto agar plates 
containing ampicillin (Fisher Scientific, 10193433) at 50 µg/ml. Plates were incubated 
overnight at 37°C. 
Colony PCR was then performed, as described previously, to check for 
insertion of DNA into the vector. Colonies containing the correct insert were then 
amplified, miniprepped to extract DNA and the DNA cleaned ready for injection.  
 
Injection of transgenic construct  





Table 2.22 – recipe for injection mixture  
Reagents Amount (µl) 
Tol2 mRNA (50 ng/µl) 1.5 
DNA (100 ng/µl) 0.75 
Phenol Red 0.75 
 
10 nl of the reaction mixture was injected into WT zebrafish embryos as 
described previously. GFP positive embryos were selected for and raised. These fish 





















2.3 - Zebrafish protocols 
 
2.3.1 – Zebrafish Husbandry  
Raising embryos 
Zebrafish embryos were raised in petri dishes containing 50 ml of dilute 
methylene blue until 5 dpf. Methylene blue was diluted by adding 2 ml of 0.1% 
methylene blue to 1 litre of water. Any unfertilised or dead embryos were removed 
from the dish at 24 hpf. The embryos were housed in an incubator at 28.5 °C, on a 14 
hour light / 10 hour dark cycle. Embryos were kept at a density of 30 fish per dish.  
 
Maintenance of juvenile and adult fish   
At 5 dpf embryos were transferred to a 3 litre tank filled with a small amount 
of water. Fish were kept at a density of 20 fish per tank. At 21 dpf the tank was filled 
and connected to flowing water. Fish were maintained at 28.5 °C on a 14 hour light / 
10 hour dark cycle.  
 
Feeding 
All zebrafish were fed three times a day. Fish were given two dry feeds and 
one wet feed. Dry feeds were obtained from SDS (Special Diet Services) and 
Skretting. SDS diets of SDS100, 200 and 300 were given, with increasing number 
corresponding to increasing fish age. These diets were composed of fish products, 
cereal grain products and by-products, by-products of oils and fats, vitamins, minerals 
and antioxidants. Diets are composed of 60% protein and 14.5% lipid. The wet feed 
was brine shrimp. Fish under the age of 21 dpf were fed paramecia rather than brine 
shrimp.    
 
2.3.2 - Survival Assay  
cepba(+/ed19) and cebpa(+/ed20) fish were incrossed and the offspring raised as 
described above. Every day the fish were counted and dead embryos removed. The 
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number of fish present each day and the number of dead fish were recorded until 21 
dpf. 
 
2.3.3 - Imaging   
Nile Red imaging  
Nile Red dye (Sigma, 72485) was added to water containing fish at a final 
concentration of 0.5 µg/ml. The fish were incubated in the dark at room temperature 
for 30 minutes. Epinephrine (Fisher Scientific, 11926891) was then added to the 
solution at a final concentration of 5 mg/ml to retract the pigment from the fish. Fish 
were then lightly anesthetised, and transferred to a petri dish lid containing a 4% 
methyl cellulose droplet. The fish was then gently positioned and imaged using a 
stereomicroscope. After imaging the fish were recovered in fresh system water.  
 
Foxp1:eGFP imaging 
Deep red Lipid-Tox (Invitrogen, H34350) was added to water containing fish 
at a 1 in 1000 dilution. The fish were incubated in the dark at room temperature for 1 
hour. Epinephrine was then added to the solution at a final concentration of 5 mg/ml 
to retract the pigment from the fish. The fish were then transferred to a solution of 
system water and MS-222 at a dilution of 1 in 20 and anesthetised until their gills had 
stopped moving. The fish was transferred to a petri dish lid containing a 4% methyl 
cellulose droplet and gently positioned. LSAT was then imaged using a 
stereomicroscope and the fish recovered.  
 
2.3.4 - High Fat Diet  
A high fat diet was set up with fish of around 1 month of age. Fish to be placed 
on the diet were stained with Nile red, imaged and recovered individually in 12 well 
dishes. The SL of the fish was then measured and fish separated into two groups with 
equal average SL. Fish were then randomly paired up and placed as two fish per 
mesh insert (Figure 2.4B). This allowed pairs of fish to be tracked through the diet.  
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The mesh inserts were placed into 10 litre tanks fitted with lids which 
accommodated 4 inserts. The location of the inserts in the tanks was rotated daily to 
account for any differences in feeding (Figure 2.4C). A random schedule detailing the 
location of each insert, for the duration of the diet, was drawn up before the diet began.  
Fish assigned to the HFD group were immersed in a 5% egg yolk solution 
(Carten et al., 2011, Semova et al.,2012, Walters et al., 2012) for 2 hours each day 
for a period of two weeks (Figure 2.4D). Control diet fish were also removed from the 
10 litre tanks and placed into fresh water. Both the control diet and high fat diet groups 


















Figure 2.4 – HFD schematic. A. Schematic of the HFD. B. Schematic showing the 
mesh insert fish are housed in for the duration of the experiment. C. Schematic 
showing the lids for 10 litre tanks, into which the mesh inserts are placed. The position 
of inserts is randomly changed each day to minimise variation due to differences in 














2.3.5 – Dissections 
PVAT dissection 
Fish were culled by schedule 1. Briefly fish were killed by an anaesthetic 
overdose and the heart was then destroyed. Fish were then placed under a 
microscope with their stomach on the right. An incision was made below the gills, 
through the transverse plane of the fish (Figure 2.5A). A second incision was then 
made, perpendicular to the first incision, towards the caudal fin of the fish. The GI 
tract, and the attached PVAT was then gently removed from the fish. The whole GI 
tract and PVAT was fixed in 4% PFA overnight at 4°C.  
 
LSAT dissection  
Fish were culled by schedule 1. The heads of the fish were then removed, and 
an incision made down the ventral side of the fish, towards the caudal fin (Figure 
2.5B). The GI tract and the caudal fin were also removed. The skin along the flank of 













Figure 2.5 – Schematics of PVAT and LSAT dissections. A. Incisions made during 
PVAT dissections. Red dotted lines show position of incisions. B. Incisions made 


















2.3.6 - Blood collection  
Fish were fasted overnight and then killed by anaesthetic overdose. Fish were 
removed from the MS-222 and their gills blotted dry with tissue. The fish was turned 
onto its back and an incision was made, with dissection scissors, below the gills and 
through the heart. A pipette was then used to extract blood, and this was stored on 
dry ice. The blood was centrifuged at 2400 rpm for 10 minutes at 4°C. The top layer 






















2.4 - Molecular biology protocols  
 
2.4.1 - Measuring RNA levels  
SVF isolation  
PVAT was dissected from multiple adult fish and the dissected tissue was 
placed in 1 ml of 0.5 mg/ml collagenase solution (Roche, 11088807001). The recipe 
of the collagenase solution is shown below.  
Table 2.23 – Recipe for collagenase solution 
Reagent Volume 
Collagenase B 5 mg 
Bovine Serum Albumin (Sigma-Aldrich, 
A3294-50G) 
40 mg 
Pen/Strep (Life Technologies, 15140148) 20 µl 
PBS 10ml 
 
Samples were then incubated at 28.5°C for 1 hour 30 minutes, with agitation. 
The digested samples were passed through a 0.22 µm filter and the remaining mixture 
centrifuged at 300g for 5 minutes. The resulting cell pellet was then used for RNA 
extraction.   
 
RNA isolation for measurement of transcript levels by qPCR 
RNA was collected using the RNeasy mini kit (Qiagen 74104). 350 µl of RLT 
buffer was added to SVF isolated cells and homogenised by pipetting. 350 µl of RLT 
buffer was also added to PVAT and the tissue homogenised using a micropestle 
(Eppendorf, 0030120.973). RNA extraction was then carried out as per the 
instructions of the kit. The optional DNase digestion step was performed (Qiagen, 
79254). RNA was eluted into 25 µl of nuclease free water.  
 
cDNA synthesis 
cDNA was synthesised using superscript IV reverse transcriptase (Invitrogen, 
18090010). All RNA samples to be reverse transcribed were first diluted to the 
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concentration of the sample with the lowest RNA concentration. The following mixture 
was made up.  
Table 2.24 – Recipe for reverse transcription 
Reagent  Volume (µl) 
Random Primers (Invitrogen, SO142) 0.5 
dNTP (10mM) (NEB, N0447S) 1 
Oligo (dT) primers (Invitrogen, AM5730G)  0.5 
RNA 10 
 
The mixture was incubated at 65°C for 5 minutes. The mixture was then cooled 
to 4°C and the following mixture added.  
Table 2.25 – Recipe for reverse transcription, part 2  
Reagent Volume (µl) 
5X buffer 4 
0.1M DTT 2 
RNase inhibitor (Promega, N2511) 1 
 
This mixture was then incubated for 2 minutes at 42°C. This was then cooled 
to 4°C and 2 µl of superscript added. The mixture was heated to 42°C for 60 minutes 
and then 70°C for 15 minutes. 1 µl of RNase was added and the mixture incubated at 
37°C for 20 minutes. cDNA was then diluted to a concentration of 5 ng/µl.  
 
qPCR 
qPCR was performed on a Roche LightCycler 480 machine. Luna qPCR 








Table 2.26 - Recipe for qPCR 




Nuclease free water 3 
 
Reactions were loaded onto a 384 well plate. The qPCR steps were as follows; 
95°C for 10 minutes, 45 cycles of 95°C for 15 seconds, 60°C for 30 seconds and 72°C 
for 30 seconds. Then 95°C for 5 seconds, 65°C for 60 seconds and finally 40°C for 
30 seconds.  
Table 2.27 - Zebrafish qPCR primers 
Gene Targeted Forward Primer Reverse Primer 
Pparg TGCCGCATACACAAGAAGAG ATGTGGTTCACGTCACTGGA 





Βactin GCCTCCGATCCAGACAGAGT TGACAGGATGCAGAAGGAGA 
foxp1a GGCCACTTTGAGGATGACTC CCTCGCCACCTAAAACTCAG 
foxp1b CATTGGCTCCTCTTTTACGC ACAGCAACGGTAGTGACAGC 
 
2.4.2 - Measuring protein levels  
Making protein lysate  
The caudal fin rays were removed from juvenile zebrafish and placed on dry 
ice. 500 µl of RIPA buffer (Thermo, 8990), containing 1x protease inhibitor (Thermo, 
A32953), was added to a pool of 7 fins. This was then homogenised using a 
TissueRuptor. The tissue was homogenised by 3, 10 second bursts of the 
TissueRuptor. The samples were then centrifuged at top speed for 15 minutes, at 4°C. 
300 µl of the clean lysate was removed and added to 75 µl of LDS blue (Novex, 
B0008) and 30 µl of reducing agent (Novex, B0009). This was heated to 95°C for 10 
minutes and then centrifuged for 1 minute at 10,000 rpm.   
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Western blot  
500 ml of 1x MOPs (Novex, B0001) buffer was made by diluting 20x stock 
solution with DI water. The loading buffer was then poured into the gel container. A 
precast 8% Bis-Tris gel (Invitrogen, NW00082BOX) was placed into the buffer. 25 µl 
of protein lysate was loaded onto the gel, alongside 8 µl of protein ladder (Thermo 
Scientific, 26619). The gel was run at 110 V for 45 minutes. The gel was then removed 
from the casing and a wet transfer performed. The gel, and the membrane it was 
transferred onto, were soaked in running buffer. The recipe for the running buffer is 
shown in the table below.   
Table 2.28 - Recipe for running buffer 
Reagent Volume  
Glycine 15 g 
Tris-Base 3.5 g 
Methanol 200 ml 
DI Water  800 ml  
 
The gel and membrane were soaked in the running buffer, and sandwiched 
between blotting paper and sponges in the transfer unit. The sponges and filter paper 
were also soaked in running buffer. The transfer cassette was then placed into the gel 
tank and filled with the running buffer. The transfer was performed at room 
temperature, at 20 V for 60 minutes. After this the membrane was removed and 
placed in a 5% milk solution, consisting of milk powder and 1x TBSTx. TBSTx was 
made by adding 500 µl of Tween-20 (Biotium, 22002) to 500 ml of 1x TBST. The 
recipe for TBST can be found in the table below.   
Table 2.29 - Recipe 10X TBSTx 
Reagent Volume  
Tris-Base 24.4 g 
NaCl 87.7 g 
DI Water 1 L 
 
The membrane was incubated in the 5% milk solution for 1 hour at room 
temperature, while rocking. The membrane was then transferred to a 5% milk solution 
containing FOXP1 antibody (PA5-26848) at a 1 in 1000 dilution and β-actin antibody 
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(Sigma, A2228) at a 1 in 25,000 dilution. The membrane was incubated in the primary 
antibody solution overnight at 4°C while rocking. The following day the membrane 
was washed 4 times in 1X TBSTx. Each wash lasted 15 minutes and all washes were 
performed while rocking. The membrane was then transferred to a 5% milk solution, 
containing HRP anti mouse (Invitrogen, 31430) and HRP anti rabbit (Invitrogen, 
31460) antibodies to recognise the β-actin and FOXP1 antibodies respectively. The 
HRP anti mouse antibody was used at a concentration of 1 in 3000, and the HRP anti 
rabbit antibody at 1 in 5000. The membrane was then incubated for 1 hour at room 
temperature while rocking. The secondary antibodies were washed from the 
membrane with 4x 15 minute washes in 1x TBSTx at room temperature while rocking.  
 
Western blot development      
Excess TBSTx was tapped off the membrane onto tissue paper. The 
membrane was then placed into a light cassette. 500 µl of ECL developing solution 
reagent A (Thermo scientific, 32209) was added to 500 µl of solution B in 1 ml tube 
and mixed by pipetting. 1 ml of the ECL solution was then pipetted onto the membrane 
and the cassette closed. The ECL solution was left on the membrane in the dark for 
1 minute. The membrane was then removed and placed into a film cassette. Clingfilm 
was used to cover the membrane and the cassette closed. The cassette was taken to 
a dark room with a red light. X-ray film was then placed over the membrane and the 
cassette closed for 20 minutes. The film was passed through an x-ray developing 
machine.  
 
2.4.3 - Lipid stains  
Fixed adipose depots were incubated with Lipid-Tox (Life Technologies, 







2.4.4 - Confocal imaging 
Confocal imaging of fixed tissue 
Fixed PVAT and LSAT depots were placed in 8 well slides (Ibidi, 80821) and 
mounted in 1% LMP agarose. All imaging was performed using a Zeiss 710 
microscope.  
 
Confocal imaging of euthanised fish 
Culled fish were placed in 8 well slides and mounted in 1% LMP agarose, 
containing MS-222 diluted by 1 in 20. All imaging was performed using a Zeiss 710 
microscope.  
 
2.4.5 - Blood assays  
Glucose (BioVision, K606-100), triglyceride (BioVision, K622-100) and 
cholesterol (BioVision, K623-100) assays were performed as per the manufacturers 
instructions. 1 µl of blood was used to perform the glucose and cholesterol assays 
and 0.2 µl used for the triglyceride assays. The fluorometric assays were used for the 
glucose and triglyceride measurements and the colorimetric assay used for the 












2.5 - Image analysis   
 
2.5.1 - Nile Red image analysis  
Total adipose area measurements  
Image J was used to analyse all images. The threshold tool was used to mark 
the total fluorescence area and the image converted to a binary image. The total 
marked area was then measured.   
 
VAT and SAT measurements  
Image J was used to analyse all the images. Individual adipose depots were 
drawn around and their area measured.  
 
2.5.2 - Adipose morphology measurements  
Image J was used to analyse the stacks generated. The line tool was used to 
measure each lipid droplet at its widest point, and this gave a measure of the lipid 
droplet diameter. The line tool was also use to draw across each lipid droplet as a 
mark of which lipid droplets had been measured.  
 
2.5.3 - Foxp1:eGFP time course image analysis 
Image Processing  
Images taken on the stereomicroscope were broken out into green, magenta and 
composite images and saved as TIF files. For each fish, images from the same 
location within SAT but in different focal planes were then stacked into one image 
using Zerene Stacker software. Image J was then used to stitch adjacent images 
together. Stitching was performed using the pairwise stitching tool (Preibisch et al., 
2009). Images which couldn’t be stitched in Image J were manually aligned in 
Photoshop and the autoblend tool used to merge the two images. This produced one 




Image analysis  
Image J was used to analyse the images generated. Progenitor cells were 
defined as GFP positive, lipid negative cells. Adipocytes were defined as GFP positive 
cells with a single lipid droplet. Each GFP positive cell was numbered and tracked 
throughout the time-course imaging. The number of progenitor cells and adipocytes 
were recorded. The area of each lipid droplet was also recorded. The number of 
branching events per LSAT was measured and branching events were defined as a 
chain of 3 or more adipocytes which branch away from the main line of the LSAT at a 
roughly 45° angle. Finally, the location of new cells within LSAT was measured. Dorsal 
and ventral cells were defined as cells separated by more than 2 adipocytes vertically 
from the main horizontal line of LSAT. 
 
2.5.4 - Liver area image analysis  
Image J was used to analyse the images. Each liver was drawn around and 















Chapter 3 – foxp1 regulates adiposity levels in 






















3.1 - Introduction  
 
Obesity is a global health problem (WHO). The World Health Organisation has 
estimated that 13% of the adult population worldwide were obese in 2016 and that 
globally more people are now obese than underweight (WHO). Obesity is 
characterised by excess adipose tissue accumulation and is defined clinically by a 
Body Mass Index (BMI) of over 30 kg/m2 (WHO). The classification of obesity as a 
health problem is due to the increased disease risk it confers, with obesity being linked 
to an increased risk of cardiovascular disease and diabetes (Martin et al., 2015). 
However, the mechanisms through which increased levels of adipose tissue (AT) lead 
to an increased risk of disease are not yet fully understood.  
Multiple theories exist to explain why obesity is associated with increased 
disease risk. One of these theories is the adipose expandability hypothesis (Virtue 
and Vidal-Puig, 2008). The adipose expandability hypothesis states that adipose 
tissue has a limited capacity to expand and that when this is reached, for example 
during obesity, the adipose tissue becomes dysfunctional (Virtue and Vidal-Puig, 
2008). Adipose tissue expands via hyperplastic growth, an increase in adipocyte cell 
number, and hypertrophic growth, an increase in adipocyte cell size (Spiegelman and 
Flier, 1996). Dysfunctional adipose tissue is associated with hypertrophic growth and 
increased adipocyte cell size (Crewe et al., 2017). It is further characterised by 
hypoxia, cellular senescence and necrotic adipocyte death (Crewe et al., 2017). 
Dysfunctional adipose tissue also loses its ability to store lipid, which results in ectopic 
deposition of lipid in the liver and insulin resistance (Lafontan, 2014). Therefore, a 
better understanding of how adipose tissue function can be maintained during obesity 
could lead to the development of treatments to alleviate obesity associated disease.  
Obesity and body weight are known to be partly genetically regulated (Maes 
et al., 1997). For example, data from monozygotic twin studies have estimated the 
heritability of BMI to be between 50-90% (Maes et al., 1997). In some cases, the 
causes of obesity can be attributed to the large effect of a single monogenic mutation 
(Khera et al., 2019). However, in the vast majority of cases the genetic causes of 
obesity are thought to result from the cumulative effect of many genes, with each gene 
having a modest effect (Khera et al., 2019). Therefore, although some genes which 
confer a large effect on body weight have been identified, the genetic regulation of 
body weight is still poorly understood. Consequently, the overall goal of this project is 
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to identify genetic factors which influence adipose levels, and to understand the 
molecular mechanisms by which they exert this influence.  
Genome wide association studies (GWAS) have been used to identify novel 
genetic factors underpinning obesity and body weight. GWAS studies take large 
human populations and look for SNPs (Single Nucleotide Polymorphisms) which 
appear more frequently in one condition than another (Visscher et al., 2012). For 
example, a GWAS study may look for SNPs which occur more frequently in obese 
subjects than in lean subjects (Speakman et al., 2018). A recent GWAS found that 
variation at the FOXP1 locus (encoding Forkhead Box P1) was associated with BMI 
(Kichaev et al., 2019). A second GWAS study identified variation at eight novel loci 
associated with anorexia nervosa, characterised by decreased body fat levels, 
including variation at the FOXP1 locus (Watson et al., 2019). Finally, a GWAS study 
in 2012 found that variation at the FOXP1 locus was associated with levels of 
subcutaneous adipose tissue (SAT) (Fox et al., 2012). Aditionally, that FOXP1 mRNA 
levels in SAT have been shown to be positively associated with BMI, insulin levels, 
an increased blood triglycerides (Civelek et al., 2017). Altogether, multiple GWAS 
studies have implicated FOXP1 in the regulation of body weight and increased FOXP1 
expression levels in SAT are associated with increased body weight and adverse 
metabolic outcomes. 
The data described above suggest that FOXP1 may play a role in regulating 
body weight, adiposity levels and metabolic health; however, the role of FOXP1 in 
adipose tissue is largely unknown. FOXP1 or Forkhead box P1 is a transcription factor 
and is part of the Fox family of proteins, which contain a winged helix DNA binding 
domain (Hannenhalli and Kaestner, 2009). FOXP1 is expressed in multiple tissues, 
including adipose tissue (Fagerberg et al., 2014). Data from GTex (Genotype-Tissue 
expression portal), which catalogues the results of RNA-Seq experiments in human 
tissues, has shown that FOXP1 mRNA is more abundant in human subcutaneous 
adipose tissue than in visceral (Fagerberg et al., 2014). This is also true in mice, with 
microarray data from adipocytes showing that Foxp1 mRNA is more highly expressed 
in SAT (Gesta et al., 2006). In addition to expression data, there is also data available 
relating to the function of Foxp1 in adipose tissue (Liu et al., 2019). A recent study 
found that mutant mice, which lack Foxp1 expression in adipose tissue, have slightly 
reduced levels of white AT on a control diet and gain less white AT in response to a 
high fat diet (Liu et al., 2019). However, the study primarily focused on the role of 
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Foxp1 in thermogenic brown and beige AT and the role of Foxp1 within white AT was 
largely unaddressed (Liu et al., 2019). Therefore, Foxp1 is known to influence adipose 
tissue levels, however the mechanism by which it does this is unknown.  
One known function of Foxp1 is to promote the renewal of stem and progenitor 
cells (Gabut et al., 2011, Li et al., 2017). For example, Foxp1 is known to stimulate 
the expression of genes required for pluripotency and to repress the expression of 
genes required for the differentiation of embryonic stem cells (Gabut et al., 2011). 
Furthermore, Foxp1 has been shown to be essential for the proliferation and self-
renewal of mesenchymal stem cells (Li et al., 2017). Overall, this suggests that Foxp1 
may regulate adiposity levels by influencing adipose progenitor cell proliferation and 
differentiation. My hypothesis is therefore that Foxp1 maintains progenitor cell 
populations in adipose tissue and is required for adipose tissue expansion.  
In this chapter I use zebrafish as a model to investigate the hypothesis that 
foxp1 maintains adipose progenitor cell number and is required for adipose tissue 
expansion. To address this hypothesis, I have generated novel foxp1 zebrafish 
mutants using CRISPR mutagenesis. I have then used these mutants to test my 
hypothesis by measuring adipose levels in response to both a control and high fat diet 
(HFD). I found that foxp1 mutant fish showed reduced AT expansion in response to a 
HFD and that mutants had a more hypertrophic AT morphology, characterised by 
fewer but larger lipid droplets. Overall, I have found novel experimental evidence that 
foxp1 is required for AT expansion. This is the first data to suggest that foxp1 has an 
in vivo role in AT expansion and suggests that foxp1 may be a therapeutic target for 










3.2 - Results  
 
3.2.1 - foxp1 is duplicated in zebrafish, with the foxp1b gene showing the 
highest level of conservation of mammalian Foxp1 
In order to investigate if foxp1 influences adiposity levels, I have chosen to use 
zebrafish as a model system. It is well known that many genes in zebrafish and other 
teleost fish have undergone a gene duplication and to check whether this was the 
case for foxp1 I made use of the Gene-tree function on Ensembl 
(ENSGT00900000140822) (Wafer et al., 2017). Briefly, gene tree shows the 
maximum likelihood phylogenetic tree for a given gene and represents the 
evolutionary history of that gene (TreeBeST). Using gene tree, I was able to trace the 
human ortholog of FOXP1 to determine which gene or genes are present in zebrafish. 
Zebrafish have two orthologs of FOXP1, foxp1a and foxp1b (Figure 3.1). I then 
wished to determine which zebrafish foxp1 paralog is most closely related to 
mammalian Foxp1. To do this I compared the sequences of human, mouse and 
Xenopus Foxp1 to that of the zebrafish foxp1a and foxp1b (Figure 3.1A & B). I made 
use of Clustal Omega sequence alignment software to compare the cDNA and protein 
sequences from the previously mentioned species and found that foxp1b shows 
greater sequence homology to mammalian orthologs than foxp1a (Figure 3.1B & C). 
Foxp1a was found to show 62.05% amino acid conservation to human FOXP1, while 
Foxp1b showed a greater level of conservation at 77.59% (Figure 3.1C). The greater 
level of conservation in foxp1b suggests that this gene has been under greater 
selective pressure than foxp1a and implies that foxp1b may be more likely to have 
retained the ancestral function of Foxp1. 
 
3.2.2 - The functional domains of zebrafish Foxp1 proteins are highly 
conserved to mammalian FOXP1 
At a whole gene level, both Foxp1a and Foxp1b show only moderate levels of 
conservation to human FOXP1. Therefore, I also wanted to determine how well the 
functional domains of FOXP1 were conserved between zebrafish and mammals. 
foxp1 is named for the presence of a forkhead DNA binding domain (FHD) and as a 
transcription factor one of its main roles is to bind DNA (Hannenhalli and Kaestner, 
2009). In addition to it’s DNA binding domain, FOXP1 also contains a zinc finger 
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domain which mediates protein-protein interactions and is thought to be important in 
the dimerization of FOXP1 (Li et al., 2004). I therefore wished to determine to what 
extent the forkhead and zinc finger domains (ZFD) of FOXP1 are conserved to 
zebrafish. Using the protein summary feature on Ensembl (ENSDARP00000107924.2 
& ENSDARP00000064937.3), and the Pfam and Smart databases (El-Gebali et al., 
2019, Letunic and Bork, 2018), I was able to confirm that both foxp1a and foxp1b 
contained both a forkhead DNA binding domain and a zinc finger protein-protein 
interaction domain (Figure 3.1C & D). With this information, and information on the 
mouse sequences of the FHD and ZFD, I was able to identify the protein sequences 
of the functional domains in foxp1a and foxp1b (Li et al., 2004, Stroud et al., 2006). 
By comparing these sequences to that of their human ortholog, I found that the protein 
sequences of the Foxp1a and Foxp1b FHD and ZFD are well conserved. The Foxp1a 
FHD shows 95.4% similarity to the human FOXP1 FHD and the Foxp1b FHD shows 
98.85% similarity (Figure 3.1E). The Foxp1a ZFD shows 87.50% similarity and the 
Foxp1b ZFD shows 91.67% similarity to the human FOXP1 ZFD sequence (Figure 
3.1E). The protein alignments of the ZFD and the FHD can be found in the appendix 
(Figure 7.1A & B). In summary both Foxp1a and Foxp1b show high levels of 
conservation in functional protein domains and Foxp1b appears to be more conserved 




Figure 3.1 – The foxp1 gene is duplicated in zebrafish, with the foxp1b gene 
showing the highest level of conservation to mammalian Foxp1. 
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Figure 3.1 – The foxp1 gene is duplicated in zebrafish, with the foxp1b gene 
showing the highest level of conservation to mammalian Foxp1. A. Unrooted 
phylogenetic tree showing conservation between amino acid sequences. Amino acid 
sequences were aligned using Clustal Omega. Unrooted was used to generate the 
tree (Pole Bioinformatique Lyonnais). Scale bar shows amino acid changes per site. 
B. Comparison of Foxp1 isoforms homologous to the human isoform 202. Numbers 
correspond to isoforms as identified on Ensembl. Sequences were aligned using 
Clustal Omega. C. Comparison of FOXP1 protein sequences homologous to the 
human isoform 202. Numbers correspond to isoforms as identified on Ensemble. 
Sequences were aligned using Clustal Omega. D. Schematic of foxp1a and foxp1b 
transcripts. Orange marks functional domains. E. Schematic of Foxp1a and Foxp1b 
proteins. Both proteins contain a zinc finger domain (Pfam) and a forkhead DNA 
binding domain (El-Gebali et al.). Domains shown in orange. Percentages show 
conservation between the sequence of the zebrafish and human functional domains. 
















3.2.3 - foxp1 is expressed in adipose tissue in zebrafish  
I next wanted to determine whether foxp1 is expressed in zebrafish adipose 
tissue. In mammals FOXP1 is known to be expressed in AT, however it is not known 
if foxp1a or foxp1b are expressed in zebrafish AT (Fagerberg et al., 2014, Gerin et 
al., 2009). To examine whether foxp1 is expressed in zebrafish AT, RNA was 
extracted from pancreatic visceral adipose tissue (PVAT) and foxp1 transcript levels 
measured by RT-qPCR (Figure 3.2A & B). I found that both foxp1a and foxp1b were 
expressed in PVAT, as were the known regulators of adipogenesis pparg and cebpa 
(Figure 3.2B). foxp1a was found to be more highly expressed than foxp1b and both 
were expressed to a lesser extent than pparg or cebpa (Figure 3.2B). cepba was 
expressed more highly than any other gene tested (Figure 3.2B). Together this 
demonstrates that both foxp1a and foxp1b are expressed in AT in zebrafish.  
 
3.2.4 - foxp1 is expressed in the SVF in zebrafish  
To test whether foxp1a and foxp1b are expressed exclusively in adipocytes, I 
next measured mRNA levels in the stromal vascular fraction (SVF). To do this I 
dissected PVAT from wild type (Cawthorn et al.) fish and digested the tissue using 
collagenase (Figure 3.2A). The adipocytes were then separated from the other cell 
types in AT by centrifuging the digested tissue (Figure 3.2A). The adipocytes were 
discarded, leaving behind the SVF (Figure 3.2A). The SVF consists of multiple cell 
types including adipocyte progenitor cells, vascular cells, haematopoietic cells and 
fibroblasts (Figure 3.2A). RNA was extracted from the SVF and mRNA levels 
measured by RT-qPCR (Figure 3.2A). Both foxp1a and foxp1b were found to be 
expressed in the SVF (Figure 3.2C). The dynamics of expression in the SVF were 
very similar to that of the whole PVAT, with cebpa again being the most highly 
expressed (Figure 3.2B & C). pparg showed the lowest expression in the SVF and 
had very similar levels of expression to both foxp1a and foxp1b (Figure 3.2C). 
Together these data show that the expression of foxp1 in the adipose depot is not due 
to expression of foxp1 exclusively in adipocytes and demonstrates that foxp1 is 







Figure 3.2 – foxp1a and foxp1b are expressed in the adipose tissue 
compartment and in the stromal vascular fraction. A. Schematic showing which 
cell types RNA was extracted from. B. n = 2-3. Error bars show standard deviation. A 
one-way ANOVA was performed, F3,6 = 39.71 p = 0.0002. Letters indicate differences 
between groups, different letters indicate significant differences between groups and 
the same letters indicate no difference.  C. n = 3. Error bars show standard deviation. 
A one-way ANOVA was performed, F3,8 = 6.972 p = 0.0127. Letters indicate 
differences between groups, different letters indicate significant differences between 







3.2.5 - CRISPR/Cas9 was used to generate zebrafish with heritable 
mutations in foxp1a and foxp1b 
To test the role of foxp1 in adipose tissue expansion, I next generated loss of 
function foxp1a and foxp1b alleles. To achieve this, I made use of the CRISPR/Cas9 
system. CRISPR/Cas9 is a system which has been adapted from bacteria and allows 
site specific double stranded DNA breaks to be created through the use of a Cas9 
enzyme (Hwang et al., 2013). I first designed a series of guide RNAs (gRNAs) 
targeting the different functional domains of foxp1a and foxp1b (Figure 3.3A). I 
targeted close to the translational start site to try and disrupt as much protein function 
as possible, the zinc finger domain was targeted to stop the proteins from dimerising 
and the forkhead domain was targeted to prevent DNA binding (Figure 3.3A). The 
gRNAs were then synthesised and injected into WT zebrafish embryos at the one cell 
stage, along with the Cas9 nuclease protein (Figure 3.3A). The mutagenic activity of 
each of the guides was then assessed using a T7 endonuclease 1 (T7E1) assay 
(Stage 1 Figure 3.3A & Figure 3.4A). gRNAs which produced a different banding 
pattern to that of uninjected fish were deemed to be active and inducing mutations 
(Stage 1 - Figure 3.4A). The active gRNAs were then reinjected into WT embryos, in 
order to generate stable lines (Stage 1 - Figure 3.3A). These embryos were raised 
until adulthood and became the G0 generation (Stage 2 - Figure 3.3A & B). In order 
to generate stable mutant lines, G0 fish with germline mutations were identified. Adult 
G0 fish were outcrossed to WT fish and their progeny screened by T7E1 assay for 
lesions at the CRISPR target locus (Stage 2 - Figure 3.3B & Figure 3.4B). G0 fish 
found to have germline mutations were again crossed to WT fish and their offspring 
raised to adulthood, to generate F1 fish with germline foxp1 mutations (Figure 3.3B). 
In summary this strategy generated a F1 generation of fish with heritable mutations 
in either foxp1a or foxp1b.   
 
3.2.6 - The nature of the mutations generated by CRISPR/Cas9 were 
identified and mutations predicted to have a severe effect on protein 
function were selected  
The CRISPR/Cas9 system does not induce mutations in all F1 fish and the 
effect of the mutations induced is also not likely to be the same. To determine if a 
mutation had occurred and the nature of the mutation, DNA from F1 fish was sent for 
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sequencing (Stage 3 - Figure 3.3C). Tissue from the caudal fin of adult F1 fish was 
taken and gDNA extracted (Stage 3 - Figure 3.3C). This gDNA was then sent for 
sequencing. Predicted frameshift mutations in all domains were selected for, as these 
were predicted to severely disrupt protein function (Stage 3 – Figure 3.3C). In frame 
mutations at the ZFD and FHD were also selected for, as these were predicted to 
disrupt the function of individual domains without affecting overall protein function. 
The selected F1 mutants were then outcrossed to WT fish (Figure 3.3D). This then 
produced a breeding stock, 50% of which were WT and 50% of which were 
heterozygous for a known mutation (Figure 3.D). Overall I was able to generate a 
series of mutant alleles (described in the next section) which were predicted to have 










Figure 3.3 – Injection of CRISPR guides targeting foxp1 leads to mutations in 
foxp1a and foxp1b. Schematic showing strategy for creating stable mutants. A. 
Schematic showing generation of guide RNAs, injection into zebrafish embryos and 
testing of CRISPR efficiency. B. Schematic showing the outcrossing of GO fish and 
the testing of CRISPR guide efficiency in F1 embryos. C. Schematic showing the 
identification of mutations in F1 adults. D. Schematic showing outcrossing of F1 fish 




Figure 3.4 – CRISPR/Cas9 induces mutations at the foxp1a and foxp1b loci. 
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Figure 3.4 – CRISPR/Cas9 induces mutations at the foxp1a and foxp1b loci. A. 
T7E1 assay gels used to test CRISPR guide efficiency. See stage 1 of Figure 3.3. 
Guides are cutting if the banding pattern in the injected lane is different to that of the 
uninjected lane. Arrowheads highlight changes in the banding patterns in the injected 
fish. Pools of 10 embryos were tested. The dotted line indicates that some lanes of 
the gel have been removed. The complete gel image can be found in the appendix. 
B. T7E1 assay gels used to test CRISPR activity in F1 embryos. See stage 2 of Figure 
3.3. Guides are cutting if the banding pattern in the injected lane is different to that of 
the uninjected lane. Arrowheads highlight changes in the banding patterns in the 
injected fish. Pools of 10 embryos were tested. The dotted line indicates that some 
lanes of the gel have been removed. The complete gel image can be found in the 


















3.2.7 - A series of nine mutant alleles, predicted to have severe effects 
on Foxp1 protein function, were generated using CRISPR/Cas9 
Using CRISPR/Cas9 and the strategy outlined above, I was able to generate 
nine foxp1 mutant alleles. I generated one frameshift mutation close to the 
transcriptional start site of foxp1a, which is predicted to introduce an early stop codon 
and cause the protein to be non-functional (Figure 3.5A & B). I also generated a 
frameshift mutation at the ZFD of foxp1a and this again is predicted to introduce an 
early stop codon and result in a non-functional protein (Figure 3.5A & C). An inframe 
mutation targeting the ZFD of foxp1a was also selected and this mutant protein is 
predicted to be unable to dimerise but able to bind DNA (Figure 3.5A & C). The final 
foxp1a mutant alleles generated are two frameshift mutations targeting the FHD and 
both are predicted to be loss of function mutations due to the lack of a DNA binding 
domain (Figure 3.5A & D). In addition to the foxp1a mutants, I generated 4 foxp1b 
mutants (Figure 3.5E & F). Three of the foxp1b mutant alleles are the result of 
frameshifts at the FHD and one is the result of an inframe mutation at the FHD (Figure 
3.5E & F). All of the foxp1b mutants are predicted to be unable to bind DNA. In 
summary, using CRISPR/Cas9 I effectively induced mutations in both foxp1a and 
foxp1b and generated a series of novel zebrafish mutants.  
 
3.2.8 - Mutations targeting the forkhead domain of foxp1a and foxp1b 
show high levels of transcript degradation   
Having generated a series of foxp1a and foxp1b mutant alleles, I next wanted 
to identify the alleles most likely to have the strongest loss of function. It was 
hypothesised that the alleles with the greatest levels of transcript degradation would 
also show the greatest levels of protein reduction and therefore the most severe 
phenotypes. I therefore assessed the alleles generated for transcript degradation. 
From the sequencing of F1 fish I was able to identify alleles which resulted in a 
predicted frameshift across all the functional domains of foxp1a (Figure 3.5A, B, C & 
D). I was also able to identify an inframe mutation and frameshift mutations at the 
forkhead domain of foxp1b (Figure 3.5E & F). Of the nine alleles identified, I was able 
to use PCR and restriction digests to genotype seven alleles. The remaining two 
alleles, foxp1a(ed14/ed14) and foxp1a(ed15/ed15), were unable to be genotyped due to the 
repetitive nature of the sequences surrounding the mutations (Figure 3.5B & D). For 
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the alleles I was able to genotype, I extracted RNA from pools of WT and mutant 
embryos at 5 dpf. Levels of foxp1a and foxp1b transcripts were then measured by 
RT-qPCR and the fold change calculated (Figure 3.5G). High levels of transcript 
degradation were observed for all frameshift alleles, with foxp1a(ed18/ed18) showing the 
highest levels with a 38.6 fold reduction in foxp1a mRNA. (Figure 3.5C & G). The 
only allele not to show high levels of transcript degradation was the foxp1b(ed26/ed26) 
allele, which does not result in a frameshift and shows only a 1.3 fold reduction in 
foxp1b mRNA levels (Figure 3.5F & G). In summary 5 out of the 6 alleles tested 
showed high levels of transcript degradation.  
 
3.2.9 - Alleles targeting the forkhead domain of foxp1a and foxp1b were 
selected for further functional studies 
Of the nine mutant alleles generated, I chose to use FHD mutants to test my 
hypothesis. I chose these mutants as they were predicted to disrupt the ability of 
Foxp1a and Foxp1b to bind DNA, which is the central function of Foxp1. I chose the 
foxp1a(ed16/ed16) allele, as it showed high levels of transcript degradation with a 3.3 fold 
reduction, and the foxp1b(ed25/ed25) allele, which showed similar levels of transcript 
degradation with a 2.8 fold reduction (Figure 3.5G). For the remainder of this thesis, 
I will focus on these two alleles to test the role of foxp1a and foxp1b in AT expansion. 
For simplicity these alleles will now be referred to as foxp1a(-/-) and foxp1b(-/-).  I have 
used both of these alleles individually to test my hypothesis and I have also generated 
foxp1a(-/-);foxp1b(-/-) double mutants to help test my hypothesis. Overall, I chose to 
make use of the foxp1a and foxp1b alleles which target the FHD and show high levels 





Figure 3.5 – Frameshift mutations in foxp1 lead to transcript degradation. 
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Figure 3.5 – Frameshift mutations in foxp1 lead to transcript degradation. A. 
Schematic of the foxp1a exon structure. B. foxp1a(ed14/ed14) mutant shows a 7bp indel 
resulting in a frameshift. C. foxp1a(ed17/ed17) allele shows a 45bp indel which does not 
change in the reading frame. foxp1a(ed18/ed18) allele shows a 10bp indel, resulting in a 
frameshift. D. foxp1a(ed15/ed15) allele shows a 7bp indel resulting in a frameshift. 
foxp1a(ed16/ed16) allele shows a 13bp indel resulting in a frameshift. E. Schematic of the 
foxp1b exon structure. F. foxp1b(ed23/ed23) allele shows a 5bp deletion resulting in a 
frameshift. foxp1b(ed24/ed24) allele shows a 2bp deletion resulting in a frameshift. 
foxp1b(ed25/ed25) allele shows a 4bp indel resulting in a frameshift. foxp1b(ed26/ed26) allele 
shows a 12bp insertion, which doesn’t alter the reading frame. B.C.D. & F. Letters 
represent DNA bases. Red letters show changed based in the mutants. Thick dashed 
lines under the bases represent codons. Small dashes lines show deletions in the 


















3.2.10 - The foxp1a(-/-) allele is predicted to have a reduced ability to bind 
DNA       
To test the hypothesis that foxp1 is required for adipose tissue expansion, I 
first examined the role of foxp1a. The foxp1a allele I chose to use is foxp1(-/-), which 
is caused by a 13bp indel in the FHD (Figure 3.6A & B). This mutation consisted of 
an 8bp deletion and a 4bp change and is predicted to lead to a frameshift and the 
introduction of an early stop codon within the FHD (Figure 3.6A & B). I first wanted 
to predict the likely effect of this mutation on the FHD of foxp1a and therefore on the 
ability of foxp1a to bind DNA. As the mutation in foxp1a(-/-) is towards the 3’ end of the 
FHD the function of this domain could be retained in the mutant (Figure 3.6A). To 
determine whether this was likely I identified the sequence of the FHD in zebrafish. In 
mouse the FHD of Foxp1 is made up of 90 highly conserved amino acids, and these 
residues are well conserved to zebrafish (Stroud et al., 2006). In the foxp1a(-/-) mutants 
8 residues of the FHD were predicted to be changed and 16 were predicted to be 
absent (Figure 3.6C & D). Furthermore, 4 amino acids known to be involved in DNA 
binding were absent or altered in the foxp1a(-/-) mutant (Figure3.6D). The altered or 
absent residues include a tryptophan residue, which interacts extensively with the 
sugar phosphate backbone of DNA and stabilises the DNA protein complex (Stroud 
et al., 2006) (Figure 3.6D). Two arginine residues, which also stabilise the Foxp1 
DNA complex are also absent in the foxp1a(-/-) mutants (Stroud et al., 2006) (Figure 
3.6D). Taken together this suggests that the foxp1a(-/-) mutants will be unable to bind 
DNA. 
   
3.2.11 - foxp1a(-/-) mutants do not show genetic compensation   
foxp1a(-/-) mutants were selected based on the fact that these mutants show 
high levels of transcript degradation. However, a recent paper has shown that mutant 
mRNA degradation is linked to increased expression of related genes (El-Brolosy et 
al., 2019). I therefore wished to measure the mRNA levels of genes closely related to 
foxp1a and determine whether they are altered in the foxp1a(-/-) mutants. To do this, 
5 dpf fish were genotyped and RNA extracted from pools of 3 embryos. I then used 
RT-qPCR to measure the levels of all of the foxp genes in foxp1(-/-) mutants and WT 
siblings (Figure 3.6F). I found that levels of foxp1b, foxp2, foxp3a, foxp3b and foxp4 
were not significantly increased in foxp1a(-/-) mutants (Figure 3.6F). Together these 
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data suggest that it is reduced levels of foxp1a and not increased levels of other foxp 
transcripts that are responsible for any phenotypes observed in foxp1a(-/-) mutants.  
 
3.2.12 - foxp1a(-/-) mutants show a large reduction in Foxp1 proteins levels 
To determine the severity of the foxp1a(-/-) allele, I next wanted to assess 
Foxp1 protein levels. Protein lysate was extracted from the caudal fins of pools of 7 
juvenile fish, and a Western blot was then performed using antibodies against FOXP1 
and ACTB (Beta-Actin), with ACTB acting as a loading control (Figure 3.6G). 
Zebrafish Foxp1a protein is predicted to be 72 kDa and Foxp1b is predicted to be 78 
kDa. Based on this and previous studies in mouse the zebrafish Foxp1 protein is 
expected to be between 70 and 80 kDa (Rao et al., 2010). Western blotting using a 
FOXP1 antibody revealed a band in the WT sample at around 65 kDa (Figure 3.6G). 
Foxp1 protein levels were found to be severely reduced in foxp1a(-/-) mutants (Figure 
3.6G). Whole mount antibody staining was also attempted in adipose tissue, though 
this did not work (data not shown). The staining also did not appear to work in non-
adipose tissues, such as the heart and brain (data not shown). In summary foxp1a(-/-) 
mutants are likely to be loss of function mutants, as evidenced by reduced levels of 


















Figure 3.6 – A 13bp indel in foxp1a leads to a predicted frameshift mutation. A. 
Schematic showing the exon structure of foxp1a(+/+) and foxp1a(-/-). Orange bars show 
exons coding for functional domains (Pfam and Smart). ATG (ATG transcriptional start 
site). ZFD (zinc finger domain). FHD (forkhead domain). Dotted line shows where 
qPCR primers target B. Schematic showing changes to DNA in foxp1a(-/-) mutants. 
Letters indicate DNA bases. Small dashed lines show where a deletion has taken 
place. Red letters show changed bases. Dashed lines under the bases show the 
reading frame. The red line shows the presence of an early stop codon. C. Schematic 
showing the protein structure of Foxp1a(+/+) and Foxp1a(-/-). Orange bars show 
functional domains. The green bar shows changes to the protein sequence in the 
mutant. Numbers show predicted amino acid protein lengths. D. Schematic showing 
the changes to the amino acid sequence of the forkhead domain in the Foxp1a(-/-) 
mutant. Letters represent amino acids and red letters show amino acids known to be 
involved in DNA binding. The red line highlights the changed amino acids in the 
Foxp1a(-/-) mutants. E.  n = 3 pools of 3 fish. A two tailed t-test was performed p < 
0.001. Error bars show standard deviation F. n = 3 pools of 3 fish. Error bars show 
standard deviation. Two tailed t-tests were performed. foxp1b, foxp2, foxp3a, foxp3b 
and foxp4 mRNA levels were not found to be significantly different in foxp1a(+/-) or 
foxp1a(-/-) mutants when compared to WT siblings. G. 20 minute exposure. Each lane 














3.2.13 - foxp1a(-/-) mutants have unaltered levels of AT during normal 
development 
To test if foxp1 is required for AT expansion, I first examined adiposity levels 
in the foxp1a(-/-) mutants. To achieve this, I incrossed foxp1a(+/-) fish and raised the 
resultant offspring until 4 weeks of age. The fish were then genotyped and foxp1a(-/-) 
mutant fish and foxp1a(+/+) siblings were stained with Nile red at 5 weeks of age. The 
fish were then imaged using a fluorescence stereomicroscope (Figure 3.7A). Image 
J was used to measure the standard length (SL) of the fish and this was compared to 
the total fluorescence area, which acts as a proxy for total AT area (Tingaud-Sequeira 
et al., 2011). Under normal fed conditions, foxp1a(-/-) mutant fish were found to show 
no differences in levels of AT relative to SL when compared to foxp1a(+/+) siblings 
(Figure 3.7C). foxp1a(-/-) fish were also found to develop normally and had an 
unaltered SL when compared to WT siblings (Figure 3.7B). In summary, foxp1a(-/-) 


















Figure 3.7 – foxp1a(-/-) mutants have unaltered levels of AT during normal 
development. A. Representative Nile Red images. Nile Red staining shown in black. 
Fish are 5 weeks of age. B. n = 106-111. Data from 6 experiments. Error bars show 
mean and standard deviation. A two tailed t-test was performed, p = 0.39  C. n = 106-
111. Data from 6 experiments. An Ancova analysis was performed, and the slope of 


















3.2.14 - foxp1a(-/-) mutants gain less AT in response to a HFD 
I next placed foxp1a(-/-) fish on a HFD to see if adipose tissue expansion in the 
mutant fish was altered in response to this dietary stimulus. I incrossed foxp1a(+/-) fish 
and raised the offspring until 4 weeks of age (Figure 3.8A). At this point the fish were 
genotyped and separated into foxp1a(+/+) and foxp1a(-/-) groups (Figure 3.8A). The fish 
were then stained with Nile Red and divided into 2 size matched groups, one HFD 
and one control diet group (Figure 3.8A). Fish within these groups were randomly 
paired (Figure 3.8A). The pairing of fish within groups minimised variation due to 
differences in fish size and allowed adipose measurements to be taken from the same 
fish before and after the diet. Fish then were subjected to a 2 week HFD, consisting 
of a 2 hour daily immersion in a 5% egg yolk solution (Carten et al., 2011, Semova et 
al., 2012, Walters et al., 2012,) (Figure 3.8A). Finally, fish were stained with Nile Red 
and imaged at the end of the diet (Figure 3.8A).  Analysis of the Nile Red 
measurements following the HFD revealed that the foxp1a(+/+) HFD fish had 
significantly more AT than foxp1a(+/+) control diet (CD) siblings, demonstrating that the 
HFD induces increased adiposity (Figure 3.8C & D). However foxp1a(-/-) HFD mutant 
fish were found to have significantly less total AT than foxp1a(+/+) HFD siblings (Figure 
3.8B & C). Nile Red measurements taken before and after the HFD also allowed me 
to measure changes in AT levels in response to the diet. foxp1a(-/-) mutants gained 
less AT in response to the HFD, though this difference was just short of significance 
(Figure 3.8D). Taken together this shows that while foxp1a(-/-) mutant fish have normal 
levels of AT on a control diet, they gain less AT than WT fish when fed a HFD.  
 
3.2.15 - foxp1a(-/-) mutants gain less SAT in response to a HFD 
As visceral and subcutaneous adipose tissue (SAT) are known to have 
different properties in mammals, I also wanted to see if there were any differences in 
the response of VAT and SAT to the HFD in the foxp1a(-/-) mutants (Ibrahim, 2010). 
AT depots in zebrafish can be classified into visceral and subcutaneous depots and 
so measurements were taken of VAT and SAT depots from the Nile Red images 
(Figure 3.8B). These measurements showed that the effect of the diet was significant 
in WT fish for both VAT and SAT (Figure 3.8E & F). However, while foxp1a(-/-) mutant 
fish gained normal levels of VAT they gained significantly less SAT than WT siblings 
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(Figure 3.8E & F). These data suggest that foxp1a may play a greater role in 







Figure 3.8 - foxp1a(-/-) mutants gain less AT in response to a HFD. 
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Figure 3.8 - foxp1a(-/-) mutants gain less AT in response to a HFD. A. Schematic 
showing how the HFD was conducted. B. Representative Nile Red images. Orange 
arrow heads show the locations of major VAT depots, PVAT (pancreatic VAT) and 
RVAT (Renal VAT). Blue arrow heads show the locations of major SAT depots, LSAT 
(lateral SAT) and aDSAT (anterior dorsal SAT) C. n = 47. Data from 4 experiments. 
An Ancova analysis was performed and the slope of the foxp1a(+/+) HFD and foxp1a(-
/-) HFD lines were found to be significantly different F1,89 = 11.43, p = 0.0011. D. n = 
24. Data from 4 experiments. A two-way ANOVA was performed and the effect of diet 
was found to be significant F1,92 = 64.12, p < 0.0001. Genotype, F1.92 = 3.928, p = 
0.0505. E. n = 24. Data from 4 experiments. A two-way ANOVA was performed and 
the effect of diet was found to be significant F1,92 = 75.65, p < 0.0001. F. n = 24. Data 
from 4 experiments. A two-way ANOVA was performed and the effects of both diet 
and genotype were found to be significant. Diet, F1,92 = 31.13, p < 0.0001. Genotype, 

















3.2.16 - foxp1a(-/-) mutants have a more hypertrophic lipid droplet 
morphology 
I next examined the morphology of the lipid droplets within adipose tissue, as 
the reduced expansion of AT in the foxp1a(-/-) mutants may be due to reduced 
hyperplastic or hypertrophic growth. To assess AT lipid droplet morphology foxp1a(-/-) 
mutant fish and WT siblings were placed on a 2 week HFD, following the same 
protocol as described previously (Figure 3.7A). Following the HFD fish were stained 
with LipidTOX and the lateral SAT (LSAT) depot imaged through the skin of 
euthanised fish, using confocal microscopy (3.9E & F). Once this imaging was 
complete the PVAT depot was dissected from the fish and the whole depot imaged 
by confocal microscopy (3.9A & B). Both the number and diameter of the lipid droplets 
present in each depot were measured. The effect of the HFD was apparent when 
looking at the morphology of both the visceral and subcutaneous depot in WT fish, 
with the average diameter of the lipid droplets being significantly increased in both 
(Figure 3.9D & H). No changes in lipid droplet number in response to the HFD were 
observed in WT fish (Figure 3.9C & G). foxp1a(-/-) mutants showed a genotype specific 
effect in LSAT only and had a significantly greater average lipid droplet diameter than 
their WT siblings (Figure 3.9H). No differences were observed between foxp1a(-/-) 
mutant fish and WT siblings in lipid droplet number in either the PVAT or LSAT depot 
(Figure 3.9C & G). Taken together these data suggest that the SAT of foxp1a(-/-) 
























Figure 3.9 – foxp1a(-/-) mutants have a more hypertrophic LSAT lipid droplet 
morphology. A. Representative maximum intensity projections of PVAT (Pancreatic 
VAT). The anterior end of the depot is to the right of the image and the posterior to 
the left. B. Schematic showing the location of PVAT. C. Number of lipid droplets per 
PVAT. N = 12 D. Average diameter of lipid droplets per PVAT. A two way ANOVA 
was performed and the effect of diet was found to be significant F1,46 = 16.85 p = 
0.0002. n = 12. E. Representative maximum intensity projections of LSAT (Lateral 
SAT). The anterior end of the depot is to the right. F. Schematic showing the location 
of LSAT. G. Number of lipid droplets per LSAT. N = 4-5. H. Average diameter of lipid 
droplets per LSAT. A two way ANOVA was performed and the effect of both diet and 
genotype were found to be significant. Diet, F1,15 = 38.08 p = 0.0001. Genotype, F1,15 



















3.2.17 - foxp1a(-/-) mutants have normal levels of blood metabolites 
As foxp1a(-/-) mutants show a defect in adipose tissue expansion in response 
to a HFD, I next wanted to determine if the metabolic health of foxp1a(-/-) mutants was 
affected. A severe defect in AT expansion would mean that a reduced amount of lipid 
would be able to be stored in AT and this would lead to increased levels of blood fatty 
acids and triglycerides (Lafontan, 2014). This could also potentially lead to increased 
levels of blood glucose and cholesterol (Lafontan, 2014).  To determine the severity 
of the AT expansion defect observed in the foxp1a(-/-) mutants, levels of lipid 
metabolites in the blood were measured following a 1 week HFD (Figure 3.10A). 
foxp1a(+/-) fish were incrossed and their offspring genotyped at 4 weeks of age (Figure 
3.10A). foxp1a(-/-) fish and WT siblings were then raised at equal stocking densities 
until 2 months of age, at which point they were placed on a 1 week HFD (Figure 
3.10A). Following the diet, fish were fasted overnight, euthanised and blood extracted 
from the fish (Figure 3.10A). The blood was then used to measure levels of glucose, 
triglyceride and cholesterol (Figure 3.10B. C. & D). No differences were observed in 
the levels of glucose, triglyceride or cholesterol in the foxp1a(-/-) mutants when 
compared to WT siblings (Figure 3.10B. C. & D). However the effect of the HFD could 
be observed with both foxp1a(-/-) and foxp1a(+/+) fish on the HFD having significantly 
higher levels of blood triglycerides than fish on the control diet (Figure 3.10C). Taken 
together this suggests that AT expansion in response to a HFD is not so severely 






Figure 3.10 – foxp1a(-/-) mutants have normal levels of blood metabolites. A. 
Schematic showing HFD protocol. B. n = 5-6. C. n = 5-6. A two way ANOVA was 
performed and the effect of diet was found to be significant. F1,19 = 26.07 p < 0.0001. 










3.2.18 - The foxp1a(-/-) mutant phenotype suggests that foxp1a plays an 
important role in AT expansion  
The most notable phenotype of the foxp1a(-/-) mutants is a reduction in adipose 
tissue expansion following a HFD (Figure 3.11A). Following a HFD, foxp1a(-/-) mutants 
gain less AT, specifically they gain less SAT and they have a more hypertrophic SAT 
morphology (Figure 3.11A). Taken together these data support the hypothesis that 
foxp1 is required for AT expansion and point to a role for foxp1a specifically within 
SAT (Figure 3.11B & C).  






Figure 3.11 - foxp1a is required for SAT expansion in response to a HFD. A. 
Summary of the phenotype of the foxp1a(-/-) mutants. B. Schematic showing lipid 
droplet morphology in foxp1a(-/-) fish on a control diet. C. Schematic showing lipid 
droplet morphology in foxp1a(-/-) mutants on a HFD.  
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3.2.19 - The foxp1b(-/-) allele is predicted to have a reduced ability to bind 
DNA   
Having examined the role of foxp1a in AT expansion (section 3.2.10 - 3.2.18), 
I next wanted to examine the role of foxp1b. As stated previously, I have made use of 
the foxp1b(-/-) allele to test my hypothesis. The foxp1b(-/-) allele is characterised by a 
4bp indel at the FHD of foxp1b (Figure 3.12). The 4bp indel is comprised of a 3bp 
change and a 1bp insertion, which leads to a frameshift and the introduction of an 
early stop codon (Figure 3.12A & B). As the mutation in foxp1b(-/-) occurs at the start 
of the FHD it was thought that it would be likely to disrupt the ability of the FHD to bind 
DNA (Figure 3.12A). To check if this was the case, I translated the predicted base 
changes in the mutant to predicted amino acid changes and then aligned this 
sequence with that of WT Foxp1b (Figure 3.12C & D). The foxp1b(-/-) mutant was 
found to retain the first 5 amino acids of the FHD but all other residues had been 
changed to nonsense sequence or were absent (Figure 3.12D). Therefore, it was 
concluded that the mutant Foxp1b protein would be unlikely to be able to bind DNA.  
 
3.2.20 - foxp1b(-/-) mutants do not show genetic compensation  
As with the foxp1a(-/-) allele, I also wanted to determine whether the foxp1b(-/-) 
mutants showed genetic compensation. To do this 5 dpf embryos were fin clipped, 
genotyped and RNA extracted from pools of 3 embryos. I then used RT-qPCR to 
measure levels of foxp1a, foxp2, foxp3a, foxp3b and foxp4 in the foxp1b(-/-) mutants 
and WT siblings (Figure 3.12F). None of the genes tested were found to be 
significantly upregulated in the foxp1b(-/-) mutants (Figure 3.12F). Interestingly levels 
of foxp3a and foxp3b were significantly downregulated in foxp1b(+/-) mutants 
compared to WT siblings (Figure 3.12F). This finding is at odds with the results from 
the foxp1b(-/-) mutants and further experiments are needed to interpret this result. 
Overall, a reduction in levels of foxp1b transcripts and no apparent compensation in 
the foxp1b(-/-) mutants gives confidence to the idea that the foxp1b(-/-) allele is a loss of 






3.2.21 - foxp1b(-/-) mutants have a large reduction in Foxp1 protein levels  
To assess the severity of the foxp1b(-/-) allele, I next measured Foxp1 protein 
levels. Protein was extracted from the caudal fin of pools of 7 mutant and WT juvenile 
fish and a western blot was performed as described previously in section 3.2.12 
(Figure 3.12G). I found that levels of Foxp1 were severely reduced in the foxp1b(-/-) 
mutants (Figure 3.12G). This suggests that the foxp1b(-/-) allele is a loss of function 







Figure 3.12 – The foxp1b(-/-) mutants have reduced foxp1b mRNA levels, 




Figure 3.12 – The foxp1b(-/-) mutants have reduced foxp1b mRNA levels, reduced 
Foxp1 protein levels and do not show genetic compensation. A. Schematic 
showing the exon structure of foxp1b(+/+) and foxp1b(-/-).  Orange bars show exons 
coding for functional domains (Pfam and Smart). ATG (ATG transcriptional start site). 
ZFD (zinc finger domain). FHD (forkhead domain). Dashed line shows the exons 
targeted by the qPCR primers. B. Schematic showing changes to the DNA sequence 
in foxp1b(-/-) mutants. Letters indicate DNA bases. Small dashed lines show where an 
insertion has taken place. Red letters show changed bases. Dashed lines under the 
bases show the reading frame. C. Schematic showing the protein structure of 
foxp1b(+/+) and foxp1b(-/-). Orange bars show functional domains. The blue bar shows 
changes to the protein sequence in the mutant. Numbers show predicted amino acid 
lengths of proteins. D. Schematic showing the changes to the amino acid sequence 
of the forkhead domain in the foxp1b(-/-) mutant. Letters represent amino acids and red 
letters show amino acids known to be involved in DNA binding. The red line highlights 
the changed amino acids in the foxp1b(-/-) mutants. E. n = 3 pools of 3 fish. A two tailed 
t-test was performed p < 0.001. Error bars show standard deviation F. n = 3 pools of 
3 fish. Error bars show standard deviation. Two tailed t-tests were performed. G. 20 
minute exposure. Each lane contains protein from a pool of 7 fish. Dashed white line 














3.2.22 - foxp1b(-/-) mutants are smaller than WT siblings but have 
unaltered levels of AT during normal development  
I next wanted to begin to test my hypothesis, that foxp1 is required for AT 
expansion, by assessing the effect of a reduction in foxp1b on AT levels. To achieve 
this, I incrossed foxp1b(+/-) fish and raised their offspring until 30 dpf. The fish were 
then genotyped and stained with Nile Red. As described previously, the fish were 
imaged using a fluorescence stereomicroscope and total AT area was measured and 
compared to SL (Figure 3.13A). foxp1b(-/-) mutant fish were found to be significantly 
smaller than WT siblings but were found to have normal levels of AT relative to their 
size (Figure 3.13B & C). These data suggest that foxp1b(-/-) mutants have reduced 


















Figure 3.13 – foxp1b(-/-) mutants are smaller than WT siblings and have unaltered 
levels of AT during normal development. A. A. Representative Nile Red images. 
Nile Red staining shown in black. B. n = 45. Data from 4 experiments. A two tailed t-
test was performed, p < 0.0001. C. n = 45. Data from 4 experiments. An Ancova 
analysis was performed and the lines were not found to be significantly different F1,86 

















3.2.23 - foxp1b(-/-) mutants gain less AT in response to a HFD 
To further test my hypothesis, that foxp1b is required for AT expansion, I next 
placed foxp1b(-/-) fish on a 2 week HFD. The purpose of the HFD was to stimulate AT 
expansion and the same HFD method described previously in section 3.2.14 was 
used. Briefly foxp1b(+/-) fish were incrossed and their offspring raised until 4 weeks of 
age (Figure 3.14A). The fish were then genotyped and at 5 weeks of age the 
foxp1b(+/+) and foxp1b(-/-) fish were stained with Nile Red (Figure 3.14A). The fish were 
then separated into size matched groups and placed on a 2 week HFD (Figure 
3.14A). Fish were also stained with Nile Red at the end of the diet (Figure 3.14A). 
Nile Red staining following the HFD showed that foxp1b(+/+) HFD fish had significantly 
more AT than foxp1b(+/+) CD fish, demonstrating that the HFD is capable of inducing 
significant adipose tissue accumulation (Figure 3.14B & C). foxp1b(-/-) HFD fish were 
found to have less total AT following the diet than foxp1b(+/+) HFD fish, though this 
difference was not significant (Figure 3.14B & C). However, when the change in total 
AT area was measured, comparing AT area before and after the diet, the effect of 
genotype was found to be significant (Figure 3.14D). Therefore, these data suggest 
that foxp1b is required for AT expansion in response to a HFD.   
 
3.2.24 - foxp1b(-/-) mutants gain less VAT in response to a HFD 
As foxp1a(-/-) mutants were found to have a specific defect in SAT expansion, 
I next wished to determine if this was also true of foxp1b(-/-) mutants. To do this I again 
used Nile Red images to measure the levels of VAT and SAT (Figure 3.14E & F). 
The effect of diet was found to be significant in both VAT and SAT, suggesting that 
the HFD induces both AT subtypes to expand (Figure 3.14E & F). However, unlike 
foxp1a(-/-) mutants, foxp1b(-/-) mutants gained significantly less VAT in response to the 
HFD and showed normal levels of SAT expansion (Figure 3.14E & F). This difference 
in phenotypes between the two mutants suggests that the foxp1a and foxp1b 
paralogues may have undergone subfunctionalisation and that the paralogues may 
play distinct roles in VAT and SAT expansion. In summary foxp1b(-/-) mutants gain 








Figure 3.14 – foxp1b(-/-) mutants gain less visceral adipose tissue in response 
to a HFD 
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Figure 3.14 – foxp1b(-/-) mutants gain less visceral adipose tissue in response to 
a HFD. A. Schematic showing how the HFD was conducted. B. Representative Nile 
Red images. C. n = 29. Data from 3 experiments. D. n = 10-11. Data from 3 
experiments. A two-way ANOVA was performed and the effect of both diet and 
genotype were found to be significant. Diet, F1,38 = 61.52, p < 0.0001. Genotype, F1,38 
= 6.419, p = 0.0155.  E. n = 10-11. A two-way ANOVA was performed and the effect 
of both diet and genotype were found to be significant. Diet, F1,38 = 35.35, p < 0.0001. 
Genotype, F1,38 = 8.087, p = 0.0071. F. n = 10-11. A two-way ANOVA was performed 
and the effect of diet was found to be significant, F1,38 = 11.02, p = 0.002.  D.E.F. Error 





















3.2.25 - foxp1b(-/-) mutants do not show changes in lipid droplet 
morphology  
As foxp1b(-/-) mutants show reduced levels of AT expansion in response to a 
HFD, I next wanted to determine whether this reduced expansion had an impact on 
adipose morphology. Adipose tissue can expand via hyperplastic or hypertrophic 
growth and so I wanted to determine whether the balance between these two modes 
of growth was altered in the foxp1b(-/-) mutants. To test this, foxp1b(-/-) fish were placed 
on a 2 week HFD, as described previously (Figure 3.14A). Following the HFD fish 
were stained with lipidTOX and LSAT imaged through the skin of euthanised fish 
(Figure 3.15E & F). PVAT was then dissected from the fish and the whole depot 
imaged (Figure 3.15A & B). Adipose morphology was assessed by measuring lipid 
droplet number and diameter. The effect of the HFD was apparent in both the PVAT 
and LSAT depots with a significantly greater average lipid droplet diameter in the HFD 
groups compared to the control diet groups (Figure 3.15D & H). No changes in lipid 
droplet number were observed in response to the HFD (Figure 3.15C & G). Similarly, 
no differences were observed between foxp1b(-/-) and foxp1b(+/+) fish in either the 
PVAT or LSAT depot (Figure 3.15C. D. G. & H). The lack of phenotype in the foxp1b(-
/-) mutants suggests that the experiment is underpowered or that the reduced VAT 
expansion in the foxp1b(-/-) mutants does not alter the balance between hypertrophic 















Figure 3.15 – foxp1b(-/-) mutants show no changes in adipose morphology 
following a HFD. A. Representative maximum intensity projections of PVAT depots. 
The anterior end of the depot is to the right of the image and the posterior to the left. 
B. Schematic showing the location of the PVAT depot. C. n = 9-11 D. n = 9-11. A two 
way ANOVA was performed and the effect of diet was found to be significant F1,34 = 
34.24 p < 0.0001. E. Representative maximum intensity projections of sections of the 
LSAT depot. The anterior of the depot is to the right of the image. F. Schematic 
showing the location of the LSAT depot. G. n = 4-5. H. n = 4-5. A two way ANOVA 
was performed and the effect of diet was found to be significant F1,14 = 9.131 p = 




3.2.26 - foxp1b(-/-) mutants do not have altered levels of blood metabolites 
Finally, I wanted to determine how severe the defect in AT expansion was in 
the foxp1b(-/-) mutants. As a readout of defective AT expansion, I looked at levels of 
blood metabolites. Long term exposure to a HFD can lead to improper lipid storage 
and altered levels of blood metabolites. In mutants which already have impaired AT 
expansion altered levels of lipid metabolites may be observed after shorter periods of 
exposure. I therefore examined levels of lipid metabolites in the blood of foxp1b(-/-) 
mutants, and I again made use of a HFD. foxp1b(-/-) fish were raised until 2 months of 
age and then placed on a 1 week HFD (Figure 3.16A). Following the HFD fish were 
euthanised and blood collected (Figure 3.16A). Levels of glucose, cholesterol and 
triglycerides were measured (Figure 3.16B. C. & D). No differences were observed 
between foxp1b(-/-) mutant fish and WT siblings, though the effect of the diet on 
triglyceride levels could be observed (Figure 3.16B. C. & D). Together these data 
suggest that AT expansion in foxp1b(-/-) mutants is not impaired to the extent as to 










Figure 3.16 – foxp1b(-/-) mutants do not have altered levels of blood metabolites. 
A. Schematic showing HFD protocol. CD (Control Diet). HFD (High Fat Diet). C. A 
two way ANOVA was performed and the effect of diet was found to be significant. F1,16 











3.2.27 - The foxp1b(-/-) mutant phenotype suggests that foxp1b is required 
for visceral AT expansion in response to a HFD 
In summary, I have found evidence to support the hypothesis that foxp1 is 
required for AT expansion. foxp1b(-/-) mutants have reduced levels of foxp1b mRNA, 
reduced levels of Foxp1 protein and show no signs of genetic compensation (Figure 
3.17A). foxp1b(-/-) mutants are also significantly smaller than WT siblings but have 
normal levels of AT relative to their size (Figure 3.17A). Following a HFD foxp1b(-/-) 
mutants gain less AT and specifically they gain less VAT (Figure 3.17A). Therefore, 
loss of foxp1b seems not to effect AT expansion during a control diet, but is sufficient 
to cause impaired VAT expansion during a HFD (Figure 3.17B & C). Together these 
data support my hypothesis about the role of foxp1b in AT expansion. It also allows 
me to refine my hypothesis with regards to foxp1b and to hypothesise that foxp1b is 






Figure 3.17 – foxp1b is required for VAT expansion in response to a HFD 
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Figure 3.17 – foxp1b is required for VAT expansion in response to a HFD. A. 
Summary of the main phenotypes of the foxp1b(-/-) mutants. B. Schematic illustrating 
what is hypothesised to occur during AT expansion on a control diet. C. Schematic 
























3.2.28 - foxp1a(-/-);foxp1b(-/-) mutants have reduced levels of foxp1a and 
foxp1b mRNA  
To test the hypothesis that foxp1 is required for AT expansion I have also 
made use of foxp1a(-/-);foxp1b(-/-) double mutants. These mutants were generated by 
crossing foxp1a(-/-) and foxp1b(-/-) mutants. foxp1 transcript levels are known to be 
reduced in the single mutants, however I also wanted to check whether foxp1 levels 
were reduced in the double mutants. To achieve this, 5 dpf fish were fin clipped, 
genotyped and RNA extracted from pools of 2-3 embryos. RT-qPCR was then used 
to determine the levels of foxp1a and foxp1b mRNA (Figure 3.18A & B). Levels of 
foxp1a and foxp1b were found to be reduced by 3.56 fold and 2.9 fold respectively in 
the foxp1a(-/-);foxp1b(-/-) mutants (Figure 3.18B). This demonstrates that the foxp1a(-/-
);foxp1b(-/-) double mutants show similar levels of transcript degradation to the single 
mutants.  
 
3.2.29 - foxp1a(-/-);foxp1b(-/-) mutants do not show genetic compensation 
As reduction in levels of foxp1a and foxp1b could lead to genetic 
compensation, I also measured the levels of other foxp genes in the foxp1a(-/-);foxp1b(-
/-) mutants. Using the RNA collected from the 5dpf embryos, levels of foxp2, foxp3a, 
foxp3b and foxp4 were measured by RT-qPCR (Figure 3.18C). It was found that none 
of the other foxp genes were upregulated in the foxp1a(-/-);foxp1b(-/-) mutants (Figure 
3.18C). This suggests that any phenotypes observed in the foxp1a(-/-);foxp1b(-/-) 
mutants will be due to a reduction in the levels of foxp1a and foxp1b, and not due to 
increased expression of other foxp genes.  
 
3.2.30 - foxp1a(-/-);foxp1b(-/-) mutants have reduced levels of Foxp1 protein  
To determine the likely severity of the foxp1a(-/-);foxp1b(-/-) mutants, I also 
checked to see if levels of Foxp1 protein were decreased in the mutants. To do this 
protein was extracted from the caudal fins of pools of 7 juvenile fish. The protein lysate 
was then run on a western blot and probed with antibodies against FOXP1 and ACTB 
(Figure 3.18D). A strong band was found for Foxp1 at around 65 kDa in the 
foxp1a(+/+);foxp1b(+/+) sample. A much weaker band was found in the same position in 
the foxp1a(-/-);foxp1b(-/-) mutant sample, and levels of Foxp1 were found to be severely 
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reduced (Figure 3.18D). This suggests that any phenotypes observed in the foxp1a(-


















Figure 3.18 – levels of foxp1 mRNA and Foxp1 protein are reduced in foxp1a(-/-





Figure 3.18 – levels of foxp1 mRNA and Foxp1 protein are reduced in foxp1a(-/-
);foxp1b(-/-) mutants and no genetic compensation is observed. A. Schematic 
showing the location of qPCR primers. The location of the ed16 and ed25 mutations 
are marked. Functional domains are shown in orange. B. n = 3 pools of 1-2 fish. Two 
tailed t-tests were performed, p < 0.001. Error bars show standard deviation. C. n = 2 
pools of 1-2 fish. Two tailed t-tests were performed, no differences were significant. 
D. 20 minute exposure. Each lane contains protein from 7 fish. Dotted line shows 





















3.2.31 - foxp1a(-/-);foxp1b(-/-) mutants have reduced levels of AT 
To investigate my hypothesis with regards to the foxp1a(-/-);foxp1b(-/-) mutants, 
I first looked at levels of AT in the mutant fish. foxp1a(-/-);foxp1b(-/-) fish were raised until 
30 dpf and then stained with Nile Red. Total AT area was then quantified and plotted 
relative to fish length. Similarly to the foxp1b(-/-) mutants foxp1a(-/-);foxp1b(-/-) mutants 
were found to be significantly smaller than their WT siblings (Figure 3.19A & B). 
foxp1a(-/-);foxp1b(-/-) mutants were also found to have less AT relative to SL than their 
WT siblings (Figure 3.19C). foxp1a(-/-);foxp1b(-/-) mutants were found to have reduced 
levels of AT when compared to foxp1a(-/-) and foxp1b(-/-) single mutants (Figure 




















Figure 3.19 – foxp1a(-/-);foxp1b(-/-) mutants have reduced levels of AT. A. 
Representative Nile Red images. Nile Red staining shown in black. B. n = 43. Data 
from 3 experiments. Error bars show mean and standard deviation. A two tailed t-test 
was performed, p = 0.007. C. n = 43. Data from 3 experiments. An Ancova analysis 
was performed and the slope of the lines found to be significantly different, F1,92 = 17.9 
p < 0.0001. D. n = 45-105. Data from 3 experiments. An Ancova analysis was 
performed and the slope of the lines found to be significantly different, F2,191 = 24.86 











3.2.32 - foxp1a(-/-);foxp1b(-/-) mutants have reduced levels of AT following 
a HFD 
To further test my hypothesis, I placed the foxp1a(-/-);foxp1b(-/-) mutants on a 
HFD to stimulate adipose tissue expansion (Figure 3.20A). foxp1a(-/-);foxp1b(-/-) 
mutant fish and WT siblings were raised until 5 weeks of age and then placed on a 2 
week HFD, as described previously (Figure 3.20A). Following the HFD, 
foxp1a(+/+);foxp1b(+/+) HFD fish were found to have significantly more AT than 
foxp1a(+/+);foxp1b(+/+) CD fish and this demonstrated that the HFD could induce 
significant AT expansion (Figure 3.20B & C). foxp1a(-/-);foxp1b(-/-) HFD mutant fish 
were found to have slightly less total adipose tissue than WT siblings, though this 
difference was not significant (Figure 3.20B & C). Similarly, when change in AT was 
calculated foxp1a(-/-);foxp1b(-/-) mutants were found to gain less AT than WT fish but 
again this was not significant (Figure 3.20D). No significant differences were found 
between levels of VAT or SAT when comparing foxp1a(-/-);foxp1b(-/-) mutants to WT 
siblings (Figure 3.20 E & F). In summary foxp1a(-/-);foxp1b(-/-) mutants seem to have 
a reduced response to a HFD, which supports the hypothesis that foxp1 is required 
for AT expansion. The fact that the reduced response of the foxp1a(-/-);foxp1b(-/-) 
mutants to the HFD was not significant, could be explained by variations in the SL of 










Figure 3.20 – foxp1a(-/-);foxp1b(-/-) mutants gain less AT in response to a HFD. A. 
Schematic of the HFD protocol. CD (Control Diet). HFD (High Fat Diet). B. 
Representative Nile Red images. Nile Red staining shown in black. C. n = 19-20 per 
group. Data from 3 experiments. An Ancova analysis was performed between 
foxp1a(+/+);foxp1b(+/+) CD and foxp1a(+/+);foxp1b(+/+) HFD groups, F1,161 = 3.904e15 p < 
0.0001. D. A two-way ANOVA was performed and the effect of diet was found to be 
significant, F1,44 = 13.41 p = 0.0007. E. A two-way ANOVA was performed and the 
effect of diet was found to be significant, F1,44 = 9.205 p = 0.004. F. A two-way ANOVA 
was performed and the effect of diet was found to be significant, F1,44 = 12.26 p = 




















3.2.33 - foxp1a(-/-);foxp1b(-/-) mutants have a more hypertrophic adipose 
lipid droplet morphology  
To determine whether the reduced AT expansion observed in foxp1a(-/-
);foxp1b(-/-) mutants is accompanied by an altered mode of AT expansion, I next 
examined AT morphology. The PVAT depot was dissected from foxp1a(-/-);foxp1b(-/-)  
mutant and WT adult fish. The depot was then stained with lipidTOX and the whole 
depot imaged using confocal microscopy (Figure 3.21A & B). Analysis of the lipid 
droplets showed that foxp1a(-/-);foxp1b(-/-) mutants had a more hypertrophic adipose 
morphology than WT siblings (Figure 3.21C & D). The PVAT depot of foxp1a(-/-
);foxp1b(-/-) mutants was found to have fewer lipid droplets, with greater average 
diameter (Figure 3.21C & D). Due to the low sample size of this experiment statistical 
testing was not performed. These data suggest that adipose tissue expands by 














Figure 3.21 – foxp1a(-/-);foxp1b(-/-) mutants have a more hypertrophic adipose 
morphology. A. Schematic showing the location of the PVAT depot. B. 
Representative maximum intensity projections. The anterior end of the depot is to the 
right of the image C. n = 2-3. Error bars show mean and standard deviation. D. n = 2-














3.2.34 - foxp1a(-/-);foxp1b(-/-) mutants have increased levels of blood 
glucose 
An inability of adipose tissue to expand can lead to ectopic lipid deposition and 
increased levels of lipid metabolites in the blood (Bluher, 2010). To test if the foxp1a(-
/-);foxp1b(-/-) mutants have adipose tissue which is impaired in its ability to store lipid, I 
measured levels of blood metabolites. Adult fish were euthanised, blood extracted 
and levels of blood glucose, triglyceride and cholesterol were measured (Figure 
3.22A. B. & C). Levels of blood glucose were found to be increased in the foxp1a(-/-
);foxp1b(-/-) mutants when compared to WT siblings, while levels of triglyceride and 
cholesterol were unchanged (Figure 3.22A. B. & C). Due to the low sample size of 
the experiment no statistical tests were performed and further data is needed to 
determine if the observed increase in blood glucose is statistically significant. Overall 















Figure 3.22 – foxp1a(-/-);foxp1b(-/-) mutants have increased levels of blood 
glucose. A. n = 3. A two tailed t-test was performed, p = 0.0255. B.  n = 3. C. n = 3-
















3.3 - Discussion  
 
To summarise, I have presented data which supports the hypothesis that 
foxp1 is required for AT expansion (Figure 3.23A). These data have allowed me to 
build models of how AT expansion is affected in each of the mutants described. For 
example, foxp1a(-/-) mutants have reduced levels of foxp1a, which results in normal 
levels of AT on a control diet but reduced AT expansion in response to a HFD (Figure 
3.23B). foxp1a(-/-) mutants specifically gain less SAT in response to a HFD and this 
depot was found to have a more hypertrophic morphology (Figure 3.23B). In contrast 
foxp1b(-/-) mutants had reduced levels of foxp1b, which resulted in normal levels of AT 
on a control diet but reduced visceral AT expansion in response to a HFD (Figure 
3.23C). Overall data from foxp1a(-/-) and foxp1b(-/-) mutants support the proposed 
hypothesis that foxp1 is required for AT expansion and suggest adipose tissue depot 
specific roles for foxp1a and foxp1b.  
Data from the foxp1a(-/-);foxp1b(-/-) mutants is also supportive of a role for foxp1 
in adipose tissue expansion. foxp1a(-/-);foxp1b(-/-) mutants have reduced levels of 
foxp1, reduced levels of AT on a control diet and reduced AT expansion in response 
to a HFD (Figure 3.23D). Furthermore, foxp1a(-/-);foxp1b(-/-) mutants also show signs 
of dysfunctional AT, with a more hypertrophic AT morphology and increased levels of 
blood glucose (Figure 3.23D). Some of the data presented from the foxp1a(-/-);foxp1b(-
/-)  mutants, such as the response to the HFD, does not fully fit with the data presented 
from the single mutants. This is due to the fact that data from the foxp1a(-/-);foxp1b(-/-) 
mutants is preliminary and needs to be expanded upon. Increasing the sample sizes 
of the foxp1a(-/-);foxp1b(-/-) experiments will hopefully reduce the variation observed.   
In this chapter I have identified FOXP1 as a novel regulator of adipose levels. 
I have generated novel zebrafish foxp1 mutants to investigate the hypothesis that 
foxp1 is required for AT expansion. Using these mutants, I have found data consistent 
with my hypothesis and shown that loss of foxp1 leads to reduced AT accumulation, 
a more hypertrophic adipose morphology and increased levels of blood glucose. In 
this section I will discuss the limitations of the data I have presented. A broader 
discussion detailing how this work fits into the existing literature and expanding on 
future directions can be found in the general discussion section (Chapter 6).  
foxp1 was found to be expressed in the PVAT depot. However, due to the 
nature of the experiment performed more precise expression patterns could not be 
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determined. It is currently unclear if foxp1 is expressed either in mature adipocytes or 
in adipocyte progenitors, as predicted. This is a major limitation as my hypothesis is 
that foxp1 directly influences adipose progenitor behaviour. The role of foxp1 in 
adipose progenitors is the major focus of chapter 4. Briefly I have generated a 
transgenic zebrafish line in which GFP is expressed exclusively in adipocytes and 
pre-adipocytes. The SVF of fish on the transgenic background could be isolated and 
GFP positive cells selected. foxp1 expression in adipose progenitor cells could then 
be assessed.  
Another limitation of the data presented is that all of the data comes from 
whole body foxp1 mutants. FOXP1 is known to be widely expressed in humans and 
therefore any phenotypes observed in the foxp1 mutants may not be due to the effect 
of foxp1 on adipose exclusively.  For example, Foxp1 is known to play a role in the 
liver and is involved in the regulation of glucose homeostasis (Zou et al., 2015). Foxp1 
inhibits gluconeogenesis in the liver and therefore loss of foxp1 in the zebrafish 
mutants could result in increased glucose production and directly impact adipose 
phenotypes (Zou et al., 2015). One way to overcome this problem would be to create 
adipose tissue specific mutants. However, a simpler way to show that the phenotype 
of the foxp1 mutants was caused by defects in adipose progenitor behaviour would 
be to grow those cells in culture. Comparing the proliferation and differentiation of 
adipose progenitor cells from foxp1 mutants with those from WT siblings, would allow 
me to determine if there were any adipose autonomous effects of foxp1 in the 
mutants. 
Finally, the foxp1 mutants I generated targeted the FHD of the Foxp1 protein 
rather than the translational start site. Although levels of Foxp1 are reduced in the 
zebrafish mutants some protein does still remain, and this leaves open the possibility 
that the mutant protein may have a function in the mutants. The Foxp1 protein 
contains a forkhead DNA binding domain, and a zinc finger protein-protein interaction 
domain. The presence of this protein-protein interaction domain allows FOXP1 to form 
heterodimers with other members of the FOXP family (Li et al., 2004). Therefore, the 
foxp1a(-/-) and foxp1b(-/-) mutants described may produce mutant Foxp1 proteins which 
are able to form heterodimers with other members of the Foxp family and alter the 
activity of these genes. Comparing the phenotype of foxp1 mutants lacking a ZFD 
with those already examined could determine whether the phenotypes observed in 
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the foxp1a(-/-);foxp1b(-/-) mutants are the result of loss of foxp1 function or due to the 
altered activity of other foxp family members.   
In summary I have presented results which broadly agree with the hypothesis 
that foxp1 maintains progenitor populations in adipose and is required for adipose 
tissue expansion. Here I have detailed the major limitations of the data I have 
presented, and a fuller discussion can be found in chapter 6. The results I have 
presented have not fully addressed the role of foxp1 in progenitor cell maintenance 





Figure 3.23 – foxp1 is important in AT expansion. 
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Figure 3.23 – foxp1 is important in AT expansion. A. Schematic showing how 
foxp1 is hypothesised to maintain progenitor cells in AT. B. Summary of the foxp1a(-/-
) mutant phenotype and a model of the effect loss of foxp1a is thought to have on AT. 
C. Summary of the foxp1b(-/-) mutant phenotype and a model of the effect loss of 
foxp1b is thought to have on AT. D.  Summary of the foxp1a(-/-);foxp1b(-/-) mutant 
phenotype and a model of the effect loss of foxp1a and foxp1b has on AT expansion. 






















Chapter 4 – foxp1a plays role in the control of the 

























4.1 - Introduction   
 
Obesity is known to be partially genetically regulated (Maes et al., 1997). 
However, the genetic regulation of obesity is poorly understood and a better 
understanding of how genes influence adipose tissue expansion is needed. One gene 
thought to play a role in adipose tissue expansion is Foxp1. Foxp1 is a transcription 
factor which is known to promote the renewal of stem and progenitor cells from 
multiple compartments (Gabut et al., 2011, Li et al., 2017). For example, Foxp1 has 
been shown to stimulate the expression of genes required for pluripotency and to 
repress the expression of genes required for the differentiation of embryonic stem 
cells (Gabut et al., 2011). Based on Foxp1’s roles in proliferation and differentiation 
the hypothesis set out earlier in this thesis was that Foxp1 maintains progenitor cell 
populations in adipose tissue and is required for adipose tissue expansion. 
Accordingly, genetic variation at the FOXP1 locus is associated with BMI (Kichaev et 
al., 2019). In chapter 3 I have shown that loss of function foxp1 mutant zebrafish have 
less AT than WT siblings, a more hypertrophic lipid droplet morphology within adipose 
and increased levels of blood glucose (Chapter 3.2). These data suggest that foxp1 
is required for AT expansion and specifically for hyperplastic AT expansion. However, 
my data in chapter 3 do not address the role of foxp1 within adipose progenitor cells. 
Therefore, the aim of this chapter was to investigate the role of foxp1 within adipose 
progenitor cells and to further understand the cellular and molecular mechanisms by 
which foxp1 promotes adipose formation.  
White adipose progenitor cells are fibroblast like cells which are capable of 
giving rise to mature lipid filled adipocytes (Hepler et al., 2017). Adipose progenitor 
cells were first described in 1969 by Hollenberg and Vost. The study used tritiated 
thymidine to measure DNA synthesis in WAT and found a progression of radioactivity 
from the SVF to mature adipocytes over time, therefore suggesting that adipocyte 
precursor cells in the SVF were differentiating into mature adipocytes (Hollenberg and 
Vost, 1969). Later experiments in the 1970’s found that cells derived from the SVF of 
adipose tissue, and which initially resembled fibroblasts, were capable of 
accumulating triglycerides (Poznanski et al., 1973). Further studies went on to show 
that these fibroblast like cells go on to display the morphology of mature white 
adipocytes (Van et al., 1976). However, the fibroblast like cell population extracted 
from the SVF is heterogeneous and can also be induced to differentiate into 
osteoblasts, myoblasts and chondrocytes (Brzoska et al., 2005). Furthermore, cells 
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taken from the SVF can also show variable rates of adipogenesis (Cawthorn et al., 
2012). The establishment of clonal preadipocyte cell lines has produced cells which 
show very high rates of adipogenesis, with the murine 3T3-L1 cell line being the most 
widely used (Green and Kehinde, 1976). The 3T3-L1 cell line is a preadipocyte cell 
line which undergoes synchronous differentiation in response to a hormonal cocktail 
(Green and Kehinde, 1976). The use of lines such as the 3T3-L1 line has allowed 
much of the molecular control of adipocyte differentiation to be uncovered (Lefterova 
and Lazar, 2009, Lowe et al., 2011). However, while facilitating the discovery of many 
aspects of adipogenesis, preadipocyte cell lines do not allow for the in vivo study of 
adipose progenitors.   
Study of adipose progenitor cells in vivo is important as freshly isolated 
adipose progenitor cells have been shown to express different cell surface markers 
than cells in culture (Varma et al., 2007). This suggests that adipose progenitor cells 
in vitro may not behave in the same manner as those in vivo and highlights the 
importance of in vivo studies. Much work has been done to determine the in vivo 
origins and nature of adipocyte progenitor cells. For example, Rodeheffer et al (2008) 
used FACS (Fluorescence activated cell sorting) sorting to sort cells from adipose 
SVF and determined the nature of cells which give rise to mature adipocytes. It was 
found that CD29 (integrin beta 1) and CD34 positive cells had high adipogenic 
potential, with CD29 and CD34 both being expressed by several stem cell populations 
(Rodeheffer et al., 2008). The adipose progenitor cell population was further refined 
and a CD31 (Platelet endothelial cell adhesion molecule), CD45 (Protein tyrosine 
phosphatase receptor type C) and Ter119 negative population and CD29, CD34, 
Sca1 (Ataxin 1), CD24 positive population was found to have a high adipogenic 
potential (Rodeheffer et al., 2008). The adipose progenitor cells isolated by FACS 
were also found to be capable of differentiating into adipocytes in vivo (Berry and 
Rodeheffer, 2013). As the FACS based method of defining the adipose progenitor cell 
population requires multiple markers, multiple studies have employed lineage tracing 
methods to identify adipose progenitor cells in vivo (Jiang et al., 2017, Tang et al., 
2008, Vishvanath et al., 2016). Using lineage tracing Pdgrfa (Platelet derived growth 
factor receptor alpha) was found to be expressed by preadipocytes but not adipocytes 
(Berry and Rodeheffer, 2013). Preadipocytes have also been shown to express 
Pdgfrb, Pparg and Zfp423 (Zinc finger protein 423) (Tang et al, 2008, Vishvanath et 
al., 2016). Further lineage tracing suggested that endothelial cells may give rise to 
adipocytes (Tran et al., 2012). However, a later study found that the expression 
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reported by Tran et al (2012) was likely to come from blood vessels closely associated 
with adipocytes and not from adipocytes themselves (Berry and Rodeheffer, 2013). 
Tang et al (2008) used genetically marked mice to determine that adipose progenitors 
reside in the mural compartment of the adipose vasculature. Later work also showed 
that these cells reside in a niche, initially located distal to the blood vessel and 
occupying a mural perivascular position later in adipose depot development (Jiang et 
al., 2014). Finally, it was shown that both Pdgfrb and Vegf (Vascular endothelial 
growth factor) are required for the maintenance of adipose progenitor cells within the 
perivascular niche (Jiang et al., 2017). Overall adipose progenitor cells can be 
identified in vivo through the use of multiple markers however the nature of the in vivo 
models employed means that adipose progenitors cannot be imaged in live animals.   
As adipose progenitor cells have been increasingly studied it has become 
apparent that heterogeneity within this population exists. Jiang et al (2014) used 
lineage tracing in mice to report that two populations of adipose progenitor cells exist, 
developmental progenitors which are required for adipose organogenesis and adult 
progenitors which are required for adipose homeostasis. More recent work has used 
single cell RNA-Seq to divide adipose progenitors into even more populations 
(Schwalie et al.,2018, Hepler et al., 2018, Sempere et al,2014). Schwalie et al (2018) 
used single cell RNA-Seq to identify multiple populations of adipose progenitor cells 
and found one population to be capable of inhibiting adipocyte differentiation. 
Meanwhile another study used the same method to identify three adipose progenitor 
cell populations which gave rise to adipocytes with differing rates of lipolysis 
(Raajendiran et al., 2019). Finally, Hepler et al (2018) also used single cell RNA-Seq 
to identify multiple adipose progenitor cell populations, one of which showed pro-
inflammatory characteristics. Together this highlights the heterogeneity of adipose 
progenitor cells. However, nearly all of these studies have relied on the culturing of 
adipose progenitor cells in vitro and do not allow for the imaging of adipose progenitor 
cells in vivo in live animals.  
Zebrafish are a useful model organism and are especially well suited to in vivo 
imaging. Zebrafish are optically transparent from fertilization however pigment in the 
skin develops soon after (Flynn et al., 2009). Mutant zebrafish which lack pigment 
exist and this allows for the imaging of developmental processes, including adipose 
tissue formation and growth (Flynn et al., 2009). Lipid dyes can be used to stain 
adipose tissue in zebrafish and real time imaging of adipose tissues is also possible 
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(Flynn et al., 2009). However adipose progenitor cells, which lack any lipid, cannot 
currently be visualised. Many transgenic reporter zebrafish lines exist, including those 
which mark the vasculature and immune cells (Rafferty and Quinn, 2018). However, 
a transgenic line which marks adipocytes or adipose progenitor cells does not exist in 
zebrafish. Therefore, the aim of this chapter is to develop a method for imaging 
adipose progenitor cells in zebrafish to further investigate the hypothesis that foxp1 
maintains progenitor cell populations in adipose tissue and is required for adipose 
tissue expansion.  
In this chapter I have generated a new transgenic line that enables, for the first 
time, zebrafish adipocytes and adipose progenitors to be visualised. I use this new 
transgenic line to map adipose tissue expansion in zebrafish and show that LSAT 
(Lateral subcutaneous adipose tissue) expands via steady hypertrophic growth with 
bursts of hyperplastic growth. I have also built a model of spatial LSAT expansion and 
have shown that LSAT expands first by adding new adipocytes to the centre of the 
depot and then by forming chains of adipocytes which branch away from the main 
LSAT body. I then show that rates of hyperplastic and hypertrophic LSAT expansion 
are unaltered in foxp1a(-/-) and foxp1b(-/-) mutants during normal development. 
However, foxp1a(-/-) mutants do show an altered spatial expansion of LSAT. Overall, I 
have compiled novel data on LSAT expansion in zebrafish and have found data which 













4.2 - Results  
 
4.2.1 – A candidate enhancer, thought to be active during adipogenesis, 
was identified using published DNase-Seq data  
In order to generate a transgenic line which marks adipocytes and adipocyte 
progenitors, I first identified putative enhancer elements which might be capable of 
driving GFP expression in adipose. Zebrafish transgenic lines can be created through 
the use of enhancers linked to minimal promoters, which are then inserted into the 
zebrafish genome through the use of the Tol2 transposase (Rafferty and Quinn, 
2018). To identify potential enhancers, I used data from a study by Siersbaek et al 
(2011). Siersbaek et al (2011) induced adipogenesis in the murine 3T3-L1 cell line 
and then performed DNase-Seq at four different timepoints. 34,269 DNase 
hypersensitive sites were identified, which were then divided into four profiles 
(Siersbaek et al., 2011). The first profile was characterised by sites which opened 
early in adipogenesis and remained open (Siersbaek et al., 2011). The second and 
third profiles were characterised by sites which opened and closed transiently during 
adipogenesis, at 4 hours and 24 hours respectively (Siersbaek et al., 2011). The 
fourth profile was characterised by sites which opened late in adipogenesis and 
remained open (Siersbaek et al., 2011). As foxp1 was shown in Chapter 3 to be 
required for AT expansion, I looked around the Foxp1 locus for DNase hypersensitive 
sites (DHS). Two DHS sites were found at the mouse Foxp1 locus (Figure 4.1A).  
As the DHS sites identified by Siersbaek et al (2011) were discovered in a 
mouse cell line, conservation to zebrafish was next examined. Zebrafish conserved 
non-coding elements (CNEs), which were conserved to mouse, have been described 
by Hiller et al (Figure 4.1A) (Hiller et al., 2013). The study designed a comparative 
genomics framework to align isolated genomes, such as the zebrafish genome, with 
the mouse and human genome and identify CNEs (Hiller et al., 2013). When the two 
mouse DNase hypersensitive sites were examined only one was found to be 
conserved to zebrafish (Figure 4.1A). This site, which is located within intron 1 of 
Foxp1, is potentially active due to its DNase hypersensitivity and is conserved to 
zebrafish. This site is now referred to as CNE450. Therefore, CNE450 within intron 1 




4.2.2 – The CNE in intron 1 of Foxp1 has activity in adipocytes and 
adipose progenitors 
CNE450 within intron 1 of Foxp1 is found on chromosome 6 at position 
99,466,614-99-747-342 (Figure 4.1A). The CNE is a 385bp element and contains 
multiple predicted transcription factor binding sites (Figure 4.1A & B). Using 
MatInspector it was found that the 385bp element contains predicted transcription 
factor binding sites for five different factors, including the known regulators of 
adipogenesis Cebpa, Cebpb, and Cebpd (Figure 4.1B). Predicted binding sites for 
Hoxa5 (Homeobox A5) and Nr3c1 (Nuclear Receptor subfamily 3 Group C member 
1) were also found (Figure 4.1B). Two zebrafish CNEs are found at CNE450, a 40bp 
CNE and a 130bp CNE, and both contain predicted transcription factor binding sites 
(Figure 4.1B). The zebrafish 40bp region contains six predicted binding sites, 
including for cebpa, cebpb and cebpd and the 130bp region contains 30 predicted 
binding sites, again including sites for cebpa, cebpb and cebpd (Figure 4.1B).  
To determine if CNE450 could drive GFP expression in adipose a reporter 
construct was generated. The CNE was PCR amplified from mouse genomic DNA 
and cloned into an expression vector. The expression vector contained the CNE, a 
cFOS minimal promoter and eGFP, flanked by two Tol2 sites. This construct was then 
injected, along with Tol2 mRNA, into the zebrafish embryo at the one cell stage. 
Following outcrossing, F2 fish were identified with GFP expression exclusively in 
adipose tissue. Together this demonstrates that the CNE element at Foxp1 can drive 
GFP expression in adipose tissue. The zebrafish elements were also tested for 
enhancer activity but neither element was capable of driving GFP activity in adipose 
(data not shown). A combination of both zebrafish elements was also not able to drive 
GFP activity in adipose (data not shown). In summary, CNE450 can drive GFP 















Figure 4.1 – A conserved enhancer element is present at the Foxp1 locus. A. 
Schematic showing the enhancer found in intron 1 of the mouse Foxp1 gene. DHS 
(DNase hypersensitive sites), and histone modifications are shown. GERP (Genome 
evolutionary rate profiling) identifies conserved regions of the genome, with a peak 
indicating conservation.  B. Schematic showing the enhancer within intron 1 of Foxp1. 
The two regions conserved to zebrafish are also shown. The numbers show the size 
of the enhancer in base pairs. The coloured lines show the predicted transcription 






















4.2.3 – GFP expression in the Foxp1:eGFP transgenic line is restricted to 
regions in which AT depots are known to form and the timing of GFP 
expression coincides with AT development.   
The expression pattern of CNE450, now referred to as Foxp1:eGFP, was next 
examined. Foxp1:eGFP fish were imaged under a stereomicroscope and whole body 
GFP expression was assessed in fish of different stages (Figure 4.2A). Adipose 
development has been fully mapped in zebrafish, with 34 regionally distinct adipose 
depots described in the adult fish (Minchin and Rawls, 2017). The first depot known 
to form is the PVAT depot (Pancreatic visceral AT) at around 4.2 mm SL, and this 
depot is found close to the pancreas (Minchin and Rawls, 2017). GFP expression in 
the Foxp1:eGFP line was therefore examined in fish larger than 4.2 mm SL. GFP 
expression in fish of over 4.2 mm SL was found localised to the PVAT depot, with this 
group of cells going on to show the same saucepan like morphology as has been 
described of the PVAT depot in older fish (Figure 4.2A) (Minchin and Rawls, 2017). 
The appearance of GFP expression at the anatomical location of previously described 
adipose depots and at the developmental stage described was observed for all 
adipose depots in the Foxp1:eGFP line (Minchin and Rawls, 2017). Examples of this 
include GFP expression in the adipose depots found in the head of zebrafish (Figure 
4.2B). Minchin and Rawls (2017) have described three adipose depots in the head, 
which are visible from around 6.6 mm SL. These adipose depots are found close to 
the operculum (OPC), the eye (OCU) and the hyoid apparatus (HYD) and GFP 
expression in the Foxp1:eGFP line was found in all these locations (Figure 4.2B) 
(Minchin and Rawls, 2017). Another example concerns the LSAT depot, with GFP 
expression observed at the location of this depot in Foxp1:eGFP fish (Figure 4.2B). 
The LSAT depot has been shown to appear at 8.2 mm SL and runs laterally along the 
trunk of the zebrafish at the horizontal myoseptum, with expansion primarily along the 
anterior posterior axis (Minchin and Rawls, 2017). The LSAT depot also appears to 
be constrained by somite boundaries (Minchin and Rawls, 2017). The first GFP 
expression at the LSAT depot in the Foxp1:eGFP line occurs at around 8.2 mm SL 
and matches the previously described stage of LSAT development (Figure 4.2B). 
Furthermore, the group of cells marked by GFP in the Foxp1:eGFP line also have the 
same morphology as described of the LSAT depot (Figure 4.2B). As a final example, 
AT depots described in the caudal fin show corresponding GFP expression in the 
Foxp1:eGFP line (Figure 4.2A & B). Three AT depots are found in the caudal fin, the 
DSAT (dorsal SAT), VSAT (ventral SAT) and CFRSAT (caudal fin ray SAT) depots 
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(Minchin and Rawls, 2017). DSAT is the first depot to form at around 9.5 mm SL and 
is found in a long thin streak along the dorsal trunk (Figure 4.2A & B) (Minchin and 
Rawls, 2017). VSAT is found from 9.8 mm SL and is found in a long thin streak 
between the anal fin and caudal fin (Figure 4.2B) (Minchin and Rawls, 2017). 
CFRSAT is formed at 10.8 mm SL and extends across the dorsal ventral axis 
connecting the DSAT to the VSAT (Figure 4.2B) (Minchin and Rawls, 2017). The 
presence of these depots close to the caudal fin is marked by GFP expression in the 
Foxp1:eGFP line and the appearance of GFP matches the timing of the appearance 
of these depots (Figure 4.2B). Overall the Foxp1:eGFP line appears to have 
expression exclusively within adipose tissue and appears to mark all AT depots in 
zebrafish.  
 
4.2.4 – The Foxp1:eGFP transgenic line labels both adipocytes and 
adipose progenitor cells  
In order to determine which cell types within adipose tissue showed GFP 
expression in the Foxp1:eGFP line, further imaging at higher magnification was 
performed (Figure 4.2B). When adipose depots in the tail, head and along the flank 
of the fish were imaged it became apparent that GFP was being expressed by cells 
which resembled adipocytes (Figure 4.2B). The cells labelled by GFP were generally 
found to be large, spherical, and with a large space in the centre unlabelled by GFP 
(Figure 4.2B). The large space is suggestive of the lipid droplet found within 
adipocytes and this morphology is the classic morphology of a white adipocyte 
(Figure 4.2B). To determine if these cells were indeed adipocytes, Foxp1:eGFP fish 
were incubated with LipidTOX which marks the neutral lipid found within adipocytes 
(Figure 4.2C). The LSAT depot was then imaged using confocal microscopy (Figure 
4.2C). The LSAT depot was chosen for its location just below the surface of the skin, 
which allows this depot to be imaged through the skin of live fish (Figure 4.2C). Nearly 
all GFP positive cells were stained by LipidTOX, indicating that the cells are indeed 
adipocytes (Figure 4.2C). The only exceptions were a few GFP positive cells which 
remained unstained and which were much smaller than those stained by LipidTOX 
(Figure 4.2C). These GFP positive, LipidTOX negative cells were much more 
fibroblast like in shape and were long and thin (Figure 4.2C). These cells were 
hypothesised to be adipose progenitor cells (Figure 4.2C). Later time course imaging, 
which followed the same fish over multiple consecutive days, has suggested that the 
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hypothesised adipose progenitors do go on to become mature lipid filled adipocytes 
and are in fact adipose progenitor cells (Figure 4.5B). Taken together this imaging 
shows that the Foxp1:eGFP line marks adipocytes and adipose progenitor cells, and 









Figure 4.2 – The Foxp1:eGFP line has activity in both adipocytes and adipose 
progenitor cells. A. Fluorescence stereomicroscope images showing GFP 
expression in the whole fish. GFP expression appears to be confined to adipose tissue 
and appears to be expressed by all adipose depots. Increased GFP expression and 
increased levels of adipose tissue can be observed in the larger fish, in the lower 
panel. The white arrow shows the PVAT depot. Arrows and arrow heads show the 
locations of the adipose depots highlighted in section B. The white arrow head shows 
AT depots in the caudal fin. The red arrow head shows the LSAT depot and the red 
arrow shows AT depots in the head. B. Fluorescence stereomicroscope images. GFP 
expression is found at the location of known adipose depots and in large cells 
resembling adipocytes. From left to right, GFP expression in the head, tail and body 
of the fish. C. Confocal Z stacks presented as maximum intensity projections showing 
that GFP is expressed by adipocytes and preadipocytes. The large GFP positive cells 
are stained by LipidTOX and are shown to contain neutral lipid. GFP positive, lipid 
negative cells are highlighted by the arrow heads in the lower panel and are believed 
to be adipose progenitor cells. The adipose progenitor cells have a more fibroblast 
like morphology than the mature adipocytes. The LSAT depot is shown in both images 















4.2.5 - Adipocyte number, adipocyte progenitor number and average lipid 
droplet area all show a positive correlation with standard length 
Having determined that the Foxp1:eGFP line can be used to image LSAT 
growth in live fish, I next wanted to examine the cellular dynamics of LSAT expansion. 
In order to do this I imaged LSAT at different timepoints during zebrafish development 
(Figure 4.3A). LSAT first develops at 8.2 mm SL (Minchin and Rawls, 2017). I 
therefore raised a clutch of Foxp1:eGFP fish to approximately 8.2 mm SL, removed 5 
fish, stained the fish with LipidTOX and imaged the LSAT of each fish (Figure 4.3A). 
I then removed an additional 5 fish every 8 days and repeated the imaging process, 
in order to obtain fish at a range of sizes (Figure 4.3A).  At each timepoint I measured 
the SL of each fish and this was shown to increase across the timepoints, 
demonstrating that the fish were growing between each timepoint (Figure 4.3B & C). 
In addition I measured the number of adipocytes, defined as cells which are both GFP 
positive and LipidTOX positive, and the number of adipose progenitor cells, defined 
as cells which are GFP positive but LipidTOX negative. The lipid droplet area of each 
cell was also quantified. I found that the number of adipocytes per LSAT showed a 
strong positive correlation to SL, therefore adipocyte number increases as zebrafish 
grow (Figure 4.3D & E). I also found adipose progenitor number to be positively 
correlated with SL, demonstrating that the number of adipose progenitors increases 
as fish grow (Figure 4.3F & G). Finally, I found that average lipid droplet area is 
positively correlated with SL and this shows that LSAT expands by hypertrophic 
growth as the fish grows (Figure 4.3H & I). Overall, these data demonstrate that as 
zebrafish grow the number of adipocytes and adipose progenitor cells within LSAT 





Figure 4.3 - Adipocyte number, adipocyte progenitor number and average lipid 
droplet area all show a positive correlation with standard length. 
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Figure 4.3 - Adipocyte number, adipocyte progenitor number and average lipid 
droplet area all show a positive correlation with standard length. A. Schematic 
showing the experimental protocol. T1 (Timepoint 1). B. Graph showing SL of fish 
across the experimental timepoints. n = 15. Error bars show mean and standard 
deviation. A one way ANOVA was performed and the difference between the groups 
was found to be significant F2,12 = 62.67 p < 0.0001. A post hoc Tukey’s multiple 
comparison was performed, T1 vs T2 p = 0.3626. T1 vs T3 p < 0.0001. T2 vs T3 p < 
0.0001. Letters signify differences between groups, different letters indicate significant 
differences between groups and the same letters indicate no difference. C. 
Fluorescence stereoscopic images of whole fish, showing increased SL across the 
timepoints. T1 (Timepoint 1). D. Scatter graph showing relationship between SL and 
number of adipocytes. R2 = 0.7801. n = 15. The slope of the line is significantly non 
zero F1,13 = 46.11 p < 0.0001. E. Representative maximum intensity projections of 
LSAT from each timepoint. All images were taken from the anterior end of the LSAT. 
The anterior end of the LSAT is to the right of the image. T1 (Timepoint 1). F. Scatter 
graph showing relationship between SL and number of adipose progenitor cells. R2 = 
0.3987. n = 15. The slope of the line is significantly non zero F1,13 = 8.619 p = 0.0116. 
G. Representative maximum intensity projections of LSAT showing the presence of 
adipose progenitor cells. Adipose progenitor cells are defined as GFP positive, lipid 
negative cells. White arrow heads highlight progenitor cells. Images were taken from 
the posterior end of the LSAT, the anterior end of the LSAT is to the right of the 
images. H. Scatter graph showing relationship between SL and average lipid droplet 
area. R2 = 0.3227. n = 15. The slope of the line is significantly non zero F1,13 = 6.192 
p = 0.0272. I. Representative maximum intensity projections showing increased area 
of lipid droplets across the timepoints. Images were taken from the anterior end of 










4.2.6 - New cells appear most often at the centre of the LSAT depot  
In addition to examining the cellular dynamics of LSAT expansion, I also 
wanted to examine the spatial expansion of LSAT. The LSAT depot is a long thin 
adipose depot which runs horizontally along the zebrafish at the horizontal 
myoseptum (Minchin and Rawls, 2017). Expansion occurs primarily along the 
anterior-posterior axis however expansion also occurs along the dorsal-ventral axis 
to produce a long thin depot (Minchin and Rawls, 2017). In order to better understand 
the spatial expansion of LSAT, I wanted to determine how expansion across these 
axes occurred. To do this I performed two timecourse experiments and measured the 
locations in which new cells were added to LSAT. Foxp1:eGFP fish were raised until 
approximately 15 mm SL for experiment 1 and 11 mm SL for experiment 2 (Figure 
4.4A).  The fish were then stained with lipidTOX, and the LSAT depot imaged under 
a stereomicroscope (Figure 4.4A). The fish were recovered and the imaging repeated 
every 24 hours, over the course of 3 or 5 days (Figure 4.4A). This allowed LSAT 
expansion in individual fish to be tracked. To examine LSAT expansion along the 
anterior-posterior axis I divided the LSAT of each fish into 3 equally sized sections 
along this axis (Figure 4.4 B.C. & D). I then quantified the number of new cells added 
to each section of LSAT between each timepoint (Figure 4.4B. C. & D). I found that 
cells were most often added to the middle of the LSAT depot, suggesting the LSAT 
first grows by adding cells to the centre of the depot (Figure 4.4B.C. & D). I also 
examined LSAT expansion along the dorsal-ventral axis (Figure 4.4E & F). The 
middle region of LSAT was defined as a region which extended two adipocytes dorsal 
of the horizontal midline of the LSAT and two adipocytes ventral (Figure 4.4E & F). 
The dorsal region was found above the middle region and the ventral region below 
(Figure 4.4E & F). When the appearance of new cells was quantified, it was found 
that most cells were added to the middle region (Figure 4.4E & F). Taken together 
these data suggest that LSAT first expands by adding new adipocytes to the centre 







Figure 4.4 – LSAT expands by adding new adipocytes to the centre of the depot. 
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Figure 4.4 – LSAT expands by adding new adipocytes to the centre of the depot. 
A. Schematic showing the experimental protocol. Data is taken from two experiments, 
one with 3 timepoints and one with 5 timepoints. E1/E2 (experiment 1/2). Data from 
experiment 2 takes WT data from a foxp1a(+/+) and foxp1a(-/-) experiment. B. Maximum 
intensity projection of whole LSAT at T1 and T2. The black boxes on the lower panel 
are the result of an image processing technique used to stitch multiple images 
together. The unprocessed images can be found in the appendix. Asterisks highlight 
the appearance of new cells in the lower panel. C. Scatter dot plot showing the 
location of new cells within the LSAT depot. n = 3. Each point shows the number of 
new cells which appear in the LSAT of one fish across the 5 timepoints measured. 
Two tailed t-tests were performed. The difference between the anterior and middle 
groups were found to be significant, p = 0.0072. The difference between the middle 
and posterior groups was not found to be significant, p = 0.4913. The difference 
between the anterior and posterior groups was not found to be significant, p = 0.4930. 
Error bars show mean and standard deviation. D. Schematic showing how the 
anterior, middle and posterior regions of LSAT were defined. LSAT was divided into 
three equally sized regions along the anterior-posterior axis. E. Scatter dot plot 
showing the location of new cells within the LSAT depot. n = 3. Each point shows the 
number of new cells which appear in the LSAT of one fish across the 5 timepoints 
measured. Two tailed t-tests were performed and the difference between the groups 
was not found to be significant. Dorsal v middle, p = 0.0754. Ventral v middle, p = 
0.0826. Dorsal v ventral, p = 0.9656. Error bars show mean and standard deviation. 
F. Schematic showing how the dorsal, middle and ventral regions were defined. The 
boundary between the dorsal and middle region was set two adipocytes above the 
midline of the LSAT. The boundary between the ventral and middle region was set 









4.2.7 - LSAT branching and branch length is correlated with standard 
length 
To further examine the spatial expansion of LSAT I also wanted to examine 
adipocytes which branch away from the main LSAT body. I noticed that in fish taken 
from T1 of the timecourse experiment, with an average SL of 11 mm, LSAT appeared 
to be formed of one horizontal line of adipocytes (Figure 4.5A). However, the LSAT 
of fish taken from T5, with an average SL of 12 mm, showed lines of adipocytes 
branching away from the main horizontal body of the LSAT (Figure 4.5A) These lines 
of adipocytes were found to branch away from the main LSAT body at a roughly 45° 
angle, both dorsally and ventrally, and appear to be found close to somite boundaries 
(Figure 4.5A). To determine if the presence of these branches of adipocytes was 
associated with LSAT expansion, I counted the number of branching events in each 
LSAT (Figure 4.5B & C). A branching event was defined as a chain of 3 or more 
adipocytes which branch away from the main LSAT body at a roughly 45° angle. I 
found that the number of branching events was positively correlated with SL 
suggesting that branching events increase as the fish grows (Figure 4.5B). However, 
change in SL was not correlated with change in the number of branching events 
(Figure 4.5C). This suggests that there is a nonlinear relationship between increases 
in SL and increases in branching events.  In addition to counting the number of 
branching events per LSAT, I also measured the length of each branch which was 
defined as the number of cells per branch (Figure 4.5D & E). Similarly to branch 
number, I found that branch length was positively correlated with SL but that change 
in SL was not correlated with change in branch length (Figure 4.5D & E). Overall, this 
suggests that LSAT branching is a key feature of LSAT growth and that both branch 
number and branch length increase as zebrafish grow. This also allows a model of 
spatial LSAT expansion to be proposed (Figure 4.5F). In this model LSAT first 
expands by adding new adipocytes to the centre of the depot and then further 
expands by forming chains of adipocytes which branch away from the main LSAT 






Figure 4.5 - LSAT branching and branch length is correlated with SL. 
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Figure 4.5 - LSAT branching and branch length is correlated with SL. A. 
Maximum intensity projections showing the increase in branching events at an 
increased SL. White arrow heads highlight branches. A branch was defined as 3 or 
more adipocytes which form a line branching away from the main LSAT body at a 
roughly 45° angle. The anterior end of the LSAT is to the right of the image B. Scatter 
graph comparing the number of branching events to SL. N = 3. R2 = 0.8623. The slope 
of the line is significantly non zero F1,12 = 75.13 p < 0.0001. C. Scatter graph 
comparing the change in the number of branching events between timepoints to 
change in SL. N = 3. R2 = 0.009379. The slope of the line is not significantly non zero 
F1,9 = 0.08521 p = 0.777. D. Scatter graph comparing the average number of cells per 
branch to SL. N = 3. R2 = 0.4967. The slope of the line is significantly non zero F1,12 = 
11.84 p = 0.0049. E. Scatter graph comparing the average change in the number of 
cells per branch to change in SL. N = 3. R2 = 0.007319. The slope of the line is not 
significantly non zero F1,9 = 0.06636 p = 0.8025. F. Schematic showing the proposed 
model of LSAT growth. Arrow heads at stage 2 highlight adipocytes added to the 
















4.2.8 - LSAT undergoes steady hypertrophic expansion with bursts of 
hyperplastic expansion  
Having examined the spatial expansion of LSAT, I next wanted to look at rates 
of hypertrophic and hyperplastic growth within LSAT. To do this I used the images 
taken from the previously described timecourse imaging, in which fish were imaged 
every 24 hours for either 3 or 5 days (Figure 4.6A). The SL of each fish was measured 
at each timepoint, and as individual fish could be tracked, the change in SL across 
each 24 hour period could be calculated (Figure 4.6B). Fish were found to increase 
in SL between all timepoints, except for two fish between T2 and T3 (Figure 4.6B & 
C). On average SL increased across the timepoints, with the average increase in SL 
being 227 µm (Figure 4.6D). The number of adipocytes, the number of adipose 
progenitor cells and the area of adipocyte lipid droplets was also measured at each 
timepoint (Figure 4.6B.E. & G). The change in both cell number and cell area were 
calculated and different growth dynamics were observed at different timepoints 
(Figure 4.6B & E). Hyperplastic growth was observed between T1 (average 13.9 mm 
SL) and T2 (average 14.1 mm SL), with a large increase in the number of mature 
adipocytes present and a decrease in the number of progenitor cells present (Figure 
4.6B & E). Cell numbers then remained steady between T2-T3 and T3-T4 (Figure 
4.6B & E). A second burst of hyperplastic growth was observed between T4-T5, with 
an increase in the number of adipocytes (Figure 4.6B & E). On average the number 
of adipocytes increased between timepoints, with an average increase of 44 
adipocytes, and the number of progenitors decreased, with an average decrease of 
24 progenitors (Figure 4.6F). In contrast to the bursts of hyperplastic growth, 
hypertrophic growth remained relatively steady across the experiment, with a slight 
increase between T4-T5 (Figure 4.6B & G). Change in lipid droplet area was 
calculated by measuring the change in the lipid droplet area of each cell and the 
calculating the average of this value. A positive increase in average lipid droplet area 
was observed between each timepoint and the average increase in area was 347 µm2 
(Figure 4.6B.G. & H). In summary LSAT expands by steady hypertrophic growth with 













Figure 4.6 – LSAT shows steady hypertrophic growth and bursts of hyperplastic 
growth. A. Schematic showing the experimental protocols. Data is taken from two 
experiments, one with 3 timepoints and one with 5 timepoints. E1/E2 (experiment 1/2). 
B. Representative maximum intensity projections of a section of LSAT in the same 
fish across 5 timepoints. White arrowheads highlight the appearance of new cells. 
Images are taken from the posterior end of the LSAT, the anterior end of the LSAT is 
found to the right of the images. C. Scatter dot plot showing change in SL across each 
experimental timepoint. n = 2-7. Each point shows the change in the SL of one fish 
across two timepoints. A one way ANOVA was performed and the difference between 
the groups was not found to be significant F3,15 = 1.564 p = 0.2394. D. Scatter dot plot 
showing change in SL for all fish across all timepoints. n = 2-7. Each point shows the 
change in the SL of one fish across two timepoints. E. Scatter dot plot showing change 
in cell number across each experimental timepoint. n = 2-7. Each point shows the 
change in the number of cells present in the LSAT of one fish across 2 timepoints. A 
two way ANOVA was performed and the difference between the cell types and the 
interaction between the cell types and the timepoints were found to be significant. Cell 
types, F1,34 = 23.2 p < 0.0001. Interaction, F3,34 = 19.64 p < 0.0001. F. Scatter dot plot 
showing change in cell number for all fish across all timepoints. Each point shows the 
change in the number of cells of one fish across two timepoints. A two tailed t-test 
was performed and the groups were found to be significantly different p < 0.0001. G. 
Scatter dot plot showing the average change in lipid droplet area across each 
experimental timepoint. n = 2-7. Each point shows the average change in the lipid 
droplet of each cell of one fish across two timepoints. A one way ANOVA was 
performed and the difference between the groups was found to be significant F3,17 = 
4.01 p = 0.0279. A post-hoc Tukey’s multiple comparisons test was performed and 
the difference between T2-T3 and T4-T5 was found to be significant p = 0.0182. H. 
Scatter dot plot showing change average lipid droplet area for all fish across all 
timepoints. Each point shows the change in the average lipid droplet area of one fish 







4.2.9 – Changes in average lipid droplet area but not changes in 
adipocyte number or progenitor number are correlated with changes in 
SL 
I next wanted to examine the relationship between somatic fish growth and 
changes in cell number and lipid droplet area within LSAT. To do this I plotted change 
in SL against both change in adipocyte number and change in progenitor number 
(Figure 4.7A & B). I found that neither change in adipocyte number nor change in 
progenitor number are correlated with change in SL (Figure 4.7A & B). This suggests 
that increases in SL do not result in a linear increase in cell number. I also plotted 
change in average lipid droplet area against change in SL and found a positive 
correlation between the two variables (Figure 4.7C). The lack of relationship between 
change in SL and change in cell number, and the relationship between change in lipid 
droplet area and change in SL is highlighted by Figure 4.7F. No real changes can be 
seen in cell number between T2-T3 or between T3-T4 (Figure 4.7F). However, while 
SL remains constant at 12.48 mm between T2-T3, it does increase by 270 µm to 
12.75 mm between T3-T4 (Figure 4.7F). This demonstrates the same change in cell 
number can be observed in both fish which are increasing in SL and fish which are 
not (Figure 4.7A & F). In contrast no change in lipid droplet area can be seen between 
T2-T3 when SL does not change, but an increase in lipid droplet area can be observed 
between T3-T4 when SL increases (Figure 4.7F). Change in adipocyte number was 
also plotted against change in average lipid droplet area but no correlation was found 
(Figure 4.7D). Finally, the change in adipocyte number was plotted against the 
change in progenitor number and a strong negative correlation was found (Figure 
4.7E). However, this is not surprising as progenitor cells go on to form adipocytes. In 
conclusion, change in adipocyte number and change in progenitor number are not 
correlated with changes in SL, while change in average lipid droplet area is positively 
correlated with changes in SL. This suggests that while there is not a linear 
relationship between increased SL and increased cell number, there is a linear 












Figure 4.7 – Changes in average lipid droplet area are correlated with changes 
in SL. A. Scatter graph comparing change in SL to change in adipocyte number. n = 
7. Each point shows the change in adipocyte number vs the change in SL for 1 fish 
between 2 timepoints. R2 = 0.02708. The slope of the line is not significantly non-zero 
F1,15 = 0.4176 p = 0.5279. B. Scatter graph comparing change in SL to change in 
progenitor number. n = 7. Each point shows the change in progenitor number vs the 
change in SL for 1 fish between 2 timepoints. R2 = 0.004597. The slope of the line is 
not significantly non-zero F1,17 = 0.0785 p = 0.7827. C. Scatter graph comparing 
change in SL to change in area lipid droplet area. n = 7. Each point shows the change 
in average lipid droplet area vs the change in SL for 1 fish between 2 timepoints. R2 
= 0.2507. The slope of the line is significantly non-zero F1,15 = 5.01 p = 0.0408. D. 
Scatter plot comparing change in adipocyte number to change in average lipid droplet 
area. n = 7. Each point shows the change in adipocyte number vs the change in 
average lipid droplet area for 1 fish between 2 timepoints. R2 = 0.02167. The slope of 
the line is not significantly non-zero F1,17 = 0.3766 p = 0.5476. E. Scatter plot 
comparing change in adipocyte number to change in progenitor number. n = 7. Each 
point shows the change in adipocyte number vs the change progenitor number for 1 
fish between 2 timepoints. R2 = 0.7677. The slope of the line is significantly non-zero 
F1,17 = 56.18 p < 0.0001.  F. Representative maximum intensity projections showing 
lack of correlation between change in SL and change in cell number and the 
correlation between change in average lipid droplet area and change in SL. Note that 
cell number remains constant despite no change in SL between T2-T3 and an 
increase in SL between T3-T4. Lipid droplet area is unchanged between T2-T3 where 
no change in SL is observed and increases between T3-T4 when SL also increases. 
Images are taken from the anterior end of the LSAT, the anterior end of the LSAT is 










4.2.10 – New cells do not appear most often at the centre of the LSAT 
depot in foxp1a(-/-) mutants  
Having built a model of how LSAT expands in WT fish, I next wanted to 
examine the role of foxp1 in LSAT expansion. To do this I first looked at the role of 
foxp1a and began by examining its role in the spatial expansion of LSAT. I performed 
a five day timecourse experiment using both foxp1a(-/-) mutant fish and WT siblings 
(Figure 4.8A). Foxp1:eGFP:foxp1a(+/-) fish were incrossed, raised until approximately 
12.6 mm SL and genotyped. WT fish and foxp1a(-/-) mutants were then incubated with 
LipidTOX and LSAT was imaged using a stereomicroscope (Figure 4.8A). The fish 
were recovered and the imaging was repeated every 24 hours for a period of 5 days 
(Figure 4.8A). This allowed LSAT expansion in individual WT and foxp1a(-/-) mutant 
fish to be tracked. To examine the spatial expansion of LSAT, I examined the location 
of new cells added to LSAT along the anterior-posterior axis and along the dorsal-
ventral axis. I began by looking at expansion across the anterior-posterior axis. To do 
this I divided the LSAT of each fish into 3 equally sized sections along the anterior-
posterior axis and quantified the number of new cells added to each section between 
each timepoint (Figure 4.8B & C). I found that, as shown previously, new cells were 
most often added to the middle of the depot in WT fish (Figure 4.8B & C). However, 
this preference was not found in mutant fish with an equal number of cells being added 
to the anterior, middle and posterior sections (Figure 4.8B & C). I also examined 
LSAT expansion along the dorsal-ventral axis, with LSAT being divided into three 
sections along this axis (Figure 4.8B & D). When the appearance of new cells was 
quantified, most cells were again added to the middle region in WT fish (Figure 4.8B 
& D). This was not true of foxp1a(-/-) fish with equal numbers  of cells being added to 
each region (Figure 4.8B &D). Taken together this suggests that the spatial 
expansion of LSAT is altered in foxp1a(-/-) mutants and that LSAT in these mutants 















Figure 4.8 – foxp1a(-/-) mutants show an altered spatial pattern of LSAT growth. 
A. Schematic showing the experimental protocol. B. Representative maximum 
intensity projections of the whole LSAT of foxp1a(+/+) and foxp1a(-/-) fish at two 
timepoints. Dorsal and ventral cells were defined as cells separated by more than 2 
adipocytes vertically from the main horizontal line of LSAT. Asterisks highlight the 
appearance of new cells. White asterisks show cells considered to be added to the 
middle of the LSAT. Yellow asterisks show cells added ventrally and blue asterisks 
show cells added dorsally. Black boxes on the foxp1a(-/-)  mutant images are created 
by the image processing software used to stitch the images together. Unprocessed 
images can be found in the appendix. C. Scatter dot plot showing the location of new 
cells within the LSAT depot. n = 3. Each point shows the number of new cells which 
appear in the LSAT of one fish across the 5 timepoints measured. A two way ANOVA 
was performed and the difference between the groups was not found to be significant. 
D. Scatter dot plot showing the location of new cells within the LSAT depot.  n = 3. 
Each point shows the number of new cells which appear in the LSAT of one fish 
across the 5 timepoints measured. A two way ANOVA was performed and the 
difference between the genotypes and the location of the new cells were found to be 
significant. Genotype – F1,12 = 4.76 p = 0.0497. Location of new cells – F2,12 = 9.2 p = 














4.2.11 – The average number of cells per LSAT branch is greater in 
foxp1a(-/-) mutants    
I next wanted to examine LSAT branching, which is the second key feature of 
my model of spatial LSAT expansion. To do this I first measured the number of 
branching events in each LSAT. A branch was defined as a chain of three or more 
cells which branch away from the main LSAT body at a roughly 45° angle (Figure 
4.9A). I found that the number of branches was positively correlated with SL in both 
foxp1a(-/-) mutant and WT fish (Figure 4.9A & B). Furthermore I found that the number 
of branching events relative to SL was not significantly different in WT and foxp1a(-/-) 
mutant fish (Figure 4.9A & B). I also found that change in SL was not correlated with 
change in branch number in WT or foxp1a(-/-) mutant fish (Figure 4.9C). I next 
examined branch length by counting the number of cells per branch. I found that, 
similar to branch number, the average number of cells per branch was positively 
correlated with SL in both foxp1a(-/-) mutant and WT fish (Figure 4.9A & D). However, 
the average number of cells per branch was significantly greater in foxp1a(-/-) mutant 
fish (Figure 4.9A & D). This suggests that the spatial expansion of LSAT is altered in 
foxp1a(-/-) mutant fish. Finally I found that there was no correlation between the change 
in the average number of cells per branch and the change in SL in either foxp1a(-/-) 
mutant or WT fish (Figure 4.9E). Overall this suggests that spatial LSAT expansion 
is altered in foxp1a(-/-) mutant fish. In the WT model of LSAT expansion, LSAT first 
expands by adding new cells to the centre of the depot and then further expands by 
forming chains of adipocytes which branch away from the main LSAT body. LSAT in 
foxp1a(-/-) mutants does not expand by adding cells to the centre of the depot and 
although branches are formed, they contain significantly more cells than those of WT 
























Figure 4.9 - LSAT branching is altered in foxp1a(-/-) mutants. A. Maximum intensity 
projections showing the branching events in WT fish and foxp1a(-/-) mutants. White 
arrow heads highlight branches. A branch was defined as 3 or more adipocytes which 
form a line branching away from the main LSAT body at a roughly 45° angle. The 
anterior end of the LSAT is to the right of the image B. Scatter graph comparing the 
number of branching events to SL. N = 6. foxp1a(+/+), R2 = 0.8182. The slope of the 
line is significantly non zero F1,21 = 94.48 p < 0.0001. foxp1a
(-/-), R2 = 0.639. The slope 
of the line is significantly non zero F1,20 = 35.4 p < 0.0001. An ancova analysis was 
performed and the slopes of the lines were not significantly different F1,41 = 1.594 p = 
0.214. C. Scatter graph comparing the change in the number of branching events 
between timepoints to change in SL. N = 6. foxp1a(+/+), R2 = 0.07213. The slope of the 
line is not significantly non zero F1,15 = 1.166 p = 0.2973. foxp1a
(-/-), R2 = 0.03992. The 
slope of the line is not significantly non zero F1,13 = 0.5406 p = 0.4752. D. Scatter 
graph comparing the average number of cells per branch to SL. N = 6. foxp1a(+/+), R2 
= 0.6895. The slope of the line is significantly non zero F1,21 = 46.63 p < 0.0001. 
foxp1a(-/-), R2 = 0.7708. The slope of the line is significantly non zero F1,20 = 67.25 p < 
0.0001. An ancova analysis was performed and the slopes of the lines were found to 
be significantly different F1,41 = 14.23 p = 0.0005. E. Scatter graph comparing the 
average change in the number of cells per branch to change in SL. N = 6. foxp1a(+/+), 
R2 = 0.1013. The slope of the line is not significantly non zero F1,15 = 1.691 p = 0.2131. 
foxp1a(-/-), R2 = 0.064. The slope of the line is not significantly non zero F1,13 = 0.8889 












4.2.12 – Hyperplastic and hypertrophic LSAT expansion is unaltered in 
foxp1a(-/-) mutants   
Having determined that the spatial expansion of LSAT is altered in foxp1a(-/-) 
mutants, I next wanted to examine rates of hypertrophic and hyperplastic growth. To 
do this I used images taken in the previously described foxp1a(-/-) timecourse 
experiment, in which fish were imaged every 24 hours over a period of 5 days (Figure 
4.10A). The SL of each fish was measured at each timepoint and the change in SL 
across each 24 hour period calculated (Figure 4.10B & C). SL was found to increase 
across all of the timepoints, with the exception of one foxp1a(-/-) mutant fish which 
shrinks slightly between T1-T2 (Figure 4.10B & C). On average the SL of both WT 
and foxp1a(-/-) mutant fish increased across the timepoints, with average increases in 
SL of 230 µm and 133 µm respectively (Figure 4.10B & D). The number of 
adipocytes, the number of adipose progenitor cells and the area of every lipid droplet 
was also measured at each timepoint (Figure 4.10E.F. & H). When changes in cell 
number were calculated, similar dynamics were observed to that of previous WT data. 
Bursts of hyperplastic growth were observed in WT fish between T1-T2 and T4-T5 
with increased numbers of adipocytes and decreased numbers of progenitors (Figure 
4.10B.E & F). Adipocyte numbers remained steady in WT fish between T2-T3 and 
T3-T4 and this was accompanied by a fall in progenitor cells between T3-T4 (Figure 
4.10B.E. & F). Changes in adipocyte and progenitor numbers in foxp1a(-/-) mutant fish 
followed much the same pattern as those of WT fish, however there was no burst of 
hyperplastic growth between T1-T2 (Figure 4.10B & E). On average the number of 
adipocytes increased between timepoints in both WT and foxp1a(-/-) mutant fish, with 
average increases of 17 and 15 adipocytes respectively (Figure 4.10B & G). In 
contrast the number of progenitor cells decreased on average, with an average 
decrease of 7 cells in WT fish and 5 cells in foxp1a(-/-) mutant fish across the timepoints 
(Figure 4.10B & G). The change in the average area of lipid droplets per cell was 
also calculated and steady hypertrophic growth was observed across the experiment 
for both WT and foxp1a(-/-) fish (Figure 4.10B & H). On average lipid droplet area was 
found to increase by 336 µm2 in WT fish and 305 µm2 in foxp1a(-/-) fish (Figure 4.10I). 
In summary LSAT in WT fish follows the same patterns of expansion as previously 
described, namely steady hypertrophic expansion and bursts of hyperplastic 
expansion. No differences were observed in hypertrophic and hyperplastic expansion 





Figure 4.10 – foxp1a(-/-) mutants do not show altered rates of hyperplastic and 
hypertrophic LSAT expansion during normal development. 
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Figure 4.10 – foxp1a(-/-) mutants do not show altered rates of hyperplastic and 
hypertrophic LSAT expansion during normal development. A. Schematic 
showing the experimental protocol. B. Representative maximum intensity projections 
of a section of LSAT in the same WT and foxp1a(-/-) fish across 5 timepoints. White 
arrowheads highlight the appearance of new cells. Images are taken from the 
posterior end of the LSAT, the anterior end of the LSAT is found to the right of the 
images. C. Scatter dot plot showing change in SL across each experimental timepoint. 
n = 2-7. Each point shows the change in the SL of one fish across two timepoints. A 
one way ANOVA was performed and the difference between the genotypes was found 
to be significant F1,24 = 4.373 p = 0.0473. D. Scatter dot plot showing change in SL for 
all fish across all timepoints. n = 2-7. Each point shows the change in the SL of one 
fish across two timepoints. A two tailed t-test was performed and the difference 
between the groups was not found to be significant, p = 0.0831. E. Scatter dot plot 
showing change in adipocyte number across each experimental timepoint. n = 2-7. 
Each point shows the change in the number of cells present in the LSAT of one fish 
across 2 timepoints. A two way ANOVA was performed and the difference between 
the groups was not found to be significant. F. Scatter dot plot showing change in 
progenitor number across each experimental timepoint. n = 2-7. Each point shows the 
change in the number of cells present in the LSAT of one fish across 2 timepoints. A 
two way ANOVA was performed and the difference between the groups was not found 
to be significant. G. Scatter dot plot showing change in cell number for all fish across 
all timepoints. Each point shows the change in the number of cells of one fish across 
two timepoints. A two way ANOVA was performed and the difference between cell 
types was found to be significant F1,62 = 17.15 p = 0.0001. H. Scatter dot plot showing 
the average change in lipid droplet area per cell across each experimental timepoint. 
n = 2-7. Each point shows the change in the average area of the lipid droplets present 
in the LSAT of one fish across two timepoints. A two way ANOVA was performed and 
the difference between the timepoints was found to be significant F3,25 = 3.719 p = 
0.0244. I. Scatter dot plot showing change average lipid droplet area for all fish across 
all timepoints. Each point shows the change in the average lipid droplet area of one 
fish across two timepoints. A two tailed t-test was performed and the difference 
between the groups was not found to be significant. C-I. Error bars show mean and 




4.2.13 – Changes in average lipid droplet area are not correlated with 
changes in SL in foxp1a(-/-) mutants  
As a final measure of LSAT expansion in the foxp1a(-/-) mutants, I examined 
the relationship between changes in cell number and lipid droplet area within LSAT 
and somatic growth. To do this I first plotted change in cell number against change in 
SL (Figure 4.11A & B). I found no correlation between changes in adipocyte number 
and changes in SL or between changes in progenitor cell number and changes in SL 
for either WT or foxp1a(-/-) fish (Figure 4.11A & B). This is in keeping with previous 
WT data and suggests that increases in SL do not result in a linear increase in cell 
number. I also plotted change in the average lipid droplet area per cell against SL and 
found a positive correlation for WT fish but not for foxp1a(-/-) mutant fish (Figure 
4.11C). In contrast when change in adipocyte number was plotted against change in 
average lipid droplet area no correlation was found for WT fish but a positive 
correlation was found for foxp1a(-/-) fish (Figure 4.11D). Finally change in adipocyte 
number was plotted against change in progenitor number and while a negative 
correlation was found for WT fish, no correlation was present for foxp1a(-/-) mutant fish 
(Figure 4.11E). Taken together these data suggest that the relationship between 
LSAT expansion and somatic growth is altered in foxp1a(-/-) mutant fish. The lack of 
correlation between change in lipid droplet area and change in SL suggests that 
increased SL doesn’t result in increased hypertrophic growth in foxp1a(-/-) mutant fish. 
Furthermore the lack of relationship between change in adipocyte number and 
change in progenitor number suggests altered adipose progenitor behaviour in 













Figure 4.11 – Changes in lipid droplet area are not correlated with changes in 












Figure 4.11 – Changes in lipid droplet area are not correlated with changes in 
SL in foxp1a(-/-) mutants. A. Scatter graph comparing change in SL to change in 
adipocyte number. n = 6. Each point shows the change in adipocyte number vs the 
change in SL for 1 fish between 2 timepoints. foxp1a(+/+), R2 = 0.005. The slope of the 
line is not significantly non zero F1,15 = 0.0075 p = 0.9323. foxp1a
(-/-), R2 = 0.1084. The 
slope of the line is not significantly non zero F1,13 = 1.58 p = 0.2309. B. Scatter graph 
comparing change in SL to change in progenitor number. n = 6. Each point shows the 
change in progenitor number vs the change in SL for 1 fish between 2 timepoints. 
foxp1a(+/+), R2 = 0.004. The slope of the line is not significantly non zero F1,15 = 0.0609 
p = 0.8084. foxp1a(-/-), R2 = 0.0076. The slope of the line is not significantly non zero 
F1,13 = 0.9896 p = 0.7581. C. Scatter graph comparing change in SL to change in area 
lipid droplet area. n = 6. Each point shows the change in average lipid droplet area vs 
the change in SL for 1 fish between 2 timepoints. foxp1a(+/+), R2 = 0.2527. The slope 
of the line is significantly non zero F1,15 = 5.071 p = 0.0397. foxp1a
(-/-), R2 = 0.00079. 
The slope of the line is not significantly non zero F1,13 = 0.01031 p = 0.9207. D. Scatter 
plot comparing change in adipocyte number to change in average lipid droplet area. 
n = 6. Each point shows the change in adipocyte number vs the change in average 
lipid droplet area for 1 fish between 2 timepoints. foxp1a(+/+), R2 = 0.2294. The slope 
of the line is not significantly non zero F1,15 = 4.465 p = 0.0518. foxp1a
(-/-), R2 = 0.2877. 
The slope of the line is significantly non zero F1,13 = 5.251 p = 0.0391. E. Scatter plot 
comparing change in adipocyte number to change in progenitor number. n = 6. Each 
point shows the change in adipocyte number vs the change progenitor number for 1 
fish between 2 timepoints. foxp1a(+/+), R2 = 0.7389. The slope of the line is significantly 
non zero F1,15 = 42.46 p < 0.0001. foxp1a
(-/-), R2 = 0.0282. The slope of the line is not 












4.2.14 – New cells are added to the centre of LSAT in foxp1b(-/-) mutants  
Having determined that LSAT expansion is altered in foxp1a(-/-) mutants I next 
wanted to examine LSAT expansion in foxp1b(-/-) mutants. To do this I first examined 
the spatial expansion of LSAT along the anterior-posterior and dorsal-ventral axes 
(Figure 4.12B). I incrossed Foxp1:eGFP:foxp1b(+/-) fish and raised their offspring until 
approximately 10 mm SL. Fish were then genotyped and foxp1b(-/-) mutants and WT 
siblings were incubated with LipiTOX and imaged using a stereomicroscope (Figure 
4.12A). Fish were recovered and the imaging repeated every 24 hours over a 3 day 
period (Figure 4.12A). To examine LSAT expansion along the anterior-posterior axis, 
LSAT was divided into three sections along this axis and the number of new cells in 
each section recorded (Figure 4.12B & C). In contrast to previous WT data, no 
difference was observed between the number of cells present in each section (Figure 
4.12B & C). This may be due to a small sample size. The same number of cells were 
also found across all three locations in foxp1b(-/-) mutant fish (Figure 4.12B & C). 
LSAT expansion was next measured along the dorsal-ventral axis, with LSAT being 
divided into three sections along this axis (Figure 4.12B & D). Here new cells were 
found most often in the middle region in both WT and foxp1b(-/-) mutant fish (Figure 
4.12B & D). In summary, the spatial expansion of LSAT appears to be unaltered in 



















Figure 4.12 – foxp1b(-/-) mutants do not show altered spatial LSAT expansion. A. 
Schematic showing the experimental protocol. B. Representative maximum intensity 
projections of the whole LSAT of foxp1b(+/+) and foxp1b(-/-) fish at two timepoints. Dorsal 
and ventral cells were defined as cells separated by more than 2 adipocytes vertically 
from the main horizontal line of LSAT. Asterisks highlight the appearance of new cells 
C. Scatter dot plot showing the location of new cells within LSAT. n = 3. Each point 
shows the number of new cells which appear in the LSAT of one fish across the 5 
timepoints measured. A two way ANOVA was performed and the difference between 
the groups was not found to be significant. D. Scatter dot plot showing the location of 
new cells within LSAT. n = 3. Each point shows the number of new cells which appear 
in the LSAT of one fish across the 5 timepoints measured. A two way ANOVA was 
performed and the difference between the groups was not found to be significant. C-


















4.2.15 – The number of branching events per LSAT is not correlated with 
SL in foxp1b(-/-) mutant fish 
As foxp1b(-/-) mutants show unaltered LSAT expansion along the anterior-
posterior and dorsal-ventral axes, I next examined LSAT branching. I first measured 
the number of branches per LSAT in both WT and foxp1b(-/-) mutant fish (Figure 4.13A 
& B). A branch was defined as a chain of three or more cells which branch away from 
the main LSAT body at a roughly 45° angle (Figure 4.13A). I found that while branch 
number is positively correlated with SL in WT fish no such relationship exists in 
foxp1b(-/-) mutant fish (Figure 4.13A & B). I also plotted the change in the number of 
branching events against the change in SL and found no correlation between the two 
variables for either WT or foxp1b(-/-) fish (Figure 4.13C). I next measured the number 
of cells per branch and plotted the average number of cells per branch against SL 
(Figure 4.13A & D). I found a positive correlation between average branch length and 
SL for both WT and foxp1b(-/-) fish, and no significant difference in branch length was 
found between the two groups (Figure 4.13D). Finally, I plotted change in average 
branch length against change in SL and found no correlation between the variables 
in either WT or foxp1b(-/-) mutant fish (Figure 4.13E). Taken together this suggests 
that LSAT branching in foxp1b(-/-) mutants is largely unaltered, though the number of 
branches per LSAT does not show a positive correlation to SL in the foxp1b(-/-) 
mutants. Overall foxp1b(-/-) mutants seem to follow the proposed spatial model of 
LSAT expansion with cells first added to the centre of the LSAT depot and LSAT 








Figure 4.13 – The number of branching events per LSAT in foxp1b(-/-) mutants is 














Figure 4.13 – The number of branching events per LSAT in foxp1b(-/-) mutants is 
not correlated with SL. A. Representative maximum intensity projections showing 
unaltered number of branching events in foxp1b(-/-) mutants and WT fish at one 
timepoint. White arrowheads highlight branching events. Branches are defined as a 
chain of 3 or more adipocytes which branch away from the main line of the LSAT at a 
roughly 45° angle. The anterior end of LSAT is found to the right of the images. B. 
Scatter graph comparing the number of branching events to SL. n = 3. foxp1b(+/+), R2 
= 0.9605. The slope of the line is significantly non zero F1,7 = 170.3 p < 0.0001. foxp1b
(-
/-), R2 = 0.3318. The slope of the line is not significantly non zero F1,7 = 3.477 p = 
0.1045. C. Scatter graph comparing the change in the number of branching events 
between timepoints to change in SL. N = 3. foxp1b(+/+), R2 = 0.132. The slope of the 
line is not significantly non zero F1,4 = 0.6081 p = 0.4791. foxp1b
(-/-), R2 = 0.003135. 
The slope of the line is not significantly non zero F1,4 = 0.01258 p = 0.9161. D. Scatter 
graph comparing the average number of cells per branch to SL. N = 3. foxp1b(+/+), R2 
= 0.9892. The slope of the line is significantly non zero F1,7 = 639.4 p < 0.0001. foxp1b
(-
/-), R2 = 0.5986. The slope of the line is significantly non zero F1,7 = 10.44 p = 0.0144. 
An ancova analysis was performed and the slopes of the lines were not found to be 
significantly different F1,14 = 2.776 p = 0.1179. E. Scatter graph comparing the average 
change in the number of cells per branch to change in SL. N = 3. foxp1b(+/+), R2 = 
0.3045. The slope of the line is not significantly non zero F1,4 = 1.751 p = 0.2563. 
foxp1b(-/-), R2 = 0.05662. The slope of the line is not significantly non zero F1,4 = 0.2401 











4.2.16 - foxp1b(-/-) mutants do not show altered  hyperplastic or 
hypertrophic LSAT expansion 
I next wanted to examine hypertrophic and hyperplastic LSAT expansion in 
the foxp1b(-/-) mutants. To do this I used images from the foxp1b(-/-) timecourse 
experiment described previously in which fish were imaged every 24 hours over a 
period of 3 days (Figure 4.14A). The SL of each fish was measured at each timepoint 
and the change in SL between each timepoint calculated (Figure 4.14B & C). SL was 
found to increase between each timepoint in both WT and foxp1b(-/-) mutant fish with 
an average increase in SL across all timepoints of 328 µm and 311 µm respectively 
(Figure 4.14D). The change in the number of adipocytes and progenitor cells between 
each timepoint was also measured (Figure 4.14B.E. & F). Hyperplastic growth, i.e. 
increases in adipocyte number, has previously been shown to occur in bursts. Bursts 
of hypertrophic growth are hard to see in this experiment as it was made up of only 
three timepoints (Figure 4.14E). Adipocyte number is found to increase between T1-
T2 and T2-T3 for both WT and mutant fish, though with only three timepoints and 
three fish per genotype it is hard to call any of these changes bursts of hyperplastic 
growth (Figure 4.14E). Progenitor number was found to generally fall between T1-T2 
and T2-T3 for WT fish, though it appeared to remain steady in foxp1b(-/-) mutant fish 
(Figure 4.14F). When the change in cell number across all timepoints was plotted it 
became clear that WT and foxp1b(-/-) mutant fish were showing the same patterns of 
growth, with increases in adipocyte number and little change in progenitor number 
(Figure 4.14G). WT fish showed an average increase of 19 adipocytes and an 
average increase of 1 progenitor cell (Figure 4.14G). Meanwhile, foxp1b(-/-) mutant 
fish showed similar changes, with an average increase of 19 adipocytes and an 
average increase of 3 progenitor cells (Figure 4.14G). The average change in lipid 
droplet area per cell was also calculated and a steady increase in lipid droplet area 
was observed across all timepoints for both WT and foxp1b(-/-) mutant fish (Figure 
4.14B & H). foxp1b(-/-) mutant fish showed a slightly lower increase in lipid droplet area 
than WT fish, with an average increase of 237 µm2 (Figure 4.14I). The average 
increase in lipid droplet area in WT fish was 324 µm2 and the difference in the increase 
in lipid droplet area between the two genotypes was not found to be significant (Figure 
4.14I). In summary although bursts of hyperplastic growth in WT fish were not 
observed in this experiment no differences in hypertrophic or hyperplastic growth 
were observed between WT fish and foxp1b(-/-) mutants. Therefore, hyperplastic and 









Figure 4.14 – foxp1b(-/-) mutants do not show altered rates of hyperplastic and 
hypertrophic growth. A. Schematic showing the experimental protocol. B. 
Representative maximum intensity projections of a section of LSAT in the same WT 
and foxp1b(-/-) fish across 3 timepoints. White arrowheads highlight the appearance of 
new cells. Images are taken from the posterior end of the LSAT, the anterior end of 
the LSAT is found to the right of the images. C. Scatter dot plot showing change in SL 
across each experimental timepoint. n = 3. Each point shows the change in the SL of 
one fish across two timepoints. A two way ANOVA was performed and the difference 
between the groups was not found to be significant. D. Scatter dot plot showing 
change in SL for all fish across all timepoints. n = 3. Each point shows the change in 
the SL of one fish across two timepoints. A two tailed t-test was performed and the 
difference between the groups was not found to be significant, p = 0.8628. E. Scatter 
dot plot showing change in adipocyte number across each experimental timepoint. n 
= 3. Each point shows the change in the number of cells present in the LSAT of one 
fish across 2 timepoints. A two way ANOVA was performed and the difference 
between the groups was not found to be significant. F. Scatter dot plot showing 
change in progenitor number across each experimental timepoint. n = 3. Each point 
shows the change in the number of cells present in the LSAT of one fish across 2 
timepoints. A two way ANOVA was performed and the difference between the groups 
was not found to be significant. G. Scatter dot plot showing change in cell number for 
all fish across all timepoints. Each point shows the change in the number of cells of 
one fish across two timepoints. A two way ANOVA was performed and the difference 
between cell types was found to be significant F1,20 = 21.85 p = 0.0001. H. Scatter dot 
plot showing the average change in cell area across each experimental timepoint. n 
= 3. Each point shows the change in the average area of the lipid droplets present in 
the LSAT of one fish across two timepoints. A two way ANOVA was performed and 
the difference between the groups was not found to be significant. I. Scatter dot plot 
showing the change in average lipid droplet area for all fish across all timepoints. Each 
point shows the change in the average lipid droplet area of one fish across two 
timepoints. A two tailed t-test was performed and the difference between the groups 






4.2.17 – Changes in adipocyte number, progenitor number and lipid 
droplet area are not correlated with changes in SL in foxp1b(-/-) mutants 
As a final measure of LSAT expansion in foxp1b(-/-) mutants, I looked at the 
relationship between somatic growth and changes in adipocyte and progenitor 
number and lipid droplet area within LSAT. I first plotted change in adipocyte number 
against change in SL and found no correlation between the two variables for either 
WT or foxp1b(-/-) mutant fish (Figure 4.15A). I also found no correlation between 
change in progenitor number and change in SL for either genotype (Figure 4.15B). 
This lack of correlation between changes in cell number and changes in SL has 
previously been observed in WT fish. Change in lipid droplet area was previously 
shown to be correlated with change in SL in WT fish, however this relationship was 
not found for either WT or mutant fish in this experiment (Figure 4.15C). The lack of 
correlation between change in average lipid droplet area and change in SL in this 
experiment may be due to a small sample size (Figure 4.15C). Change in adipocyte 
number was found not to be correlated with change in average lipid droplet area in 
both WT and foxp1b(-/-) mutant fish (Figure 4.15D). Finally change in adipocyte 
number was not found to be correlated with change in progenitor number in either 
genotype (Figure 4.15E). Change in adipocyte number has previously been shown 
to be negatively correlated with change in progenitor number in WT fish and the lack 
of observed correlation here may again be due to a small sample size (Figure 4.15E). 
Taken together these data suggest that the relationship between somatic growth and 
changes in adipocyte number, progenitor number and lipid droplet area are not altered 
in foxp1b(-/-) mutant fish. Overall LSAT expansion does not appear to be altered in 






Figure 4.15 – Changes in, adipocyte number, progenitor number and lipid 













Figure 4.15 – Changes in, adipocyte number, progenitor number and lipid 
droplet area are not correlated with changes in SL in foxp1b(-/-) mutants. A. 
Scatter graph comparing change in SL to change in adipocyte number. n = 3. Each 
point shows the change in adipocyte number vs the change in SL for 1 fish between 
2 timepoints. foxp1b(+/+), R2 = 0.3965. The slope of the line is not significantly non zero 
F1,4 = 2.628 p = 0.1803. foxp1b
(-/-), R2 = 0.2289. The slope of the line is not significantly 
non zero F1,4 = 1.187 p = 0.3371. B. Scatter graph comparing change in SL to change 
in progenitor number. n = 3. Each point shows the change in progenitor number vs 
the change in SL for 1 fish between 2 timepoints. foxp1b(+/+), R2 = 0.08413. The slope 
of the line is not significantly non zero F1,4 = 0.3674 p = 0.5771. foxp1b
(-/-), R2 = 0.0788 
The slope of the line is not significantly non zero F1,4 = 0.3422 p = 0.59. C. Scatter 
graph comparing change in SL to change in average lipid droplet area. n = 3. Each 
point shows the change in average lipid droplet area vs the change in SL for 1 fish 
between 2 timepoints. foxp1b(+/+), R2 = 0.0007026. The slope of the line is not 
significantly non zero F1,4 = 0.002812 p = 0.9602. foxp1b
(-/-), R2 = 0.1081. The slope 
of the line is not significantly non zero F1,4 = 0.4849 p = 0.5246. D. Scatter plot 
comparing change in adipocyte number to change in average lipid droplet area. n = 
3. Each point shows the change in adipocyte number vs the change in average lipid 
droplet area for 1 fish between 2 timepoints. foxp1b(+/+), R2 = 0.3684. The slope of the 
line is not significantly non zero F1,4 = 2.333 p = 0.2014. foxp1b
(-/-), R2 = 0.1897. The 
slope of the line is not significantly non zero F1,4 = 0.9363 p = 0.388. E. Scatter plot 
comparing change in adipocyte number to change in progenitor number. n = 3. Each 
point shows the change in adipocyte number vs the change progenitor number for 1 
fish between 2 timepoints. foxp1b(+/+), R2 = 0.1347. The slope of the line is not 
significantly non zero F1,4 = 0.6225 p = 0.4742. foxp1b
(-/-), R2 = 0.0001215. The slope 









4.2.18 - foxp1a(-/-):foxp1b(-/-) mutants do not have an altered LSAT 
appearance  
I next examined LSAT expansion in foxp1a(-/-):foxp1b(-/-) double mutants. As 
foxp1a(-/-):foxp1b(-/-) mutants have previously been shown to have a more severe 
phenotype than either of the single mutants, I performed a shorter preliminary 
experiment using the foxp1a(-/-):foxp1b(-/-) double mutants (Figure 4.16A). 
Foxp1:eGFP:foxp1a(+/-):foxp1b(+/-) fish were incrossed and their offspring raised until 
approximately 13 mm SL. Fish were then genotyped and foxp1a(-/-):foxp1b(-/-) mutant 
fish and WT siblings were incubated with LipidTOX and their LSAT imaged using a 
stereomicroscope (Figure 4.16A). Following imaging all fish were recovered and 
used to establish breeding stocks (Figure 4.16A).  I first examined the appearance of 
LSAT in the foxp1a(-/-):foxp1b(-/-) mutants. The overall appearance of LSAT in the 
foxp1a(-/-):foxp1b(-/-) mutants was normal, with LSAT present as a long thin depot which 
extended primarily along the anterior-posterior axis. LSAT branching was also 
observed in the foxp1a(-/-):foxp1b(-/-)  mutants (Figure 4.16B). I next quantified the 
number of branching events per LSAT in both the WT and foxp1a(-/-):foxp1b(-/-) mutant 
fish (Figure 4.16B & C). I found no correlation between branch number and SL in WT 
fish but a positive correlation was present in foxp1a(-/-):foxp1b(-/-) mutant fish (Figure 
4.16C). The lack of correlation in WT fish is likely due to a small sample size. No 
differences in the number of branching events were observed between WT and 
foxp1a(-/-):foxp1b(-/-) mutant fish (Figure 4.16C). I then examined branch length and 
plotted the average number of cells per branch against SL (Figure 4.16B & D). Here 
I found no correlation between branch length and SL for either genotype and again 
this is likely to be caused by a small sample size (Figure 4.16D). No differences in 
the average number of cells per branch were observed between the two genotypes 
(Figure 4.16D). Overall the LSAT depot appears to have a normal morphology in 
foxp1a(-/-):foxp1b(-/-) mutants and there are no changes in LSAT branching in foxp1a(-/-























Figure 4.16 – foxp1a(-/-):foxp1b(-/-) mutants do not have an altered LSAT 
appearance. A. Schematic showing the experimental protocol. B. Representative 
maximum intensity projections showing increasing number of branching events with 
increasing SL in both foxp1a(-/-):foxp1b(-/-) mutants and WT siblings. Each panel 
shows LSAT from a different fish. White arrowheads highlight branching events. 
Branches are defined as a chain of 3 or more adipocytes which branch away from 
the main line of the LSAT at a roughly 45° angle. The anterior end of the LSAT is 
found to the right of each image. C. Scatter graph comparing the number of 
branching events to SL. n = 3. foxp1a(+/+):foxp1b(+/+), R2 = 0.899. The slope of the line 
is not significantly non zero F1,1 = 8.901 p = 0.2059. foxp1a
(-/-):foxp1b(-/-), R2 = 1.00. 
The slope of the line is significantly non zero F1,1 = 327467 p = 0.0038. An Ancova 
analysis was performed and the slopes of the lines were not found to be significantly 
different. D. Scatter graph comparing the average number of cells per branch to SL. 
N = 3. foxp1a(+/+):foxp1b(+/+), R2 = 0.8077. The slope of the line is not significantly non 
zero F1,1 = 4.2 p = 0.289. foxp1a
(-/-):foxp1b(-/-), R2 = 0.9636. The slope of the line is 
not significantly non zero F1,1 = 26.47 p = 0.1222. An ancova analysis was 
performed and the slopes of the lines were not found to be significantly different F1,14 














4.2.19 - foxp1a(-/-);foxp1b(-/-) mutants show no differences in adipocyte 
number, progenitor cell number or lipid droplet area.  
Finally, I wanted to determine whether adipose progenitor numbers and 
adipose morphology were altered in the LSAT of foxp1a(-/-);foxp1b(-/-) mutants. To do 
this I measured adipocyte number, progenitor cell number and lipid droplet area in the 
LSAT of the foxp1a(-/-):foxp1b(-/-) mutant fish and their WT siblings (Figure 4.17A.C.E 
& G). The SL of all fish was measured and no difference was found between the SL 
of foxp1a(-/-):foxp1b(-/-) mutants and WT fish (Figure 4.17B). The number of adipocytes 
per LSAT was found to be positively correlated with SL in WT fish but not in foxp1a(-/-
):foxp1b(-/-)  mutants (Figure 4.17C & D). The number of adipocytes per LSAT was not 
found to be significantly different in foxp1a(-/-):foxp1b(-/-) and WT fish (Figure 4.17C & 
D). Progenitor number was also measured and this was found to be correlated to SL 
in foxp1a(-/-):foxp1b(-/-) mutants but not in WT fish (Figure 4.17E & F). The lack of 
correlation between cell number and SL in both WT and foxp1a(-/-):foxp1b(-/-) mutants 
is likely due to a small sample size. The number of progenitor cells per LSAT was not 
found to be significantly different in foxp1a(-/-):foxp1b(-/-) mutants and WT fish (Figure 
4.17E & F). Finally, average lipid droplet area was plotted against SL and no 
correlation was observed for either genotype (Figure 4.17G & H). Again, as a 
correlation between these variables has previously been observed in WT fish, the lack 
of correlation here is likely due to a small sample size. A significant difference in lipid 
droplet area between the two genotypes was not found. In conclusion foxp1a(-/-













Figure 4.17 – foxp1a(-/-);foxp1b(-/-) mutants have a normal LSAT morphology 
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Figure 4.17 – foxp1a(-/-);foxp1b(-/-) mutants have a normal LSAT morphology. A. 
Schematic showing the experimental protocol. B. Scatter dot plot showing the SL of 
WT and foxp1a(-/-):foxp1b(-/-) mutants. n = 3 per genotype. A two tailed t-test was 
performed and the difference between the groups was not found to be significant, p = 
0.6059. C. Scatter graph comparing number of adipocytes per LSAT to SL. n = 3. 
foxp1a(+/+):foxp1b(+/+), R2 = 0.9995. The slope of the line is significantly non zero F1,1 = 
2086 p = 0.0139. foxp1a(-/-):foxp1b(-/-), R2 = 0.8232. The slope of the line is not 
significantly non zero F1,1 = 4.657 p = 0.2763. An Ancova analysis was performed and 
the slopes of the lines were not found to be significantly different. D. Representative 
maximum intensity projections showing increasing adipocyte number with increasing 
SL in both foxp1a(-/-);foxp1b(-/) mutants and WT siblings. Each panel shows LSAT from 
a different fish. The anterior end of the LSAT depot is found to the right of each image. 
E. Scatter graph comparing number of progenitor cells to SL. n = 3. 
foxp1a(+/+):foxp1b(+/+), R2 = 0.3646. The slope of the line is not significantly non zero 
F1,1 = 0.5738 p = 0.5873. foxp1a
(-/-):foxp1b(-/-), R2 = 0.9961. The slope of the line is 
significantly non zero F1,1 = 258.2 p = 0.0396. An Ancova analysis was performed and 
the slopes of the lines were not found to be significantly different. F. Representative 
maximum intensity projections showing similar number of adipose progenitor cells in 
foxp1a(-/-);foxp1b(-/-) mutants and WT siblings. White arrow heads highlight adipose 
progenitor cells. The anterior end of the LSAT depot is found to the right of each 
image. G. Scatter graph comparing average lipid droplet area to SL. n = 3. 
foxp1a(+/+):foxp1b(+/+), R2 = 0.3017. The slope of the line is not significantly non zero 
F1,1 = 0.4319 p = 0.6298. foxp1a
(-/-):foxp1b(-/-), R2 = 0.5719. The slope of the line is not 
significantly non zero F1,1 = 1.336 p = 0.454. An Ancova analysis was performed and 
the slopes of the lines were not found to be significantly different H. Representative 
maximum intensity projections showing increasing adipocyte area with increasing SL 
in both foxp1a(-/-);foxp1b(-/-) mutants and WT siblings. Each panel shows LSAT from a 
different fish. Asterisks highlight large lipid droplets. The anterior end of the LSAT is 







4.3 - Discussion  
 
In this chapter I have generated a novel zebrafish transgenic line which labels 
both adipocytes and adipose progenitor cells. This transgenic line has allowed LSAT 
growth in live zebrafish to be imaged and has allowed the dynamics of normal LSAT 
growth to be quantified. Using this transgenic line I have proposed a model of spatial 
LSAT expansion, in which new cells are added to the centre of the depot and LSAT 
then further expands by forming chains of adipocytes which branch away from the 
main LSAT body. I have also shown that LSAT expands by steady hypertrophic 
growth with bursts of hyperplastic growth. I then demonstrated that foxp1a but not 
foxp1b is required for normal LSAT expansion. LSAT was found to expand normally 
in foxp1b(-/-) mutants but new cells were not added to the centre of LSAT in foxp1a(-/-) 
mutants and the number of cells per branch was found to be increased in these 
mutants. Finally the morphology of the LSAT depot was found to be normal in foxp1a(-
/-):foxp1b(-/-) mutants however further timecourse experiments are required to 
determine if LSAT expansion is impaired in these mutants. In this section I will discuss 
the limitations of the data I have presented, and a broader discussion can be found in 
the general discussion section (Chapter 6).   
The Foxp1:eGFP line has GFP expression in both adipocytes and adipose 
progenitor cells and was used to measure LSAT expansion. Adipocytes were 
identified by their morphology and an individual adipocyte was defined as a cell with 
a GFP positive cytoplasm and a singular lipid droplet. However, during the analysis 
of LSAT growth it was sometimes difficult to determine if cells in close proximity 
constituted one cell or two. Furthermore, it is known that both mammalian and 
zebrafish white adipocytes may contain multiple small lipid droplets during early 
terminal differentiation (Flynn et al., 2009). However, due to the nature of the 
Foxp1:eGFP line, early terminally differentiated adipocytes could not be distinguished 
from multiple small adipocytes. One way to overcome this challenge would be to 
express a nuclear marker in the Foxp1:eGFP transgenic line. For example, mRNA of 
fluorescently tagged histone 2B (H2B) could be injected into Foxp1:eGFP embryos at 
the one cell stage (Imrie and Sadler, 2010). H2B localises fluorescent protein 
expression to chromatin and so acts as a nuclear marker (Imrie and Sadler, 2010). 
This strategy would mark all nuclei and would allow adipocytes with multiple lipid 
droplets and small adipocytes with a single lipid droplet to be distinguished.   
225 
 
Another limitation of the data presented is that the differentiation of adipose 
progenitor cells into adipocytes cannot be visualised and instead must be inferred. 
The timing of the LSAT imaging every 24 hours meant that the appearance of many 
adipose progenitor cells was missed. This could be observed by the lack of any cells 
at one timepoint and the appearance of mature adipocytes 24 hours later. This 
problem could be overcome by imaging at reduced intervals or by continuous imaging 
of the same fish over a set time period.  
Finally, the data presented from the foxp1 mutants suggests that foxp1 may 
be involved in the spatial expansion of LSAT however no differences were observed 
in adipose progenitor cell behaviour. Strong phenotypes were not observed in the 
foxp1a(-/-) and foxp1b(-/-) single mutants during normal development. However, this is 
not too surprising as both mutants had normal levels of AT during normal development 
and only displayed a phenotype following exposure to a high fat diet. Furthermore, 
foxp1b(-/-) mutants showed normal LSAT expansion both during normal development 
and in response to a high fat diet and so the normal LSAT growth observed in the 
Foxp1:eGFP:foxp1b(-/-) mutants was not unexpected. The major limitation here is the 
lack of foxp1a(-/-);foxp1b(-/-) data. This could be overcome by performing more foxp1a(-
/-);foxp1b(-/-) imaging and by ensuring that the imaging took place over a period of three 
days, i.e. following the same protocol as outlined in section 4.2.10.  
In summary I have presented data which for the first time quantifies the cellular 
dynamics of AT expansion in zebrafish. I have also shown that foxp1 may play a role 
in regulating the expansion of LSAT, however further work is required to uncover 
whether foxp1 influences adipose progenitor cell behaviour. Here I have detailed the 
major limitations of the data presented, and a more comprehensive discussion can be 











Chapter 5 – The role of cebpa as a master regulator of 




















5.1 – Introduction 
 
Obesity is associated with adipose tissue dysfunction (Crewe et al., 2017). 
Adipose tissue (AT) dysfunction occurs when adipose tissue expands beyond its 
normal capacity (Lafontan, 2014). This leads to hypoxia, fibrosis, cellular senescence 
and necrotic adipocyte death (Crewe et al., 2017). The resulting dysfunctional adipose 
tissue is no longer able to store lipid, and this results in the ectopic deposition of lipid 
in the liver and insulin resistance (Lafontan, 2014). One factor known to influence 
adipose tissue dysfunction is adipose morphology. Adipose morphology is defined as 
the number and size distribution of adipocytes within adipose tissue (Hoffstedt et al., 
2010). A hypertrophic adipose tissue, characterised by the presence of few large 
adipocytes, is associated with dysfunctional adipose tissue (Hoffstedt et al., 2010). In 
contrast a hyperplastic adipose tissue morphology, characterised by the presence of 
many small adipocytes, is associated with a normal metabolic profile (Hoffstedt et al., 
2010). Therefore, obesity is associated with adipose tissue dysfunction and a 
hypertrophic adipose morphology is also associated with adipose tissue dysfunction.  
Adipose tissue can expand via an increase in adipocyte number or an increase 
in adipocyte size. Changes in adipocyte size are controlled by lipid entering or leaving 
the cell, while changes in cell number are controlled by cell death and the 
differentiation of progenitor cells (Lapid and Graff, 2017, Siersbaek and Mandrup, 
2011, Tsuboyama-Kasaoka et al., 2000). I will now expand on how increases in cell 
number can increase adipose tissue area and improve adipose tissue dysfunction. 
The hyperplastic growth of adipose tissue is controlled by the differentiation of 
progenitor cells into mature adipocytes in a process known as adipogenesis 
(Siersbaek et al., 2012). Adipogenesis is controlled by a network of transcription 
factors (Siersbaek et al., 2012). External factors initiate a first wave of transcription 
factors, and they in turn activate a second wave of transcription factors (Siersbaek et 
al., 2012). This second wave contains the master regulators peroxisome proliferator 
activated receptor gamma (Pparg) and CCAAT enhancer binding protein alpha 
(Cebpa), and these factors then bring about the expression of genes which result in 
the mature adipocyte phenotype (Siersbaek et al., 2012). Adipogenesis can therefore 
mediate adipose tissue expansion via hyperplastic growth.      
One of the master regulators of adipogenesis, Cebpa, is capable of influencing 
adipose tissue levels in vivo. Cebpa is a basic leucine zipper transcription factor which 
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is most abundantly expressed in adipose tissue, the liver and the placenta (Linhart et 
al., 2001). Although much of the work on uncovering the transcriptional network which 
controls adipogenesis has been done in vitro, Cebpa has also been shown to 
influence adipose levels in vivo (Linhart et al., 2001, Siersbaek et al., 2012). As whole 
body Cebpa knock out mice die shortly after birth due to liver defects, a study by 
Linhart et al (2001) generated a transgenic mouse in which Cebpa expression was 
restricted to the liver (Flodby et al., 1996, Wang et al., 1995). The line was generated 
by crossing the Cebpa knockout line to a line in which Cebpa was expressed under 
the albumin promoter (Linhart et al., 2001). This produced a mouse in which Cebpa 
expression was limited to the liver and improved the survival of the mice (Linhart et 
al., 2001). The knockout mice were found to have no white adipose tissue which 
demonstrated that Cebpa is required for the commitment of preadipocytes to 
adipocytes in vivo (Linhart et al., 2001). The transgenic mice also had increased 
serum insulin levels, despite normal glucose levels, suggestive of peripheral insulin 
resistance (Linhart et al., 2001). In summary, one of the master regulators of 
adipogenesis is capable of modulating adipose levels and metabolic regulation in 
vivo. Therefore, identification of novel genetic factors which influence adipose tissue 
levels could lead to the development of treatments to alleviate the metabolic 
dysregulation associated with obesity.  
Zebrafish are an emerging model of adipose tissue biology and have 
previously been used to test if novel candidate genes play a role in adipose tissue 
expansion (Minchin et al., 2015). Much is known about AT in zebrafish. For example, 
zebrafish are known to possess AT which is homologous to mammalian white AT, 
and which expresses many of the same molecular markers as mammalian WAT 
(Flynn et al., 2009). It is also known that zebrafish adipose tissue acts as an energy 
store, with adipose in zebrafish expanding in response to a high fat diet (Minchin and 
Rawls, 2017b). However, much of what is known about the molecular regulation of 
adipose tissue expansion in mammals is unknown in zebrafish. Therefore, a better 
understanding of the molecular regulation of adipose tissue expansion in zebrafish 
would help to further establish zebrafish as a model of adipose tissue expansion. As 
many aspects of adipose tissue biology are conserved from mammals to zebrafish, it 
seems likely this is also true of the molecular basis of adipose tissue expansion. This 
leads me to the hypothesis that cebpa controls adipose tissue expansion in zebrafish.   
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In this chapter I have generated two novel loss of function cebpa alleles, to 
investigate the hypothesis that cebpa controls adipose tissue expansion in zebrafish. 
I have used these mutants to test my hypothesis by measuring adipose levels in 
response to both a control and high fat diet. cebpa mutants were found to have 
reduced levels of adipose tissue on both a control and high fat diet. Mutants were also 
found to have a more hypertrophic adipose tissue morphology and increased levels 
of blood triglycerides. This phenotype closely mirrors that of the Cebpa knockout mice 
generated by Linhart et al (2001). Overall, I have found data which suggests a 
conserved role for cebpa in adipose tissue expansion in zebrafish. I have also used 




















5.2 – Results 
 
5.2.1 - Zebrafish possess a gene homologous to mammalian Cebpa  
In order to investigate if the molecular basis of adipogenesis is conserved in 
zebrafish, I have chosen to examine the role of the transcription factor cebpa. Cebpa 
is a master regulator of adipogenesis in mammals. To investigate the role of cebpa in 
zebrafish I first had to determine whether Cebpa is conserved in zebrafish and to what 
extent it is conserved. To do this I used the gene tree feature on Ensembl 
(ENSGT00940000162646). Briefly, gene tree shows the maximum likelihood 
phylogenetic tree for a given gene and represents the evolutionary history of that 
gene. Using gene tree, I traced the human ortholog of CEBPA to the zebrafish cebpa 
gene (Figure 5.1A). I then made use of the Clustal Omega alignment software to 
determine how well the cDNA and protein sequences of cebpa were conserved. I 
compared the cDNA and protein sequences of human, mouse and Xenopus cebpa to 
that of zebrafish cebpa (Figure 5.1B & C). Zebrafish cebpa seems to show moderate 
levels of conservation to human CEBPA, with 64.94% cDNA sequence homology and 
61.81% protein sequence homology (Figure 5.1B & C). Using the protein summary 
information on Ensembl I was also able to find that, like mammalian Cebpa, zebrafish 
cebpa is comprised of a single exon (Figure 5.1D). Zebrafish cebpa also contains two 
TAD (Transactivation Domain) domains and a bZIP DNA binding domain (Figure 
5.1D) (ENSP00000427514.1). The two TAD domains in Cebpa are thought to bind to 
transcriptional coactivators and binding of these cofactors is thought to be necessary 
for transcription of cebpa (Kovacs et al., 2003). The bZIP DNA binding domain shows 
higher conservation than the entire Cebpa protein, with 80.65% sequence homology 
between human and zebrafish sequences (Figure 5.1D & E). In summary both the 







Figure 5.1 – Zebrafish possess a gene homologous to mammalian Cebpa. A. 
Unrooted phylogenetic tree. Amino acid sequences were aligned using Clustal 
Omega. Unrooted was used to generate the tree (Pole Bioinformatique Lyonnais). 
Scale bar shows amino acid changes per site. B. Comparison of cebpa isoforms 
homologous to the human isoform 201. Numbers correspond to isoforms as identified 
on Ensembl. Sequences were aligned using Clustal Omega C. Comparison of Cebpa 
protein sequences homologous to the human isoform 201. Numbers correspond to 
isoforms as identified on Ensembl. Sequences were aligned using Clustal Omega. D. 
Schematic showing the functional domains of Cebpa. Functional domains are shown 
in green. bZIP (Pfam). Percentage conservation of the bZIP domain is shown. E. 
Alignment of the protein sequences of the bZIP domains of human and zebrafish 
Cebpa. Alignment was generated using Clustal Omega. Red letters and asterisks 
show changed amino acids. 
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5.2.2 - CRISPR/Cas9 was used to generate zebrafish with heritable 
mutations in cebpa 
To investigate the role of cebpa in adipose tissue expansion, I next wanted to 
generate loss of function cebpa alleles. To achieve this, I made use of the 
CRISPR/Cas9 system. I first designed a series of guide RNAs (gRNAs) targeting 
close to the translation start site of cebpa (Figure 3.3A). The translation start site was 
targeted to try and disrupt as much protein function as possible. The gRNAs were 
then synthesised and injected into WT zebrafish embryos at the one cell stage, along 
with the Cas9 nuclease protein (Figure 3.3A). The mutagenic activity of each of the 
guides was then assessed using a T7 endonuclease 1 (T7E1) assay (Figure 5.2A). 
gRNAs which produced a different banding pattern to that of uninjected fish were 
deemed to be active and inducing mutations (Figure 5.2A). The active gRNAs were 
then reinjected into wild type (Cawthorn et al.) embryos, in order to generate stable 
lines. These embryos were raised until adulthood and became the G0 generation 
(Figure 3.3A & B). In order to generate stable mutant lines, G0 fish with germline 
mutations were identified. Adult G0 fish were outcrossed to WT fish and their progeny 
screened by T7E1 assay for lesions at the CRISPR target locus (Figure 3.3B & 
Figure 5.2B). G0 fish found to have germline mutations were again crossed to WT 
fish and their offspring raised to adulthood (Figure 3.3B). These fish became the F1 
generation. In summary this strategy generated a F1 generation of fish with heritable 
mutations in cebpa.  
 
5.2.3 - The nature of the mutations generated by CRISPR/Cas9 were 
identified and mutations predicted to have a severe effect on protein 
function were selected  
The CRISPR/Cas9 system does not induce mutations in all F1 fish and the 
effect of the mutations induced is also not likely to be the same. To determine if a 
mutation had occurred and the nature of the mutation, DNA from F1 fish was sent for 
sequencing (Figure 3.3C - Stage 3). Tissue from the caudal fin of adult F1 fish was 
taken and gDNA extracted. This gDNA was then sent for sequencing. Predicted 
frameshift mutations were selected for, as these were predicted to severely disrupt 
protein function. The selected F1 mutants were then outcrossed to WT fish (Figure 
3.3D). This then produced a breeding stock, 50% of which were WT and 50% of which 
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were heterozygous for a known mutation (Figure 3.3D). Overall, I was able to 
generate two mutant alleles which were predicted to have a severe effect on the 











Figure 5.2 – CRISPR/Cas9 induces mutations in cebpa. 
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Figure 5.2 – CRISPR/Cas9 induces mutations in cebpa. A. T7E1 assay gels used 
to test CRISPR guide efficiency. See stage 1 of Figure 5.2. Guides are cutting if the 
banding pattern in the injected lane is different to that of the uninjected lane. 
Arrowheads highlight changes in the banding patterns in the injected fish. Pools of 10 
embryos were tested. B. T7E1 assay gels used to test CRISPR activity in F1 embryos. 
See stage 2 of Figure 5.2. Guides are cutting if the banding pattern in the injected 
lane is different to that of the uninjected lane. Arrowheads highlight changes in the 





















5.2.4 - Two mutant alleles, predicted to have severe effects on protein 
function, were generated using CRISPR/Cas9 
Using CRISPR/Cas9 and the strategy outlined above, I was able to generate 
two mutant alleles. The first allele, cebpa(ed19/ed19), is caused by a 38bp deletion close 
to the translation start site, which results in a frameshift and the introduction of an 
early stop codon (Figure 5.3A, B & C). The mutant protein is predicted to have lost 
the bZIP DNA binding domain, and also the TAD2 domain (Figure 5.3A). Therefore, 
the cebpa(ed19/ed19) allele is predicted to be non-functional. The second mutant allele, 
cebpa(ed20/ed20) is the result of a 7bp deletion (Figure 5.3A &B). The 7bp deletion is 
predicted to cause a frameshift and to introduce an early stop codon (Figure 5.3A, B 
& C). Like the cepba(ed19/ed19) allele, the cepba(ed20/ed20) allele is predicted to lack any 
functional domains and is therefore thought to be a loss of function mutant (Figure 
5.3A). In summary, using CRISPR/Cas9 I effectively induced mutations in cebpa and 
generated two predicted loss of function mutant alleles.  
 
5.2.5 - cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants do not show a decrease 
in cebpa transcript levels  
Having generated two predicted loss of function cebpa alleles, I next wanted 
to determine to what degree the alleles were affected. It was hypothesised that alleles 
showing high levels of transcript degradation would show high levels of protein 
reduction and a severe phenotype. I therefore assessed cebpa mRNA levels in the 
cebpa(ed19/ed19) and cebpa(ed20/ed20) fish. To do this I fin clipped WT and mutant fish at 5 
days post fertilisation (dpf) and extracted RNA from pools of embryos. Transcript 
levels were then measured by RT-qPCR (Figure 5.3D & E). It was found that cebpa 
transcript levels were not reduced in either the cebpa(ed19/ed19) mutants or in the 
cebpa(ed20/ed20) mutants (Figure 5.3D & E). cebpa transcript levels were increased in 
both cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants when compared to WT siblings, and 
this difference was significant in cebpa(ed19/ed19) fish (Figure 5.3D & E). cebpa(ed19/ed19) 
mutants showed a 1.5 fold increase in transcripts, while cebpa(ed20/ed20) mutants 
showed a 1.8 fold increase (Figure 5.3D & E). This increase in transcript levels was 
unexpected, however it does not provide any information about protein levels in the 
mutants. Attempts were made to assess protein levels in the mutants using a Western 
blot and an antibody which recognised the human CEBPA protein. The antibodies 
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tested were not able to recognise the zebrafish Cebpa protein, and this may be due 
to a lack of homology between the two proteins. In summary cebpa mRNA levels are 
increased in cebpa(ed19/ed19) and cebpa(ed20/ed20) fish when compared to WT siblings 




Figure 5.3 – cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants do not show a reduction 
in cebpa transcript levels. 
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Figure 5.3 – cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants do not show a reduction 
in cebpa transcript levels. A. Schematic showing the structure of the Cebpa protein 
in WT and in both cebpa(ed19/ed19) and cebpa(ed20/ed20) fish. Green bars show functional 
domains. TAD (Transactivation domain). bZIP (basic leucine zipper). Yellow bars 
indicate a change to the protein sequence in cebpa(ed19/ed19) and cebpa(ed20/ed20) 
mutants, as depicted in 5.4C. The location of qPCR primers is marked. B. Letters 
indicate DNA bases. Small dashed lines illustrate where a deletion has taken place. 
The thicker dashed lines show the reading frame. The green bar shows the start of 
the TAD2 domain. C. Letters represent amino acids. Letters in red are changed from 
the WT sequence. The green bar marks the TAD2 domain. D. n = 5-6. A two tailed t-
test was performed to compare the cebpa(+/+) and cebpa(ed19/ed19) groups, p = 0.0011. 
Error bars show standard deviation. E. n = 6. Error bars show standard deviation. Ns 


















5.2.6 - cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants show the same larval 
death phenotype as published zebrafish mutants   
To further test if the cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants are likely to be 
loss of function mutants, I compared their phenotype to that of previously published 
loss of function cebpa zebrafish mutants. A study in 2015 generated zebrafish cebpa 
mutants in which a premature stop codon had been introduced and this produced a 
truncated Cebpa protein, which lacked a bZIP domain (Yuan et al., 2015). A luciferase 
reporter assay was then used to demonstrate that the mutant protein had lost its 
transcriptional activity and that the mutant generated was a loss of function mutant 
(Yuan et al., 2015). I therefore compared the cepba(ed19/ed19) and cebpa(ed20/ed20) 
mutants to the previously published mutants, as evidence of a similar phenotype 
would lend support to the idea that the cebpa(ed19/ed19) and cepba(ed20/ed20) mutants are 
also loss of function mutants.  
The most striking phenotype of the Yuan et al (2015) mutants was the early 
death of homozygous mutants. Homozygous mutants did not survive past 3 weeks of 
age (Yuan et al., 2015). To measure survival cebpa(+/ed19) and cebpa(+/ed20) fish were 
incrossed and the survival of all ungenotyped offspring monitored for 21 days (Figure 
5.4A). It was found that around 30% of the embryos from cebpa(+/ed19) incrosses and 
15% of the embryos from cebpa(+/ed20) incrosses died (Figure 5.4A). The amount of 
death was suggestive of a homozygous lethal phenotype. To determine if the death 
observed was in fact that of the homozygous embryos, the surviving fish were fin 
clipped at 21 dpf and genotyped. At 21 dpf no cebpa(ed19/ed19) mutants were present 
and very few cebpa(ed20/ed20) mutants were present (Figure 5.4B). None of the 
cebpa(ed20/ed20) mutants present at 21 dpf survived to adulthood. Taken together these 
results show that like the cebpa mutants in the study by Yuan et al (2015) 
cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants die during larval development, before 21 
dpf.  
 
5.2.7 - cebpa(ed19/ed19) mutants show the same small liver phenotype as 
published zebrafish mutants   
As a second comparison I also looked at the second major phenotype reported 
of the Yuan et al (2015) mutants. The 2015 study reported that cebpa mutants showed 
defects in liver development, resulting in a small liver and suggested that it was this 
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defect which led to death in the mutants (Yuan et al., 2015). This liver defect has also 
been noted in Cebpa knock out mice (Flodby et al., 1996, Wang et al., 1995). To 
assess if the cause of death was likely to be similar in the mutants I had generated, I 
quantified the area of the livers in cepba(ed19/ed19) mutants (Figure 5.4C & D). Fish 
were genotyped at 3 dpf and then imaged using brightfield microscopy. The liver was 
detected by its morphology, and it can be seen as a shadow over the top left hand 
corner of the swim bladder (Figure 5.4C). When liver area was measured it was found 
that cebpa(ed19/ed19) fish had significantly smaller livers than their WT siblings (Figure 
5.4D). Therefore cebpa(ed19/ed19) fish show the same small liver phenotype as the Yuan 
et al (2015) mutants. In summary both cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants 
reproduce the previously described phenotypes of loss of function mutants, and this 












Figure 5.4 – cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants show a phenotype similar 
to that of previously published cebpa mutants. A. Survival of fish generated from 
cebpa(+/ed19) and cebpa (+/20) incrosses. Ed19, n = 181. Ed20, n = 66. B. Genotypes of 
fish surviving past 21 dpf. C. Representative bright field images of 3 dpf embryos. 
Arrow heads show livers. White dotted line shows the liver area measured. D. 
Quantification of liver area. n = 6. Error bars show mean and standard deviation. A 







5.2.8 - cebpa(+/ed19) and cebpa(+/ed20) mutants have reduced levels of 
adipose tissue during normal development  
Having determined the cebpa(ed19/ed19) and cebpa(ed20/ed20) alleles are likely to be 
loss of function alleles, I next wanted to examine the effect of loss of cebpa function 
on adipose tissue levels. Due to the fact that cebpa(ed19/ed19) and cebpa(ed20/ed20) 
homozygous mutants die before the development of AT, all experiments were carried 
out with cebpa(+/ed19) and cebpa(+/ed20) heterozygous mutants. To examine levels of 
adipose tissue, fish were raised until 30 dpf and then stained with Nile Red (Figure 
5.5A & D). The fish were then imaged using a fluorescence stereomicroscope and 
the total fluorescence area measured (Figure 5.5A & D). The total fluorescence area, 
which acts as a proxy for total AT area, was then compared to standard length (SL) 
(Tingaud-Sequeira et al., 2011). Under normal fed conditions, both cebpa(+/ed19) and 
cebpa(+/ed20) fish had significantly less AT when compared to WT siblings (Figure 5.5C 
& F). cebpa(+/ed19) fish were also found to be significantly smaller than WT siblings 
(Figure 5.5B). In summary, cebpa(+/ed19) and cebpa(+/ed20) mutants have reduced levels 














Figure 5.5 – cebpa(+/ed19) and cebpa(+/ed20) mutants show impaired adipose tissue 
expansion. A. Representative Nile red images. B. n = 26-36. A two tailed t-test was 
performed, p = 0.0051. Error bars show mean and standard deviation C. n = 26-36. 
An Ancova analysis was performed and the slopes of the lines were found to be 
significantly different. F1,58 = 9.471. p = 0.0032. D. Representative Nile red images. E. 
n = 8-15. Error bars show mean and standard deviation F. n = 8-15. An Ancova 
analysis was performed and the elevation of the slopes was found to be significantly 










5.2.9 - cebpa(+/ed19) mutants gain less adipose tissue in response to a high 
fat diet   
Cebpa knockout mice have almost no WAT and the effect of a high fat diet 
(HFD) on adipose tissue expansion has not been examined in these mice (Linhart et 
al., 2001). I therefore placed the cebpa(+/ed19) mutants on a HFD to determine whether 
AT expansion was altered in response to this stimulus. cebpa(+/ed19) mutants and WT 
siblings were placed on a 1 week HFD (Figure 5.6A). The duration of the diet was 
shorter than for previous experiments due to the more severe phenotype of the 
cebpa(+/ed19) mutants at baseline. To perform the HFD, I incrossed cebpa(+/ed19) fish 
and raised their offspring until 4 weeks of age (Figure 5.6A). Fish were then 
genotyped and separated into cebpa(+/+) and cepba(+/ed19) groups (Figure 5.6A). At 8 
weeks of age the fish were divided into two size matched groups, one control diet and 
one HFD group (Figure 5.6A). Fish were then subjected to a 1 week HFD, consisting 
of a 2 hour immersion in a 5% egg yolk solution each day (Carten et al., 2011, Semova 
et al., 2012, Walters et al., 2012) (Figure 5.6A). Following the HFD fish were stained 
with Nile Red to assess AT levels (Figure 5.6A & B). It was found that cebpa(+/+) HFD 
fish had significantly more AT than cebpa(+/+) control diet (CD) fish (Figure 5.6C & D). 
cebpa(+/ed19) HFD fish also gained adipose tissue and were found to have significantly 
more AT than cebpa(+/ed19) CD siblings (Figure 5.6C & D). Strikingly cebpa(+/ed19) HFD 
fish had less AT than cebpa(+/+) CD fish (Figure 5.6C & D). Together this shows that 
while cebpa(+/ed19) fish are capable of gaining AT in response to a HFD, this ability is 




















Figure 5.6 – cebpa(+/ed19) mutants gain less adipose tissue in response to a HFD. 
A. Schematic showing protocol used for the HFD. B. Representative Nile Red images. 
C. n = 6. An Ancova analysis was performed. The elevation of the lines of the 
cebpa(+/+) CD and cebpa(+/+) HFD groups were found to be significantly different F1,9 = 
29.29 p = 0.0004. The elevation of the lines of the cebpa(+/ed19) CD and cebpa(+/ed19) 
HFD groups were also found to be significantly different, F1,9 = 17.28 p = 0.0025. D. n 
= 6. Error bars show mean and standard deviation. A two way ANOVA was performed 
and the effect of diet and genotype were found to be significant. Diet, F1,20 = 9.328 p 




















5.2.10 - cebpa(+/ed19) and cebpa(+/ed20) mutants have a more hypertrophic 
visceral adipose tissue morphology  
Adipose expands via hyperplastic and hypertrophic growth (Lapid and Graff., 
2017). As adipose tissue expansion is impaired in cebpa(+/ed19) and cebpa(+/ed20) 
mutants, I next wanted to determine if adipose tissue morphology was altered in the 
mutants. As adipocytes are largely unilocular, lipid droplet number and size 
measurements were used as a proxy for adipocyte measurements. To examine 
adipose morphology PVAT was dissected from 2 month old cebpa(+/ed19) and cebpa(+/+) 
fish, following a 1 week HFD. The PVAT was then stained with LipidTOX and the 
whole depot imaged using confocal microscopy. This provided 3D information on lipid 
droplet size and allowed lipid droplet diameter to be accurately measured. The 
number and diameter of lipid droplets within the adipose depot was then measured 
(Figure 5.7A. B. C. & D). The cebpa(+/ed19) fish were found to have a more hypertrophic 
PVAT morphology, with significantly fewer lipid droplets than WT siblings (Figure 
5.7C). cebpa(+/ed19) mutants were also found to have lipid droplets with a significantly 
greater average diameter, within PVAT, than WT siblings (Figure 5.7D). This data 
shows that visceral adipose in cebpa(+/ed19) mutants expands via hypertrophic growth 
to a greater extent than in WT fish.    
To further test whether adipose morphology is altered in cebpa mutants I also 
looked at morphology in adult fish. PVAT was dissected from cepba(+/ed19) and 
cebpa(+/ed20) fish and WT siblings and stained with LipidTOX. Confocal imaging was 
then used to image the depots and lipid droplet number and diameter was again 
measured (Figure 5.7E &H). cebpa(+/ed19) fish were again found to have a more 
hypertrophic lipid droplet morphology, with significantly fewer lipid droplets and a 
significantly greater average lipid droplet diameter (Figure 5.7F & G). In contrast 
cebpa(+/ed20) fish were found to have an unchanged adipose morphology, with no 
changes in lipid droplet number or average lipid droplet diameter (Figure 5.7I & J). 
This difference could be due to the smaller n number of the cebpa(+/ed20) experiment 
or the cebpa(+/ed20) fish may have a more subtle phenotype. Overall cebpa mutants 











Figure 5.7 – cebpa(+/ed19) mutants have a more hypertrophic VAT morphology. A. 
Representative maximum intensity projections of PVAT (Pancreatic VAT) depots. The 
anterior end of the depot is to the right of the image and the posterior to the left. B. 
Schematic showing location of the PVAT depot in zebrafish. C. n = 2-4. Error bars 
show mean and standard deviation.  A two way ANOVA was performed. The effect of 
diet and genotype were found to be significant, as was the interaction between the 
two. Diet, F1,9 = 10.22 p = 0.0109. Genotype, F1,9 = 37.66 p = 0.0002. Interaction, F1,9 
= 10.79 p = 0.0095. D. n = 2-4. Error bars show mean and standard deviation.  A two 
way ANOVA was performed and the effect of genotype was found to be significant. 
F1,9 = 13.78 p = 0.0048. E. Representative maximum intensity projections of PVAT 
depots. The anterior end of the depot is to the right of the image and the posterior to 
the left. F. n = 10-13. Error bars show mean and standard deviation.  A two tailed t-
test was performed, p = 0.0479. G. n = 10-13. Error bars show mean and standard 
deviation.  A two tailed t-test was performed, p = 0.0276. H. Representative maximum 
intensity projections of a section of the PVAT depots. I. n = 3-5. Error bars show mean 
















5.2.11- cebpa(+/ed19) mutants have a more hypertrophic subcutaneous 
adipose tissue morphology  
To test if the changes observed in adipose morphology are confined to visceral 
adipose, I examined the adipose morphology of subcutaneous adipose tissue. To do 
this I stained live cebpa(+/ed19) fish and WT siblings with LipidTOX and then euthanised 
the fish. The LSAT depot was then imaged through the skin of euthanised fish using 
confocal microscopy (Figure 5.8A & B). Lipid droplet number and diameter was then 
measured. cebpa(+/ed19) fish were found to have a more hypertrophic LSAT 
morphology than WT siblings (Figure 5.8C & D). cepba(+/ed19) mutants had fewer lipid 
droplets and a greater average lipid droplet diameter (Figure 5.8C & D). In summary 
the altered adipose morphology observed in cepba(+/ed19) fish is not confined to visceral 
adipose tissue and cebpa(+/ed19) fish have a more hypertrophic subcutaneous adipose 

















Figure 5.8 – cebpa(+/ed19) mutants have a more hypertrophic SAT morphology A. 
Schematic showing the location of the LSAT depot. B. Representative maximum 
intensity projections of a section of the LSAT depot. C. n = 4. Error bars show mean 
and standard deviation. A two tailed t-test was performed, p = 0.0143. D. n = 4. Error 
















5.2.12 - cebpa(+/ed19) mutants have elevated levels of blood triglycerides   
As cebpa(+/ed19) and cebpa(+/ed20) mutants are less able to store lipid in adipose 
tissue, it is expected that levels of blood metabolites may be altered in these mutants. 
Cebpa knockout mice, in which Cebpa is expressed only in the liver, show normal 
levels of glucose but elevated levels of insulin, suggestive of peripheral insulin 
resistance (Linhart et al., 2001). I therefore wanted to test if cebpa(+/ed19) and 
cebpa(+/ed20) mutants showed a similar phenotype to the mouse phenotype. To do this 
I measured levels of lipid metabolites in the blood. Adult fish were euthanised, blood 
extracted, and levels of glucose, triglyceride and cholesterol measured (Figure 5.9A. 
B. C. D. E. & F). Levels of blood glucose in the cebpa(+/ed19) and cebpa(+/ed20) mutants 
were unchanged compared to WT fish, reflecting the phenotype of the mouse mutants 
(Figure 5.9A & D). Levels of cholesterol were also unchanged in both mutants 
(Figure 5.9C & F). However, levels of triglycerides were significantly increased in 
cebpa(+/ed19) mutants compared to WT siblings (Figure 5.9B). Overall cebpa(+/ed19) 













Figure 5.9 – cepba(+/ed19) mutants have elevated levels of blood triglycerides. A. 
n = 2-3 B. n = 3. A two tailed t-test was performed p = 0.0428 C.  n = 4. D. n = 2-3 E. 












5.2.13 - cebpa(+/ed19) mutants have fewer adipocytes, fewer adipose 
progenitor cells and show reduced levels of hyperplastic growth  
The results presented so far suggest that cebpa is required for adipose tissue 
expansion in zebrafish, however the role of cebpa in adipogenesis has not been 
addressed. To examine this I made use of the Foxp1:eGFP line to assess adipose 
progenitor cell behaviour and adipose growth in the cebpa(+/ed19) mutants. Details of 
how the Foxp1:eGFP was generated can be found in chapter 4. Briefly the 
Foxp1:eGFP line expresses GFP in both adipose progenitor cells and mature 
adipocytes. cebpa(+/ed19) mutants were crossed to Foxp1:eGFP fish and then 
genotyped at 1 month of age. Following this GFP positive cebpa(+/ed19) fish and WT 
siblings were stained with LipidTOX and the whole LSAT depot imaged in live fish 
using a stereomicroscope. The fish were then recovered and the imaging was 
repeated 24 hours and 48 hours after the first timepoint. The number of adipocytes 
and adipose progenitor cells in the LSAT of each fish was measured, with adipose 
progenitor cells being classified as GFP positive cells which lacked a lipid droplet. 
Analysis of cell number and lipid droplet area showed that cebpa(+/ed19) mutants had a 
reduced number of both adipose progenitor cells and mature adipocytes (Figure 
5.10A & C). cebpa(+/ed19) mutants also had a greater average lipid droplet area (Figure 
5.10B & C). Together this shows that cebpa(+/ed19) fish have a more hypertrophic LSAT 
morphology and suggests that hyperplastic growth is impaired. To examine this, I 
looked at the growth of LSAT across the timepoints. Differences in the appearance of 
LSAT between fish allowed individual fish to be tracked throughout the experiment, 
and this allowed changes in adipocyte size and number to be measured (Figure 
5.10D. E. F. & G). cebpa(+/ed19) mutants showed a smaller increase in the number of 
progenitor cells and mature adipocytes over the timepoints than WT siblings (Figure 
5.10D. F. & G). Change in lipid droplet area was very similar between cebpa(+/ed19) fish 
and WT siblings (Figure 5.10E. F. & G). Overall, the reduced number of adipose 
progenitor cells and the reduced increase in adipose progenitors and mature 
adipocytes in cebpa(+/ed19) mutants suggests that hyperplastic adipose growth and 




Figure 5.10 – cepba(+/ed19) mutants have a more hypertrophic adipose 
morphology and show reduced levels of hyperplastic growth. 
257 
 
Figure 5.10 – cepba(+/ed19) mutants have a more hypertrophic adipose 
morphology and show reduced levels of hyperplastic growth. A. n = 6 per group. 
Measurements taken from 4 fish at 3 timepoints. A two way ANOVA was performed 
and the effect of cell type, genotype and the interaction were all found to be significant. 
Cell type, F1,20 = 71.05 p < 0.0001. Genotype, F1,20 = 35.92 p < 0.0001. Interaction, 
F1,20 = 24.37 p < 0.0001. B. n = 6. Measurements taken from 4 fish at 3 timepoints. A 
two tailed t-test was performed, p = 0.1739. C. Representative maximum intensity 
projections. D. n = 4. Measurements taken from 4 fish at 3 timepoints and the 
differences between these measurements plotted. A two way ANOVA was performed 
and the effect of cell type was found to be significant, F1,12 = 5.171 p = 0.0421. E. n = 
4. Measurements taken from 4 fish at 3 timepoints and the differences between these 
measurements plotted. A two tailed t-test was performed, p = 0.7059. F. 
Representative maximum intensity projections. Arrow heads show progenitor cells. 
T1 (Timepoint one). T2 (Timepoint 2). G. Representative maximum intensity 
projections. Arrow heads show progenitor cells. T1 (Timepoint one). T2 (Timepoint 2). 
















5.2.14 - Genes involved in tissue development, regeneration and cell 
differentiation are upregulated in cebpa(+/ed19) mutants  
Analysis of the cebpa(+/ed19) and cebpa(+/ed20) mutants suggest a conserved role 
for cebpa in adipogenesis in zebrafish. This provides further evidence that zebrafish 
is a useful model for the study of adipose tissue expansion. As all the data I have 
presented so far in this chapter is already well established in mouse models I also 
wanted to use the novel zebrafish mutants generated to identify new candidate genes 
which may play a role in adipose tissue expansion. To do this I have used RNA-
Sequencing (RNA-Seq). RNA-Seq is a technique used to determine the quantity and 
sequences of RNA in a sample (Wang et al., 2009). PVAT was dissected from 
cebpa(+/+) and cebpa(+/ed19) siblings at 2 months of age and RNA extracted. RNA quality 
was then assessed by measuring RNA concentration and RNA integrity number (RIN) 
value, and the samples were sent to BGI. There the RNA was reverse transcribed into 
cDNA and amplified by PCR. The DNA was then sequenced on a BGISEQ-5000 
platform. Following sequencing, low quality reads were removed and HISAT 
(Hierarchical Indexing for Spliced Alignment of Transcripts) was used to map reads 
to the zebrafish genome. Gene expression levels were then calculated and 
differentially expressed genes reported. Overall, RNA Seq was used to detect genes 
differentially expressed in the PVAT of cebpa(+/+) and cebpa(+/ed19) fish.  
The RNA-Seq revealed that 949 genes were significantly upregulated in 
cebpa(+/ed19) mutants when compared to WT siblings and that 177 genes were 
significantly downregulated (Figure 5.11A). From this data set, genes which were 
upregulated were then grouped according to gene ontology (GO) term enrichment 
(Figure 5.11B). Gene ontology is an initiative which aims to annotate genes and to 
enable functional interpretation of experimental data (Gene Ontology, 2008). GO term 
analysis using ZebrafishMine revealed an enrichment of terms relating to tissue 
development, lipid and steroid metabolism and cell differentiation (Figure 5.11B). Of 
particular interest were genes categorised into the cell differentiation GO term (Figure 
5.11B). As cebpa is a key regulator of adipocyte differentiation, genes sorted into the 
cell differentiation GO term could be interesting candidate genes in the regulation of 
adipose tissue expansion. Interesting candidate genes will be expanded upon in the 
discussion. In summary the cebpa(+/ed19) mutants have facilitated the identification of 





Figure 5.11 – RNA-Seq profiling of cebpa(+/ed19) mutants reveals an altered 
transcriptional signature. A. Volcano plot showing significantly up and 
downregulated genes. Dashed lines indicate significance. Log2(foldchange) ≤ -1 and 
≥ 1. FDR ≤ 0.001. B. Top 20 GO terms in upregulated genes. Genes with 












5.3 - Discussion  
 
Zebrafish are an emerging model of adipose tissue expansion. Much is known 
about how AT behaves in zebrafish however it is currently unknown whether the 
molecular basis of adipose tissue expansion is conserved to zebrafish. Therefore, a 
better understanding of the molecular basis of adipose tissue expansion in zebrafish 
could help to further establish zebrafish as a model of adipose tissue expansion. 
In summary, I have presented data which suggests that the role of cebpa in 
adipose tissue expansion is conserved to zebrafish. I have generated two cebpa 
mutant alleles, both of which show defects in AT expansion (Figure 5.12A & B). 
cebpa(+/ed19) mutants have reduced levels of AT, a reduced response to a HFD, a more 
hypertrophic AT morphology and increased levels of blood triglycerides (Figure 
5.12A). While cepba(+/ed20) mutants have reduced levels of AT and a more 
hypertrophic adipose morphology (Figure 5.12B). The phenotypes of both mutants 
also mirror those of published zebrafish and mouse mutants. Together this data is 
supportive of a conserved role of cepba in adipogenesis in zebrafish (Figure 5.12C). 
In this section I will discuss the limitations of the data I have presented, and a full 
discussion can be found in the general discussion section (Chapter 6).  
One major limitation of the data I presented is that it is currently unknown if 
levels of cebpa protein are changed in the cebpa(ed19/ed19) and cepba(ed20/ed20) mutants. 
Transcript levels were found to be unchanged in the cebpa(ed20/ed20) mutants and 
significantly increased in the cebpa(ed19/ed19) mutants. As the cebpa mutant transcripts 
do not appear to be degraded and as I was unable to assess protein levels it is unclear 
how or if Cebpa expression is altered in the mutants. The fact that cebpa(+/ed19) and 
cebpa(+/ed20) mutants show phenotypes consistent with both published zebrafish and 
mouse mutants gives confidence to the idea that cepba zebrafish mutants are indeed 
loss of function mutants. However, measuring protein levels would be helpful in 
determining the true nature of the cebpa(+/ed19) and cebpa(+/ed20) mutants.   
Another limitation of the work I have presented is that all adipose phenotypes 
were assessed in the cebpa(+/ed19) and cebpa(+/ed20) heterozygous mutants. Both the 
cebpa(ed19/ed19) and the cepba(ed20/ed20) mutants die at 2 to 3 weeks of age due to a liver 
defect and as AT first develops in some fish at 12 dpf, I was unable to assess AT 
levels in these mutants.  One way to overcome this problem would be to overexpress 
cebpa only in the liver, as was done in the Cebpa mouse mutants (Linhart et al., 2001). 
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This would allow me to assess the effect of total loss of cebpa on adipose tissue 
expansion in zebrafish. Overexpressing cebpa in the liver would also give confidence 
to the idea that adipose phenotypes in the cebpa(+/ed19) and cebpa(+/ed20) mutants are 
due to the effect of cebpa in adipose expansion and not a secondary effect of poor 
liver function.  
In summary I have presented results which broadly agree with my hypothesis 
that the role of cebpa in adipogenesis is conserved to zebrafish and that cebpa is a 
key regulator of adipose tissue expansion in zebrafish. Here I have detailed the major 
























Figure 5.12 – The role of Cebpa in adipogenesis, and adipose tissue expansion, 
appears to be conserved in zebrafish. A. Summary of the phenotype of the 
cebpa(+/ed19) mutants and a model of the effect reduced levels of cebpa are thought to 
have on AT expansion. B. Summary of the phenotype of the cebpa(+/ed20) mutants and 
a model of the effect reduced levels of cebpa are thought to have on AT expansion. 
C. Schematic showing how adipogenesis is thought to proceed in zebrafish.  
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6.1 – Summary of results  
 
The findings in this thesis demonstrate three major points. Firstly, that foxp1 
is required for adipose tissue expansion, secondly that LSAT expands by steady 
hypertrophic growth with bursts of hyperplastic growth and finally that the genetic 
control of adipose tissue expansion is conserved between mammals and zebrafish. 
In chapter 3 I have provided evidence to support the hypothesis that foxp1 is required 
for adipose tissue expansion. Foxp1 has been implicated in the control of body weight 
and adiposity by multiple GWAS studies, and it is this gene which has been the 
primary focus of my thesis (Hoffmann et al., 2018, Kichaev et al., 2019, Speakman et 
al., 2018). Foxp1 was identified as a factor which may influence adipose morphology 
and expansion and further research on the known roles of Foxp1 led to the hypothesis 
that “Foxp1 maintains AT progenitor cell populations and is required for AT expansion” 
(Figure 6.1A). To investigate this hypothesis I used zebrafish as a model and using 
CRISPR mutagenesis generated three novel zebrafish mutants, foxp1a(-/-), foxp1b(-/-) 
and foxp1a(-/-);foxp1b(-/-). Using these new mutant lines, I found that foxp1a is not 
required for AT expansion during normal development but is required for AT 
expansion in response to a high fat diet. The reduced AT expansion of the foxp1a(-/-) 
mutants in response to a HFD was characterised by reduced SAT expansion and a 
more hypertrophic SAT morphology. Similarly, foxp1b was also found to be 
nonessential for AT expansion during normal development. However, in contrast to 
foxp1a, foxp1b was required for VAT expansion in response to a HFD, though 
reduced VAT expansion did not result in an altered adipose morphology. Finally, 
foxp1a(-/-);foxp1b(-/-) double mutants had reduced levels of adipose tissue both during 
normal development and in response to a high fat diet (Figure 6.1B). The reduced 
AT expansion in the foxp1a(-/-);foxp1b(-/-) mutants led to a more hypertrophic adipose 
tissue morphology and increased levels of blood glucose, thus suggesting metabolic 
impairment. (Figure 6.1B). Together these data demonstrated that foxp1 is required 
for adipose tissue expansion. 
In chapter 4 I set out to address the hypothesis that foxp1 maintains progenitor 
cell populations in adipose tissue. To do this I generated a novel transgenic line, 
Foxp1:eGFP, in which both adipocytes and adipose progenitor cells express GFP. 
Using this line I was able to propose a model of spatial LSAT expansion, in which 
LSAT expands by adding new cells to the centre of the depot and then further expands 
by forming chains of adipocytes which branch away from the main LSAT body. I also 
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show that LSAT expands via steady hypertrophic growth with bursts of hyperplastic 
growth. I then examined the role of foxp1 in LSAT expansion and found that, while 
foxp1b is not required for normal LSAT expansion, foxp1a does appear to be required 
for normal expansion. foxp1a(-/-) mutants were found to have altered spatial LSAT 
expansion and change in adipocyte number was not correlated with change in 
progenitor cell number, suggesting altered progenitor cell behaviour. Finally it was 
found that foxp1a(-/-);foxp1b(-/-) mutants showed no differences in adipose progenitor 
cell number. However further timecourse experiments are needed to fully examine 
LSAT expansion in foxp1a(-/-);foxp1b(-/-) mutants. Overall, this data suggests that 
foxp1a plays a role in LSAT expansion.  
Finally, in chapter 5 I have presented evidence which suggests that the genetic 
control of adipose tissue expansion is conserved between mammals and zebrafish. 
Much is currently known about adipose tissue in zebrafish however the genetic 
regulation of adipose tissue expansion is still poorly understood. In contrast, the 
genetic control of adipose tissue expansion in mammals is well characterised 
however the question of whether this conservation is extended to zebrafish remains 
untested. To begin to investigate the genetic conservation of AT expansion in 
zebrafish, I examined the role of a master regulator of adipogenesis and proposed 
the hypothesis that cepba is a key regulator of adipose tissue expansion in zebrafish 
(Figure 6.1D). To investigate this hypothesis, I generated two novel cebpa zebrafish 
mutants, cebpa(ed19/ed19) and cebpa(ed20/ed20). I showed that loss of cebpa in zebrafish 
has a very similar effect on adipose tissue expansion to the effect observed in mouse 
models (Figure 6.1E). I found that cebpa(+/ed19) mutants had reduced levels of adipose 
tissue during normal development and following a high fat diet (Figure 6.1E). Finally, 
I showed that cebpa(+/ed19) mutants had a more hypertrophic adipose tissue 
morphology, increased levels of blood triglycerides, and fewer adipose progenitor 
cells (Figure 6.1E). Overall, I have provided data to support the hypothesis that cepba 
controls adipose tissue expansion in zebrafish.  
In this chapter I will discuss my key findings and the significance of these 
findings. I will also discuss how this work could be taken forward and suggest follow 
up experiments. The major limitations of the work I have described are discussed in 






Figure 6.1 – Summary of key findings. 
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Figure 6.1 – Summary of key findings. A. Schematic of the hypothesis that foxp1 
maintains adipose progenitor cells and is required for adipose tissue expansion. B. 
Schematic showing the phenotype of foxp1a(-/-);foxp1b(-/-) mutants. C. Schematic 
showing the adipose progenitor phenotype of foxp1a(-/-);foxp1b(-/-) mutants. D. 
Schematic of the hypothesis that cepba is required for adipose tissue expansion in 



























6.2 – Key findings and significance  
 
6.2.1 – Predicted loss of function foxp1 zebrafish mutants are viable  
To investigate the hypothesis that foxp1 maintains adipose progenitor cell 
populations and is required for adipose tissue expansion, I first generated a series of 
predicted loss of function zebrafish mutants. All of the foxp1 mutants described in this 
report, including the foxp1a(-/-), foxp1b(-/-) and the foxp1a(-/-);foxp1b(-/-) double mutants, 
were viable and survived to adulthood. This is in contrast to whole body Foxp1 mouse 
mutants, which die at around embryonic day E14.5 due to defects in heart 
development (Wang et al., 2004). There are two possible explanations for the 
contrasting phenotypes observed, with the first being the different nature of the 
mutations generated. The mouse mutants described were generated by replacing the 
three exons of the forkhead DNA binding domain with a neomycin resistance cassette 
(Wang et al., 2004). The mouse mutants therefore contained no elements of the 
Foxp1 forkhead DNA binding domain (Wang et al., 2004). In contrast the zebrafish 
mutants were generated using CRISPR and the induced mutations did not result in 
the loss of the entire FHD domain. While the foxp1b(-/-) mutants lacked all of the FHD 
apart from 4 amino acids, much of the FHD was retained in the foxp1a(-/-) mutants. 
Furthermore, although both mRNA and protein levels are reduced in both foxp1a(-/-) 
and foxp1b(-/-) mutants detectable levels still remained. Therefore, the less severe 
nature of the mutations generated in the zebrafish could explain the discrepancy 
between the observed phenotypes.  
A second explanation for the difference between the viability of the mouse and 
zebrafish foxp1 mutants could be the differing nature of mouse and zebrafish hearts. 
While zebrafish hearts can be thought of as comparable to mouse hearts, there are 
some key differences, not least their capacity for regeneration (Kikuchi, 2014). 
Furthermore, while zebrafish have two chambered hearts, mammals such as mice 
possess four chambered hearts (Andres-Delgado and Mercader, 2016). Foxp1 is 
known to be required for cardiac outflow tract septation, a process which takes places 
during the formation of the four chambers of the heart and which does not take place 
in zebrafish (Wang et al., 2004). Therefore, it may be that while Foxp1 is required for 
mouse heart development, it is not essential to zebrafish heart development. foxp1 is 
also present as two paralogues in zebrafish and so another possibility is that the 
foxp1a and foxp1b genes may have undergone subfunctionalisation and only one 
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may be required for heart development. However, this theory has not been tested. 
Finally, it should be noted that while no obvious defects in heart function were 
observed in the zebrafish foxp1 mutants, heart development and function were not 
examined. Therefore, the possibility remains that foxp1 zebrafish mutants do show 
subtle defects in heart development or function. In summary the lack of a severe heart 
defect in the foxp1 zebrafish mutants can be explained by the differing nature of the 
mutations in foxp1 or by species specific differences in heart development.   
 
6.2.2 – foxp1b(-/-) and foxp1a(-/-);foxp1b(-/-) mutants show altered somatic 
growth  
One of the first phenotypic measures taken of the foxp1 mutant zebrafish was 
standard length. foxp1a(-/-) mutants were found to have unaltered somatic growth 
when compared to WT siblings at 30 dpf. However, both foxp1b(-/-) and foxp1a(-/-
);foxp1b(-/-) mutants were found to be significantly smaller than their WT siblings. 
These data suggest that foxp1b has a role in the somatic growth of zebrafish. As the 
whole body Foxp1 mouse mutants died early in development no differences in size 
were reported, however adipocyte specific Foxp1 knockout mice were reported to be 
normal in size (Liu et al., 2019, Wang et al., 2004). This difference in phenotype 
between the zebrafish and mouse mutants could be explained by the nature of the 
mutants. While mutation of Foxp1 was restricted to adipocytes in the mouse model, 
the zebrafish mutants generated were whole body mutants (Liu et al., 2019). As 
FOXP1 is known to be widely expressed in humans and has been shown to be widely 
expressed during zebrafish development, the reduced size of the zebrafish mutants 
could be explained by the action of foxp1 on tissues other than adipose (Cheng et al., 
2007, Fagerberg et al., 2014). For example, Foxp1 is expressed in the brain in both 
humans and mice, however brain specific Foxp1 knockout mice show no defects in 
locomotor activity (Bacon et al., 2015). In contrast Foxp1 has been shown to be 
required for the formation of motor neuron circuits in mice (Arber, 2008). Therefore it 
is possible that the foxp1b(-/-) and foxp1a(-/-);foxp1b(-/-) fish show impaired locomotion 
and are outcompeted for food by their WT siblings. To test this mutant and WT could 
be raised separately and SL then measured to see if the reduced somatic growth 
phenotype of the mutants persists.    
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Another point to consider is that the reduced size of the foxp1b(-/-) and foxp1a(-
/-);foxp1b(-/-) mutants could also be explained by a developmental delay. The stages at 
which foxp1 mutant zebrafish reached developmental milestones were not 
characterised in depth. However, no obvious developmental delays were observed. 
Parichy et al (2011) have devised a method for staging postembryonic zebrafish and 
this could be utilised to determine whether foxp1b(-/-) and foxp1a(-/-);foxp1b(-/-) mutants 
are developmentally delayed (Parichy et al., 2009). Overall foxp1b(-/-) and foxp1a(-/-
);foxp1b(-/-) mutants are significantly smaller than WT siblings and while this could be 
the result of reduced levels of foxp1 throughout the fish, further experiments are 
needed to rule out any developmental delays in the mutant fish.      
 
6.2.3 – foxp1 is required for adipose tissue expansion 
My hypothesis was that foxp1 is required for adipose tissue expansion. 
Therefore, I next examined adipose tissue development in foxp1 zebrafish mutants. 
Only the presence of white AT has been reported in zebrafish and so AT here refers 
only to WAT unless otherwise stated. foxp1a(-/-) and foxp1b(-/-) mutants were found to 
have normal levels of adipose tissue during normal development, while foxp1a(-/-
);foxp1b(-/-) mutants were found to have reduced levels of AT relative to SL when 
compared to WT siblings. This suggests that no single foxp1 paralogue is required for 
adipose tissue expansion but that foxp1 itself is required for adipose tissue expansion. 
This finding is concordant with the recent study by Liu et al (2019). Liu et al (2019) 
showed that mice with conditional loss of Foxp1 in adipose tissue had reduced levels 
of AT during normal development. This is in direct agreement with the results 
presented here, however the study proposed that the reduced levels of white adipose 
tissue observed in the mice were the result of increased brown/beige adipocyte 
differentiation (Liu et al., 2019). Zebrafish do not possess thermogenic adipose tissue 
and yet foxp1 mutants still show defects in adipose tissue accumulation, suggesting 
that foxp1 does play a role in white adipose tissue expansion. Furthermore, as the 
mouse mutants from the study by Liu et al (2019) were AT specific, together the 
mouse and zebrafish data support an adipose autonomous role of foxp1. However, 
an adipose autonomous role of foxp1 in zebrafish is yet to be shown. In summary, the 
reduced levels of adipose tissue in the foxp1a(-/-);foxp1b(-/-) mutants supports the 
hypothesis that foxp1 is required for adipose tissue expansion. 
271 
 
6.2.4 – foxp1 is required for AT expansion in response to a HFD 
To further examine the role of foxp1 in adipose tissue expansion, I made use 
of a high fat diet to stimulate adipose tissue expansion. Briefly, fish were raised until 
4 weeks of age and then stained with Nile Red to measured AT levels before the diet. 
The fish were then exposed to a 2 week HFD, which has previously been shown to 
result in significant AT accumulation in WT fish (Minchin and Rawls, 2017b). At the 
end of the diet the fish were again stained with Nile Red and this allowed AT 
accumulation in response to the diet to be calculated. All of the foxp1 zebrafish 
mutants showed reduced AT expansion in response to the HFD. This is again in 
keeping with the results published by Lui et al (2019), which showed that adipocyte 
specific Foxp1 knockout mouse mutants gained less adipose tissue in response to a 
high fat diet. Taken together these data show that foxp1 is required for AT expansion 
in response to a HFD.  
While all of the foxp1 zebrafish mutants displayed reduced AT accumulation 
in response to the HFD, the foxp1a(-/-) and foxp1b(-/-) mutants showed differences in 
VAT and SAT accumulation. foxp1a(-/-) mutants showed reduced SAT accumulation 
in response to the HFD, while foxp1b(-/-) mutants showed reduced VAT accumulation.  
The different phenotypes observed in the two mutants is suggestive of gene 
subfunctionalisation and indicates that foxp1a may have a larger role in SAT, while 
foxp1b may have a stronger role in VAT. foxp1a and foxp1b may also show different 
expression patterns in different adipose tissues. While there is no direct evidence of 
this many duplicated genes in zebrafish have been shown to divide their expression 
between tissues in which the single gene is expressed in mammals (Kleinjan et al., 
2008, Sharma et al., 2006). However, foxp1a and foxp1b expression in zebrafish 
needs to be further examined to determine if they show different patterns of 
expression.  Overall, these data support the hypothesis that foxp1 is required for AT 
expansion and suggests that foxp1a has a role in SAT expansion while foxp1b has a 
role in VAT expansion.  
 
6.2.5 – foxp1 mutants have a more hypertrophic adipose morphology  
Having determined that foxp1 is required for AT expansion I next examined 
whether the mode of adipose tissue expansion was altered in the foxp1 mutants. AT 
can expand via hyperplastic growth, an increase in adipocyte number, or hypertrophic 
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growth, an increase in cell size (Hoffstedt et al., 2010). foxp1a(-/-) mutants were found 
to have a more hypertrophic LSAT, but not PVAT, morphology following a HFD. This 
meant that foxp1a(-/-) mutants had fewer but larger lipid droplets present in SAT than 
WT siblings, following a HFD. In contrast no differences in PVAT or LSAT morphology 
were observed in foxp1b(-/-) mutants. The lack of observed phenotype could be 
explained by a more subtle effect of a loss of foxp1b on VAT morphology and a sample 
size too small to see this effect. Finally foxp1a(-/-);foxp1b(-/-) mutants were found to 
have a more hypertrophic adipose morphology during normal development in the 
PVAT depot. Together this suggests that foxp1 drives hyperplastic adipose tissue 
expansion. The hypertrophic AT morphology observed in the zebrafish mutants is 
reminiscent of the few very large adipocytes present in Pparg knockout mice (Wang 
et al., 2013a). Pparg knockout mice were found to have virtually no AT, and the 
adipocytes which were present were vastly enlarged (Wang et al., 2013a). The 
similarities between the Pparg knockout mice and the foxp1 zebrafish mutants 
suggests that, like pparg, foxp1 is an important driver of hyperplastic adipose tissue 
expansion. Furthermore, this suggests that foxp1 may play a role in adipose 
progenitor proliferation and differentiation, and this role has been examined with the 
use of transgenic zebrafish. However, Foxp1 adipocyte specific knockout mice do not 
share the hypertrophic adipose phenotype of the zebrafish mutants (Liu et al., 2019). 
The Foxp1 mutant mice described by Lui et al (2019) were described as having a 
more hyperplastic adipose morphology than WT siblings, however this observation 
was made of a singular adipose depot and adipose morphology was not quantified. 
One explanation for this discrepancy could be that the reported browning of WAT in 
the Foxp1 mutant mice may have led to mobilisation of lipid from white adipocytes 
and a more hyperplastic morphology (Liu et al., 2019). As zebrafish do not possess 
brown AT, the hypertrophic AT phenotype observed in the foxp1 zebrafish mutants 
may therefore be due to the effect of foxp1 on WAT only. In summary foxp1 zebrafish 
mutants have a more hypertrophic adipose tissue morphology, which suggests that 
foxp1 may drive hyperplastic adipose tissue expansion. However further experiments 






6.2.6 – foxp1a(-/-);foxp1b(-/-) mutants have elevated levels of blood glucose  
As adipose tissue expansion is impaired in the foxp1 mutants and is 
characterised by a hypertrophic PVAT morphology, I examined levels of blood 
metabolites to get a better picture of the overall metabolic health of the mutants. 
foxp1a(-/-) and foxp1b(-/-) mutants were found to have normal levels of blood glucose, 
triglyceride and cholesterol. In contrast foxp1a(-/-);foxp1b(-/-) mutants were found to 
have increased levels of blood glucose compared to WT siblings, and this is reflective 
of the more severe phenotype of the foxp1a(-/-);foxp1b(-/-) mutants. The increased 
levels of blood glucose could be the result of increased gluconeogenesis in the liver 
or impaired glycogen storage by the liver and muscle (Stumvoll et al., 2005). With 
both being signs of reduced insulin secretion and peripheral insulin resistance 
(Stumvoll et al., 2005). This phenotype resembles the slightly more severe phenotype 
of Cebpa and Pparg mutant mice (Linhart et al., 2001, Wang et al., 2013a). Both 
Cepba and Pparg knockout mice have been reported to show peripheral insulin 
resistance (Linhart et al., 2001, Wang et al., 2013). Together this shows that similarly 
to loss of Cepba and Pparg expression, loss of foxp1 expression leads to adverse 
metabolic outcomes.   
In contrast to the adverse metabolic outcomes associated with loss of foxp1 
in zebrafish, loss of Foxp1 in mouse models has been shown to improve glucose 
metabolism and insulin sensitivity (Liu et al., 2019). Adipose specific Foxp1 knockout 
mice gained less weight than control littermates following a HFD and showed 
improved metabolic parameters (Liu et al., 2019). Loss of Foxp1 in adipose tissue in 
mice therefore appears to improve metabolic parameters while loss of foxp1 in 
zebrafish worsens them. This discrepancy could be explained by a number of factors, 
with the influence of brown adipose tissue being one such factor. In the Foxp1 
knockout mice described, the levels and activity of brown adipose tissue are increased 
(Liu et al., 2019). It could therefore be the case that the changes in BAT, and not 
WAT, are responsible for the improved metabolic profile of the Foxp1 mutant mice. 
Zebrafish do not possess brown adipose tissue and so loss of foxp1 in WAT is 
detrimental to metabolic health (Gesta et al., 2007). A second explanation for the 
difference in metabolic outcome is that while the Foxp1 mouse mutants are adipose 
tissue specific, the zebrafish mutants are whole body mutants (Liu et al., 2019). Foxp1 
is known to play a role in the liver where it inhibits gluconeogenesis, and it may be 
that the loss of foxp1 in this pathway leads to the increased blood glucose levels 
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observed in zebrafish mutants (Zou et al., 2015). Evidence to support this idea comes 
from a study in which increased Foxp1 expression in the livers of mice, via tail vein 
injection of a recombinant adenovirus expressing Foxp1, leads to lower blood glucose 
levels (Zou et al., 2015). Therefore it may be the loss of foxp1 expression in the liver, 
rather than in AT, that is responsible for the increased levels of blood glucose in 
foxp1a(-/-);foxp1b(-/-) mutants. In summary the differences in the metabolic health of 
Foxp1 mouse and zebrafish mutants could be explained by either the lack of BAT in 
zebrafish or by the action of foxp1 in the liver. Further experiments are needed to 
determine if the effects observed in the zebrafish mutants are adipose tissue 
autonomous and details of these proposed experiments can be found in sections 3.3 
and 6.3 
 
6.2.7 – Analysis of the Foxp1:eGFP transgenic line has provided novel 
information on LSAT growth and adipose progenitor behaviour in 
zebrafish   
Having identified a role for foxp1 in the expansion of zebrafish adipose tissue, 
I next looked at whether foxp1 influences adipose progenitor cell behaviours. To do 
this I generated the Foxp1:eGFP transgenic zebrafish line, in which GFP is expressed 
by both adipocytes and adipose progenitor cells. This model allows for unprecedented 
imaging of adipose progenitor cells and adipose tissue growth in vivo. The 
Foxp1:eGFP line can be stained with lipophilic dyes to distinguish between mature 
adipocytes and progenitors. LSAT growth has previously been imaged in zebrafish, 
however this imaging relied entirely on the use of lipophilic dyes and so adipose 
progenitor cells could not be visualised (Minchin and Rawls, 2017b). The Foxp1:eGFP 
line therefore constitutes the first transgenic line capable of marking adipose 
progenitor cells in live fish. In addition to allowing for the visualisation of adipose 
progenitor cells, the Fopx1:eGFP line also allowed novel data on the cellular dynamics 
of LSAT expansion to be compiled. LSAT expansion has previously been described 
by Minchin and Rawls (2017), who showed that LSAT first appeared at 8.2 mm SL 
and that expansion of the depot occurred primarily along the anterior posterior axis. 
Expansion along the dorsal ventral axis was also reported and LSAT was reported to 
form a long thin depot (Minchin and Rawls, 2017b). These findings were corroborated 
by the findings in chapter 4. In addition, the cellular dynamics of LSAT expansion were 
described for the first time and cell number, average lipid droplet area and LSAT 
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branching were shown to correlate with SL. Furthermore, a model of the spatial 
expansion of LSAT was proposed. In this model LSAT expands by adding new cells 
to the centre of the depot and then further expands by forming chains of adipocytes 
which branch away from the main LSAT body. In summary LSAT expansion in 
zebrafish proceeds as previously described and the results described in chapter 4 are 
the most detailed quantification of zebrafish AT expansion to date.   
 
6.2.8 – LSAT expands in zebrafish via steady hypertrophic growth with 
bursts of hyperplastic growth 
In addition to providing novel information on LSAT growth, the Foxp1:eGFP 
line  has also provided new insights into LSAT growth during development. It was 
shown that LSAT expands via steady hypertrophic growth, with bursts of hyperplastic 
growth and that the LSAT depot continues to expand over a period of at least 5 days. 
In contrast the development of SAT in mice has been shown to occur over a shorter 
timeframe, with the hyperplastic growth of SAT being confined to a 4 day time period 
(Wang et al., 2013b). Furthermore, due to the nature of mouse models, no data 
currently exists on the cellular nature of SAT expansion during mouse development. 
The differing nature of SAT development in zebrafish and mice can be explained by 
the differing developmental timings of adipose formation in the two species (Minchin 
and Rawls, 2017b, Wang et al., 2013b). In rodents subcutaneous adipose depots are 
formed during embryonic development while visceral depots are formed postnatally 
(Wang et al., 2013b). In contrast, all zebrafish AT depots are formed post 
embryonically and visceral adipose depots are known to be formed prior to 
subcutaneous depots (Minchin and Rawls, 2017b). Furthermore, the use of the 
Foxp1:eGFP line and lipophilic dyes allows LSAT development to be tracked in live 
zebrafish and therefore allows information on the cellular dynamics of LSAT growth 
to be compiled. This resolution however cannot be achieved in mice, as SAT 
development must be tracked using lineage tracing techniques (Wang et al., 2013b). 
Wang et al (2013) investigated SAT formation using a lineage tracing system in which 
mature adipocytes are indelibly marked by lacZ upon treatment with doxycycline. 
Pregnant mice were given doxycycline at various timepoints and the subcutaneous 
adipose tissue of their offspring examined (Wang et al., 2013b). Mice whose mothers 
were given doxycycline between E9-E16 showed heterogeneous LacZ expression, 
while mice whose mothers were given doxycycline between E9-E18 or E19-P10 
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showed nearly 100% lacZ positive cells (Wang et al., 2013b). This shows that in mice 
adipocyte commitment in SAT is initiated between E14-E18 and suggests SAT 
adipocytes are committed and differentiated early during adipogenesis (Wang et al., 
2013b). In conclusion, hyperplastic growth of SAT in mice occurs over a shorter time 
period than in zebrafish and adipose tissue expands via steady hypertrophic growth 
with bursts of hyperplastic growth in zebrafish.   
 
6.2.9 – foxp1 doesn’t appear to influence adipose progenitor cell 
maintenance  
I next used the Foxp1:eGFP line to investigate the role of foxp1 in adipose 
progenitor cell maintenance. SAT growth was imaged in foxp1a(-/-) and foxp1b(-/-) 
mutants over a period of five and three days, however no changes in adipose 
progenitor cell numbers or modes of adipose tissue growth were observed. In contrast 
the negative correlation between change in adipocyte number and change in 
progenitor cell number, which was observed in WT fish, was not observed in foxp1a(-
/-) mutant fish. This suggests that progenitor cell behaviour is altered in foxp1a(-/-) 
mutants. foxp1a(-/-);foxp1b(-/-) double mutants however showed no significant 
difference in adipose progenitor cell number when compared to WT siblings. The 
foxp1a(-/-);foxp1b(-/-) data was taken from a single timepoint and so needs to be 
expanded upon in order to examine any differences in LSAT expansion. This 
preliminary data does not agree with the hypothesis that foxp1 maintains adipose 
progenitor cells and is not in keeping with the known function of foxp1 in other 
progenitor cell populations. For example, loss of Foxp1 in bone marrow MSCs leads 
to a decline in their self-renewal capacity (Li et al., 2017). Furthermore, loss of Foxp1 
expression in the mammary gland leads to reduced mammary progenitor cell 
proliferation (Fu et al., 2018). In contrast lack of foxp1 in adipose tissue does not 
appear to alter adipose progenitor cell number. However, while the Foxp1:eGFP line 
does mark adipose progenitor cells, the nature of the progenitor cells marked by the 
Foxp1:eGFP line remains untested. Therefore further work is needed to determine 
the nature of the progenitor cells marked by the Foxp1:eGFP line and this is discussed 
in the future directions section (Chapter 6.3.4).  In summary foxp1 does not appear to 
be required to maintain adipose progenitor cells however further work is needed to 
test this.  
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6.2.10 – The role of cebpa in liver development appears to be conserved 
to zebrafish  
In addition to exploring the role of foxp1 in adipose tissue expansion, I also 
examined the role of a master regulator of adipogenesis cebpa. To do this I 
investigated the hypothesis that cebpa is required for adipose tissue expansion in 
zebrafish. I generated two predicted loss of function zebrafish mutants, cebpa(ed19/ed19) 
and cebpa(ed20/ed20), and both mutants were found to die before 21 dpf. This early death 
phenotype is reminiscent of both published mouse and zebrafish cebpa mutants. 
Cebpa knockout mice die shortly after birth due to liver defects, and this defect has 
also been observed in zebrafish cebpa mutants (Siersbaek et al., 2012, Yuan et al., 
2015). cebpa zebrafish mutants, described by Yuan et al (2015) died at around 3 
weeks post fertilisation, had smaller livers than WT siblings and showed altered levels 
of liver cell proliferation. This small liver phenotype was also observed in the 
cebpa(ed19/ed19) mutants, suggesting that the role of cebpa in liver development is 
conserved to zebrafish. In summary the cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants 
show that same early death phenotype as published mouse and zebrafish mutants 
and this phenotype also appears to be due to defects in liver development.  
 
6.2.11 – The role of cebpa in adipose tissue expansion is conserved to 
zebrafish  
I next examined the role of cebpa in adipose tissue expansion in zebrafish and 
found cebpa(+/ed19) and cebpa(+/ed20) mutants to have impaired adipose tissue 
expansion. As cebpa(ed19/ed19) and cebpa(ed20/ed20) mutants died before the development 
of adipose tissue, levels of adipose tissue were examined in cebpa(+/ed19) and 
cebpa(+/ed20) mutants. Levels of adipose tissue were found to be significantly reduced 
in both cebpa mutants when compared to WT siblings. This finding mirrors the 
phenotype of Cebpa knockout mice. In 2001 Linhart et al generated a mouse model 
in which Cebpa is expressed only by hepatocytes. These mice showed a complete 
absence of white adipose tissue, demonstrating that Cebpa is required for the 
commitment of preadipocytes to adipocytes in vivo (Linhart et al., 2001). This 
phenotype is also similar to that of the Pparg knockout mouse, with Pparg being 
another key regulator of adipogenesis (Wang et al., 2013a). In summary, the severely 
reduced levels of AT in cebpa(+/ed19) and cebpa(+/ed20) mutants mirrors previously 
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published mouse phenotypes and suggests that cebpa is a key regulator of AT 
expansion in zebrafish.  
 
6.2.12 – cebpa(+/ed19) and cebpa(+/ed20) mutants have a more hypertrophic 
adipose tissue morphology than WT siblings 
In addition to having reduced levels of adipose tissue, both cebpa(+/ed19) and 
cebpa(+/ed20) mutants showed a more hypertrophic adipose tissue morphology than 
WT siblings. Furthermore, use of the Foxp1:eGFP line revealed cebpa(+/ed19) mutants 
to have fewer adipose progenitor cells than their WT siblings. Taken together this 
suggests reduced rates of hyperplastic growth in cebpa(+/ed19) mutants and therefore 
potentially reduced rates of adipogenesis, all of which fits with Cebpa’s known role as 
a master regulator of mammalian adipogenesis. Another known master regulator of 
mammalian adipogenesis is Pparg and Pparg knockout mice show a strikingly similar 
adipose morphology phenotype to that of the cebpa(+/ed19) mutants. Pparg knockout 
mice have nearly no AT but the adipocytes which are present are vastly enlarged 
(Wang et al., 2013a). This is a more severe but similar phenotype to the hypertrophic 
AT morphology observed in the cebpa(+/ed19) mutants. In summary the hypertrophic AT 
morphology of the cebpa(+/ed19) mutants and their reduced number of adipose 
progenitor cells provides further evidence to support the hypothesis that cebpa is a 
key regulator of zebrafish AT expansion.   
 
6.2.13 – cebpa(+/ed19) mutants have elevated levels of blood triglycerides 
Finally, I examined the levels of blood metabolites in cebpa(+/ed19) mutants to 
understand if the overall metabolic health of cebpa(+/ed19) mutants was altered. 
cebpa(+/ed19) mutants showed increased levels of blood triglycerides, while no changes 
were observed in levels of blood glucose or cholesterol. This phenotype precisely 
matches that of the Cebpa knockout mouse model, in which levels of blood triglyceride 
but not blood glucose were elevated (Linhart et al., 2001). This shows that, like in the 
mouse model, a reduction in cebpa levels results in a worsened metabolic outcome 
in zebrafish. The reduced levels of AT in cebpa(+/ed19) mutants and the increased levels 
of blood glucose are suggestive of AT dysfunction and ectopic lipid deposition. It 
would therefore be useful to examine levels of lipid in the livers of cebpa(+/ed19) 
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mutants. Overall, the elevated levels of blood triglycerides in cebpa(+/ed19) mutants 
provides further evidence that the role of cebpa in adipose tissue expansion is 






















6.3 – Future directions  
 
6.3.1 – Is the reduced adipose tissue expansion observed in foxp1 
mutants due to the effects of foxp1 on adipose tissue alone? 
All the zebrafish mutants described in this thesis are whole body mutants. This 
therefore leaves open the question of whether the phenotypes observed in these 
mutants are due to the loss of foxp1 function in adipose tissue or if the phenotypes 
observed are caused by a lack of foxp1 expression in other tissues. This problem has 
previously been discussed in section 3.3, with the generation of AT specific foxp1 
mutants and the in vitro culture of adipose progenitor cells given as examples of ways 
to overcome this issue. An additional avenue which has not yet been addressed is 
feeding behaviour in the foxp1 zebrafish mutants. One explanation for the reduced 
levels of adipose tissue in the foxp1 mutants, which is not an impaired ability of the 
adipose tissue to expand, could be reduced food consumption. Patients with 
mutations in the FOXP1 gene have been reported to have intellectual disabilities and 
brain specific Foxp1 knockout mice show broad brain morphology defects (Bacon et 
al., 2015). Therefore, due to the strong link between hunger and satiety signals from 
the brain and feeding behaviour, in addition to Foxp1’s role in the brain, it is not 
unreasonable to suppose that feeding behaviour may be altered in foxp1 mutants 
(Heisler and Lam, 2017). Food consumption was not monitored in the foxp1 zebrafish 
mutants, however feeding behaviour can be assessed in zebrafish. One way to do 
this would be to isolate individual WT and foxp1 mutant fish, give all fish the same 
amount of dry feed and monitor food consumption.   Zebrafish also hunt live prey and 
so this could be filmed to observe if this behaviour is impaired in mutant fish (Shimada 
et al., 2012). In summary further experiments are needed to confirm that the 
phenotypes observed in foxp1 mutants are due to the effect of foxp1 on adipose only 
and assessing feeding behaviour would go some way to show this.  
 
6.3.2 – Further characterisation of zebrafish foxp1 expression is needed  
FOXP1 is known to be expressed in adipose tissue in both humans and mice 
(Fagerberg et al., 2014, Liu et al., 2019). In chapter 3 I showed that foxp1a and foxp1b 
are expressed in a whole VAT depot and by cells of the SVF (section 3.2.3 & 3.2.4). 
However, whether foxp1a or foxp1b are expressed by adipocytes themselves or by 
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adipose progenitor cells remains unknown. One way to overcome this problem would 
be to make use of the Foxp1:eGFP line. Adipose tissue could be dissected from 
Foxp1:eGFP fish and the tissue digested and fractionated to separate adipocytes and 
the SVF. FACS (Fluorescence activated cell sorting) sorting could then be used to 
isolate GFP positive cells from each fraction and would give a pure population of 
adipocytes and adipose progenitor cells. RNA could then be extracted from these 
cells and foxp1 expression measured. Overall there is a lack of data on foxp1 
expression in zebrafish and the Foxp1:eGFP line could be used to determine if foxp1 
is expressed in adipocytes and preadipocytes. 
In addition to the uncertainty surrounding foxp1 expression in adipose in 
zebrafish, it is also unclear which tissues express foxp1 in juvenile zebrafish. 
Previously published expression data of foxp1 in zebrafish comes from in situ 
hybridisations in embryos (Cheng et al., 2007). This data shows that foxp1b 
expression is dynamic in the early embryo and goes from being expressed 
ubiquitously at the 4 cell stage to being expressed in the mid-hindbrain and intestinal 
tract at 5 dpf (Cheng et al., 2007). This data however only exists for foxp1b and not 
foxp1a and the expression patterns of both genes are unknown at later stages of 
development. Crucially the expression of foxp1 at the stages tested in this thesis, i.e. 
4-5 weeks post fertilisation, are unknown. This is important information to gather as 
loss of Foxp1 expression in mice results in heart, brain and liver phenotypes (Bacon 
et al., 2015, Wang et al., 2004, Zou et al., 2015). Therefore, knowing where in the 
zebrafish foxp1 is expressed could help to interpret foxp1 mutant phenotypes and to 
determine whether these phenotypes are likely due to loss of foxp1 expression in AT. 
One way to determine where foxp1 is expressed would be to perform in situ 
hybridisation against foxp1a and foxp1b in 4 week old fish. A better solution would be 
to find or generate antibodies which recognise zebrafish foxp1 and use these to 
perform immunostaining on tissues of interest. In chapter 3 I measured Foxp1 protein 
levels in foxp1a(-/-), foxp1b(-/-) and foxp1a(-/-);foxp1b(-/-) mutants, all of which showed 
reduced levels of Foxp1 protein (Section 3.2.12, 3.2.21 & 3.2.30). Foxp1 protein levels 
were tested using protein lysate from the caudal fins of zebrafish and using an 
antibody which recognised human FOXP1 protein. There is currently no data as to 
whether Foxp1a, Foxp1b, or both paralogues are expressed in the caudal fin and the 
predicted protein sizes of Foxp1a and Foxp1b are very similar at 71 kDa and 74 kDa 
respectively. Therefore, it is unknown whether the FOXP1 antibody used recognises 
Foxp1a, Foxp1b or both paralogues. One way to overcome this problem would be to 
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have antibodies manufactured which recognise the zebrafish proteins themselves. In 
summary further information on the global expression of foxp1 in zebrafish is needed, 
and this could be achieved through the use of in situ hybridisation or through the 
generation of antibodies which recognise the zebrafish Foxp1 proteins.  
 
6.3.3 – Are the effects of the HFD in zebrafish due to overnutrition or due 
to increased levels of fat in the diet?  
The 5% egg yolk based HFD used in this thesis has been shown to lead to 
significant AT accumulation over a two week period (Carten et al., 2011, Semova et 
al.,2012, Walters et al., 2012). However, the broader metabolic changes that the egg 
yolk based diet leads to have not been fully studied. Similarly, the use of HFDs in 
zebrafish is not widespread and there is little research into what constitutes a HFD for 
a zebrafish. In contrast the use of HFD’s in mouse models is widespread and these 
diets are used to achieve an obesity like phenotype in a shorter timeframe than can 
be achieved through overfeeding (Speakman, 2019). However, there is still 
discussion as to how closely these diets resemble human diets, with differences in 
not only fat content between diets but also in levels of sucrose and fatty acids 
(Speakman, 2019). HFDs in mice commonly have a 40 or 60% fat content, this is in 
contrast to a standard chow diet which contains around 10% fat (Speakman, 2019). 
HFDs containing 40% fat have also been reported in zebrafish (Meguro et al., 2015). 
However lower fat content diets, at 22%, have been reported and result in metabolic 
changes (Oka et al., 2010). The 22% fat diet lasted for 8 weeks and led to a significant 
increase in levels of blood triglycerides (Oka et al., 2010). The 5% egg yolk diet also 
led to increased levels of blood triglycerides, though after only 2 weeks (Figure 3.10). 
As there is uncertainty around the effects of different diets in zebrafish, further 
experiments are needed to test if the effect of the HFD used in this thesis results in 
an obesity like phenotype or if the observed phenotypes are due to changes in diet 
composition. This could be achieved by comparing the effects of the 5% egg yolk HFD 
with overfeeding and with other reported HFDs. Overall, little is known about how the 
composition of different diets affects AT expansion and metabolic phenotypes in 




6.3.4 – Do zebrafish adipose progenitors resemble human or mouse 
adipose progenitor cells? 
Adipose progenitor cells have been identified in zebrafish by Flynn et al 
(2009), which identified cells abundant in fabp11a transcript but lacking neutral lipid. 
fabp11a is a homologue of mammalian Fabp4 which marks both adipocytes and 
adipose progenitors (Flynn et al., 2009).  As the lipid negative cells described by Flynn 
et al (2009) were found close to fabp11a labelled lipid positive cells, the cells were 
determined to be adipose progenitor cells. In addition to the cells described by Flynn 
et al (2009), I have also identified adipose progenitor cells in chapter 4. The 
Foxp1:eGFP line marks lipid negative cells with GFP, and these cells were then 
observed to accumulate lipid and form mature adipocytes.  However very little is 
known about adipose progenitor cells in zebrafish and the vast majority of our current 
knowledge of these progenitors comes from human and mouse data. Much of the 
data on adipose progenitor cells comes from in vitro cell culture work (Siersbaek et 
al., 2012). Normally adipose tissue is dissected, digested and the SVF isolated 
(Siersbaek et al., 2012). The SVF is then placed into culture and adipogenesis 
induced through the use of a hormonal cocktail (Siersbaek et al., 2012). This process 
has never been performed on zebrafish, however it has been performed using species 
of fish which are relevant to the aquaculture industry, such as Atlantic salmon and 
grass carp (Wafer et al., 2017). As isolation and differentiation of adipose progenitor 
cells has never been successfully demonstrated in zebrafish, it would be a useful 
experiment. It would be interesting to determine whether SVF cells from zebrafish 
could undergo adipogenesis in response to the normal hormonal cocktail of insulin, 
cAMP elevating agent, glucocorticoids and growth factors used on mammalian cell 
lines (Siersbaek et al., 2012). It would also be useful to test whether zebrafish cells 
express the same genes as mammalian cells do during the progression of 
adipogenesis. In summary little data exists on adipose progenitor cells in zebrafish 
and experiments using zebrafish in vitro cell culture models could help to expand the 






6.3.5 – Further characterisation of adipose progenitor cells marked by 
the Foxp1:eGFP line is needed  
The Foxp1:eGFP line marks both mature adipocytes and adipose progenitor 
cells. However, the stage at which adipose progenitor cells are marked is unknown. 
Adipose progenitor cells are derived from mesenchymal stem cells, which have the 
ability to differentiate into osteoblasts, chondrocytes, and adipocytes (Merrick et al., 
2019). Whether the Foxp1:eGFP line marks cells capable of differentiating into 
multiple lineages or whether it marks committed preadipocytes is currently unknown. 
One way to test this would be to isolate GFP positive adipose progenitor cells from 
Foxp1:eGFP zebrafish and to place the cells in culture. The cells could then be given 
hormonal cocktails which drive each of the different lineage specifications to see 
which cell types they are capable of differentiating into. Overall it is unknown at which 
stage of adipocyte commitment the Foxp1:eGFP line marks adipose progenitor cells, 
however in vitro cell culture experiments could be used to test this.  
 
6.3.6 – Is zebrafish AT formed of a heterogeneous population of 
adipocytes   
VAT and SAT in mammals are known to have distinct properties, with 
expression profiling revealing significant differences in the expression of 100s of 
genes between the two types of AT (Gesta et al., 2006, Vidal, 2001, Vohl et al., 2004). 
Furthermore, SAT in mammals is considered to be broadly protective, with numerous 
studies correlating increased SAT relative to VAT with preserved metabolic function, 
for subjects of similar weights (Ghaben and Scherer, 2019). However, while AT in 
zebrafish can be classified into VAT and SAT based on anatomical location, it is 
unclear whether these different depots have different properties (Minchin and Rawls, 
2017b). Data from a study by Minchin et al (2015) showed that zebrafish with 
decreased levels of VAT relative to SAT had improved glucose tolerance following a 
HFD, suggesting that SAT is also protective in zebrafish. In order to further examine 
any differences in VAT and SAT in zebrafish RNA Seq could be used. VAT and SAT 
could be dissected from the Foxp1:eGFP line and GFP positive adipocytes and 
preadipocytes isolated. RNA Seq could then be used to look for genes differentially 
expressed between adipocytes and adipose progenitor cells from VAT and SAT.  
Additional data on the properties of VAT and SAT in zebrafish would be useful in 
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helping to interpret the phenotypes of foxp1a(-/-) and foxp1b(-/-) mutants, which gain 
less SAT and VAT in response to a HFD respectively.  In summary not much is known 
about the differences between VAT and SAT in zebrafish, and RNA Seq could be 
used to look for differences in gene expression between the two types of WAT.  
In addition to differences between adipose depots, multiple recent studies 
have highlighted the heterogeneous nature of adipose progenitor cells within single 
depots in mice and humans (Hepler et al., 2018, Merrick et al., 2019, Schwalie et al., 
2018, Sempere et al., 2014). In particular single cell RNA-Seq has been utilised to 
identify subpopulations of adipose progenitor cells with differing adipogenic capacities 
(Hepler et al., 2018, Schwalie et al., 2018). For example, a study by Schwalie et al 
(2018) identified a subpopulation of adipose progenitor cells which were capable of 
inhibiting adipogenesis. No data currently exists on whether zebrafish adipose 
progenitor cells represent a homogeneous population of cells. Therefore, the next 
step would be to perform single cell RNA-Seq on zebrafish adipose progenitor cells 
to determine if the cells are a homogeneous population. The Foxp1:eGFP line could 
be utilised to isolate GFP positive adipose progenitor cells. In summary much is 
known about the nature of adipose progenitor cells in mammals which remains to be 
tested in zebrafish and the sequencing of zebrafish adipose progenitor cells would be 
one way in which to start to bridge this gap. 
 
6.3.7 – Further characterisation of LSAT growth in zebrafish is needed  
The Foxp1:eGFP line has been used to image LSAT expansion in vivo. From 
these experiments I have shown that LSAT appears to expand by steady hypertrophic 
growth with bursts of hyperplastic growth. However, all the imaging presented in this 
thesis was carried out over a period of five or fewer days and a lot of questions about 
LSAT growth remain to be addressed. Further experiments are needed to observe 
LSAT growth over longer periods of time, for example over two weeks. It would also 
be useful to see how LSAT grows in response to a dietary challenge such as a high 
fat diet. In addition, LSAT growth in response to starvation and refeeding could also 
be measured. In summary although imaging of the Foxp1:eGFP line allowed novel 
data about LSAT growth to be compiled, further experiments are needed to fully 




6.3.7 – Identification of novel downstream effectors of foxp1    
In chapters 3 and 4 I have presented data to support the hypothesis that foxp1 
maintains adipose progenitor cell populations and is required for adipose tissue 
expansion. As foxp1 is a transcription factor, it is supposed that it influences the 
expression of many genes in order to maintain adipose progenitor cell populations. 
However which factors foxp1 interacts with and how these interactions drive the 
proliferation and differentiation of adipose progenitor cells remains unknown. One way 
to learn more about downstream effectors of foxp1 would be to use RNA-Seq. 
Adipose tissue could be dissected from Foxp1:eGFP; foxp1a(-/-);foxp1b(-/-) mutant fish 
and WT siblings. The SVF could then be isolated, GFP positive adipose progenitor 
cells removed and RNA extracted. Genes which are differentially expressed between 
the two groups could then be investigated as candidate downstream effectors. Overall 
additional experiments are required to identify downstream effectors of foxp1 and to 
gain a better understanding of the transcriptional network surrounding foxp1.  
 
6.3.8 – Identification of novel downstream effectors of cebpa    
Finally, having demonstrated that the role of cebpa in adipose tissue 
expansion is conserved to zebrafish, I used cebpa(+/ed19) mutants to identify novel 
downstream effectors of cebpa. RNA Seq was performed on samples extracted from 
the PVAT of cebpa(+/ed19) mutants. The sequencing revealed that 949 genes were 
significantly upregulated in cebpa(+/ed19) mutants when compared to WT siblings and 
177 were significantly downregulated. Further analysis by GO term analysis revealed 
an enrichment of terms relating to tissue development and cell differentiation. Of 
particular interest were genes found in the cell differentiation category. Genes in this 
category were chosen for further investigation as cebpa is a key regulator of the 
adipogenic cell differentiation pathway. Genes found within this category included 
cxcr4b. Chemokine receptor type 4 (CXCR4) is a chemokine receptor with potent 
chemotactic activity for lymphocytes (Lear et al., 2017). CXCR4 is a seven 
transmembrane G protein coupled receptor which is activated by the binding of one 
or more chemokines and which acts as the main receptor for CXCL12 (Lear et al., 
2017). CXCR4 is known to be involved in processes such as chemotaxis and cell 
proliferation however a role for CXCR4 in adipose tissue is unknown (Lear et al., 
2017). Loss of function cxcr4b zebrafish exist and could be used to investigate the 
287 
 
function of cxcr4b in adipose tissue expansion (Haas and Gilmour, 2006). One future 
experiment would be to cross the cxcr4b mutants to cebpa(+/ed19) mutants and examine 
whether this worsened or improved adipose tissue expansion. In summary I have 
used RNA-Seq to identify novel downstream candidate cebpa effectors, of which 











































Figure 7.1 – Alignment of the ZFD and FHD of zebrafish and human FOXP1. A. 
Alignment of the FHD of human FOXP1 with zebrafish Foxp1a and Foxp1b. The 
alignment was generated using Clustal Omega. Red letters and asterisks highlight 
amino acids changes. B. Alignment of the ZFD of human FOXP1 with zebrafish 
Foxp1a and Foxp1b. The alignment was generated using Clustal Omega. Red letters 





Figure 7.2 – Complete gels from Figure 3.4 (CRISPR/Cas9 induces mutations at 





Figure 7.3 – Unprocessed images from chapter 4. A. Unprocessed images from 
figure 4.4B. B. Unprocessed images from figure 4.8B. Images are from the foxp1a(-/-) 
mutant upper panel. C. Unprocessed images from figure 4.8B. Images are from the 
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